U.S. patent application number 14/610332 was filed with the patent office on 2015-07-23 for combination therapy for the treatment of ocular neovascular disorders.
The applicant listed for this patent is OPHTHOTECH CORPORATION. Invention is credited to Anthony P. Adamis, Perry Calias, David Shima.
Application Number | 20150202289 14/610332 |
Document ID | / |
Family ID | 34278595 |
Filed Date | 2015-07-23 |
United States Patent
Application |
20150202289 |
Kind Code |
A1 |
Shima; David ; et
al. |
July 23, 2015 |
COMBINATION THERAPY FOR THE TREATMENT OF OCULAR NEOVASCULAR
DISORDERS
Abstract
The invention features methods for treating a patient diagnosed
with, or at risk of developing, a neovascular disorder by
administering a PDGF antagonist and a VEGF antagonist to the
patient. The invention also features a pharmaceutical composition
containing a PDGF antagonist and a VEGF antagonist for the
treatment or prevention of a neovascular disorder.
Inventors: |
Shima; David;
(Hertfordshire, GB) ; Calias; Perry; (Lexington,
MA) ; Adamis; Anthony P.; (Hillsborough, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
OPHTHOTECH CORPORATION |
NEW YORK |
NY |
US |
|
|
Family ID: |
34278595 |
Appl. No.: |
14/610332 |
Filed: |
January 30, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14186149 |
Feb 21, 2014 |
|
|
|
14610332 |
|
|
|
|
12641270 |
Dec 17, 2009 |
8685397 |
|
|
14186149 |
|
|
|
|
10926806 |
Aug 26, 2004 |
7759472 |
|
|
12641270 |
|
|
|
|
60556837 |
Mar 26, 2004 |
|
|
|
Current U.S.
Class: |
424/133.1 |
Current CPC
Class: |
A61K 39/3955 20130101;
A61P 19/02 20180101; A61P 27/02 20180101; A61K 31/00 20130101; A61K
31/506 20130101; A61K 31/7088 20130101; A61K 2039/505 20130101;
A61K 45/06 20130101; A61K 39/395 20130101; A61P 29/00 20180101;
A61K 31/00 20130101; A61P 9/10 20180101; A61P 43/00 20180101; A61P
17/06 20180101; A61K 31/7088 20130101; A61K 31/52 20130101; A61P
9/00 20180101; C12N 15/1136 20130101; A61P 27/06 20180101; A61K
2300/00 20130101; A61K 39/395 20130101; A61K 2300/00 20130101; A61K
2300/00 20130101; A61K 31/52 20130101; A61K 2300/00 20130101 |
International
Class: |
A61K 39/395 20060101
A61K039/395; A61K 31/506 20060101 A61K031/506 |
Claims
1. A method for ameliorating wet type age-related macular
degeneration, comprising administering to a mammal in need thereof:
(a) a PDGF antagonist, wherein the PDGF antagonist is ST157 or a
pharmaceutically acceptable salt thereof; and (b) a VEGF
antagonist, wherein the VEGF antagonist is a humanized anti-VEGF
antibody or binding fragment thereof that binds to VEGF-A, wherein
the PDGF antagonist and the VEGF antagonist are administered
simultaneously or within 90 days of each other, and wherein the
PDGF antagonist and the VEGF antagonist are administered in an
amount effective to ameliorate the wet type age-related macular
degeneration.
2. The method of claim 1, wherein the PDGF antagonist and the VEGF
antagonist are administered within 10 days of each other.
3. The method of claim 1, wherein the PDGF antagonist and the VEGF
antagonist are administered within 5 days of each other.
4. The method of claim 1, wherein the PDGF antagonist and the VEGF
antagonist are administered within 24 hours of each other.
5. The method of claim 1, wherein the PDGF antagonist and the VEGF
antagonist are administered simultaneously.
6. The method of claim 1, wherein the PDGF antagonist and VEGF
antagonist are administered separately in individual dosage
amounts.
7. The method of claim 1, wherein the PDGF antagonist and VEGF
antagonist are administered together in the same composition.
8. The method of claim 1, wherein the mammal is a human.
9. The method of claim 1, wherein the VEGF antagonist is a
humanized anti-VEGF antibody having a heavy chain variable domain
comprising the amino acid sequence of SEQ ID NO: 26 and a light
chain variable domain comprising the amino acid sequence of SEQ ID
NO: 27, or an anti-VEGF antibody binding fragment having a light
chain variable domain comprising the amino acid sequence of SEQ ID
NO: 25 and a heavy chain variable domain comprising the amino acid
sequence of SEQ ID NO: 24.
10. The method of claim 9, wherein the VEGF antagonist is a
humanized anti-VEGF antibody binding fragment having a heavy chain
variable domain comprising the amino acid sequence of SEQ ID NO: 24
and a light chain variable domain comprising the amino acid
sequence of SEQ ID NO: 25.
11. The method of claim 9, wherein the VEGF antagonist is a
humanized anti-VEGF antibody having a heavy chain variable domain
comprising the amino acid sequence of SEQ ID NO: 26 and a light
chain variable domain comprising the amino acid sequence of SEQ ID
NO: 27.
12. The method of claim 1, wherein the dosage of the PDGF
antagonist or the VEGF antagonist is about 0.1 mg to about 250 mg
per day.
13. The method of claim 12, wherein the dosage of the PDGF
antagonist or the VEGF antagonist is about 1 mg to about 20 mg per
day.
14. The method of claim 13, wherein the dosage of the PDGF
antagonist or the VEGF antagonist is about 3 mg to about 5 mg per
day.
15. The method of claim 12, wherein the dosage of the VEGF
antagonist is about 0.15 mg to about 3.0 mg per day.
16. The method of claim 15, wherein the dosage of the VEGF
antagonist is about 0.3 mg to about 3.0 mg per day.
17. The method of claim 16, wherein the dosage of the VEGF
antagonist is about 0.1 mg to 1.0 mg per day.
Description
RELATED APPLICATIONS
[0001] This application is a division of U.S. application Ser. No.
14/186,149, filed Feb. 21, 2014, which is a division of U.S.
application Ser. No. 12/641,270, filed Dec. 17, 2009, now U.S. Pat.
No. 8,685,397, which is a division of U.S. application Ser. No.
10/926,806, filed Aug. 26, 2004, now U.S. Pat. No. 7,759,472, which
claims the benefit of U.S. Provisional Application Ser. No.
60/556,837, filed Mar. 26, 2004, the disclosure of each of which is
incorporated by reference herein in its entirety.
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
[0002] The contents of the text file submitted electronically
herewith are incorporated herein by reference in their entirety: A
computer readable format copy of the Sequence Listing (filename:
OPHT.sub.--004.sub.--10US_SeqList.txt, date recorded: Jan. 29,
2015, file size 95 kilobytes).
FIELD OF THE INVENTION
[0003] This invention relates to the fields of ophthalmology and
medicine. More specifically, this invention relates to the
treatment of neovascular disorders of the eye using a combination
of agents that inhibit both platelet-derived growth factor (PDGF)
and vascular endothelial growth factor (VEGF).
BACKGROUND OF THE INVENTION
[0004] Angiogenesis, also called neovascularization, involves the
formation of sprouts from preexistent blood vessels and their
invasion into surrounding tissue N related process, vasculogenesis,
involves the differentiation of endothelial cells and angioblasts
that are already present throughout a tissue, and their subsequent
linking together to form blood vessels.
[0005] Angiogenesis occurs extensively during development, and also
occurs in the healthy body during wound healing in order to restore
blood flow to tissues after injury or insult. Angiogenesis,
however, has also been implicated in cancer and tumor formation.
Indeed, the quantity of blood vessels in a tumor tissue is a strong
negative prognostic indicator in breast cancer (Weidner et al.,
(1992) J. Natl. Cancer Inst. 84:1875-1887), prostate cancer
(Weidner et al., (1993) Am. J. Pathol. 143:401-409), brain tumors
(Li et al., (1994) Lancet 344:82-86), and melanoma (Foss et al,
(1996) Cancer Res. 56:2900-2903). Angiogenesis has also recently
been implicated in other disease states in many areas of medicine,
including rheumatology, dermatology, cardiology and ophthalmology.
In particular, undesirable or pathological tissue-specific
angiogenesis has been associated with certain specific disease
states including rheumatoid arthritis, atherosclerosis, and
psoriasis (see e.g., Fan et al., (1995) Trends Pharmacol. Sci. 16:
57; and Folkman (1995) Nature Med. 1: 27). Furthermore, the
alteration of vascular permeability is thought to play a role in
both normal and pathological physiological processes (Cullinan-Bove
et al., (1993) Endocrinol. 133: 829; Senger et al., (1993) Cancer
and Metastasis Reviews 12: 303). Although the angiogenic process in
each of these diseases is likely to share many features with
developmental angiogenesis and tumor angiogenesis, each may also
have unique aspects conferred by the influence of surrounding
cells.
[0006] Several ocular disorders involve alterations in
angiogenesis. For example, diabetic retinopathy, the third leading
cause of adult blindness (accounting for almost 7% of blindness in
the USA), is associated with extensive angiogenic events.
Nonproliferative retinopathy is accompanied by the selective loss
of pericytes within the retina, and their loss results in dilation
of associated capillaries dilation and a resulting increase in
blood flow. In the dilated capillaries, endothelial cells
proliferate and form outpouchings, which become microaneurysms, and
the adjacent capillaries become blocked so that the area of retina
surrounding these microaneurysms is not perfused. Eventually, shunt
vessels appear between adjacent areas of micro aneurysms, and the
clinical picture of early diabetic retinopathy with micro aneurysms
and areas of nonperfused retina is seen. The microaneurysms leak
and capillary vessels may bleed, causing exudates and hemorrhages.
Once the initial stages of background diabetic retinopathy are
established, the condition progresses over a period of years,
developing into proliferative diabetic retinopathy and blindness in
about 5% of cases. Proliferative diabetic retinopathy occurs when
some areas of the retina continue losing their capillary vessels
and become nonperfused, leading to the appearance of new vessels on
the disk and elsewhere on the retina. These new blood vessels grow
into the vitreous and bleed easily, leading to preretinal
hemorrhages. In advanced proliferative diabetic retinopathy, a
massive vitreous hemorrhage may a major portion of the vitreous
cavity. In addition, the new vessels are accompanied by fibrous
tissue proliferation that can lead to traction retinal
detachment.
[0007] Diabetic retinopathy is associated primarily with the
duration of diabetes mellitus; therefore, as the population ages
and diabetic patients live longer, the prevalence of diabetic
retinopathy will increase. Laser therapy is currently used in
both-nonproliferative and proliferative diabetic retinopath Focal
laser treatment of the leaking microaneurysms surrounding the
macular area reduces visual loss in 50% of patients with clinically
significant macular edema. In proliferative diabetic retinopathy,
panretinal photocoagulation results in several thousand tiny burns
scattered throughout the retina (sparing the macular area); this
treatment reduces the rate of blindness by 60 percent. Early
treatment of macular edema and proliferative diabetic retinopathy
prevents blindness for 5 years in 95% of patients, whereas late
treatment prevents blindness in only 50 percent. Therefore, early
diagnosis and treatment are essential.
[0008] Another ocular disorder involving neovascularization is
age-related macular degeneration (AMD), a disease that affects
approximately one in ten Americans over the age of 65. AMD is
characterized by a series of pathologic changes in the macula, the
central region of the retina, which is accompanied by decreased
visual acuity, particularly affecting central vision, AMD involves
the single layer of cells called the retinal pigment epithelium
that lies immediately beneath the sensory retina. These cells
nourish and support the portion of the retina in contact with them,
i.e., the photoreceptor cells that contain the visual pigments. The
retinal pigment epithelium lies on the Bruch membrane, a basement
membrane complex which, in AMD, thickens and becomes sclerotic. New
blood vessels may break through the Bruch membrane from the
underlying choroid, which contains a rich vascular bed. These
vessels may in turn leak fluid or bleed beneath the retinal pigment
epithelium and also between the retinal pigment epithelium and the
sensory retina. Subsequent fibrous scarring disrupts the
nourishment of the photoreceptor cells and leads to their death,
resulting in a loss of central visual acuity. This type of
age-related maculopathy is called the "wet" type because of the
leaking vessels and the subretinal edema or blood. The wet type
accounts for only 10% of age-related maculopathy cases but results
in 90% of cases of legal blindness from macular degeneration in the
elderly. The "dry" type of age-related maculopathy involves
disintegration of the retinal pigment epithelium along with loss of
the overlying photoreceptor cells. The dry type reduces vision but
usually only to levels of 20/50 to 20/100.
[0009] AMD is accompanied by distortion of central vision with
objects appearing larger or smaller or straight lines appearing
distorted, bent, or without a central segment. In the wet type of
AMD, a small detachment of the sensory retina may be noted in the
macular area, but the definitive diagnosis of a subretinal
neovascular membrane requires fluorescein angiography. In the dry
type, drusen may disturb the pigmentation pattern in the macular
area. Drusen are excrescences of the basement membrane of the
retinal pigment epithelium that protrude into the cells, causing
them to bulge anteriorly; their role as a risk factor in
age-related maculopathy is unclear. No treatment currently exists
for the dry type of age-related maculopathy. Laser treatment is
used in the wet type of age-related maculopathy and initially
obliterates the neovascular membrane and prevents further visual
loss in about 50% of patients at 18 months. By 60 months, however,
only 20% still have a substantial benefit.
[0010] Multiple molecular mediators of angiogenesis have been
identified including basic and acidic fibroblast growth factors
(aFGF, bFGF), transforming growth factors alpha and beta
(TGF.alpha., TGF.beta., platelet-derived growth factor (PDGF),
angiogenin, platelet-derived endothelial cell growth factor
(PD-ECGF), interleukin-8 (IL-8), and vascular endothelial growth
factor (VEGF). Other stimulators implicated in angiogenesis include
angiopoietin-1, Del-1, follistatin, granulocyte colony-stimulating
factor (G-CSF), hepatocyte growth factor (HGF), leptin, midkine,
placental growth factor, pleiotrophin (PTN), progranulin,
proliferin, and tumor necrosis factor-alpha (TNF-alpha). In
addition, control of angiogenesis is further mediated by a number
of negative regulators of angiogenesis produced by the body
including angioarrestin, ngiostatin (plasminogen fragment),
antiangiogenic antithrombin III, cartilage-derived inhibitor (CDI),
CD59 complement fragment, endostatin (collagen XVIII fragment),
fibronectin fragment, gro-beta, heparinases, heparin hexasaccharide
fragment, human chorionic gonadotropin (hCG), interferon
alpha/beta/gamma, interferon inducible protein (IP-10),
interleukin-12, kringle 5 (plasminogen fragment), metalloproteinase
inhibitors (TIMPs), 2-methoxyestradiol, placental ribonuclease
inhibitor, plasminogen activator inhibitor, platelet factor-4
(PF4), prolactin 16 kD fragment, proliferin-related protein (PRP),
retinoids, tetrahydrocortisol-S, thrombospondin-1 (TSP-1),
vasculostatin, and vasostatin (calreticulin fragment).
[0011] Among these angiogenic regulators, VEGF appears to play a
key role as a positive regulator of the abnormal angiogenesis
accompanying tumor growth (reviewed in Brown et al., (1996) Control
of Angiogenesis (Goldberg and Rosen, eds.) Birkhauser, Basel, and
Thomas (1996) J. Biol. Chem. 271:603-606). Furthermore, recently
the role of the PDGF-B member of the PDGF family of signaling
molecules has been under investigation, since it appears to play a
role in the formation, expansion and proper function of
perivascular cells, sometimes referred to as mural cells, e.g.,
vascular smooth muscle, mesangial cells, and pericytes.
[0012] While much has been learned about angiogenesis, or
neovascularization, accompanying development, wound healing and
tumor formation, it remains to be determined whether there are
differences between these forms of angiogenesis and ocular
angiogenesis. Significantly, while angiogenesis accompanying, e.g.,
collateral blood vessel formation in the heart, may be beneficial
and adaptive to the organism, pathological ocular
neovascularization accompany, e.g., AMD, has no known benefit and
often leads to blindness (for review, see Campochiaro (2000) J.
Cell. Physiol, 184: 301-10). Therefore, although advances in the
understanding of the molecular events accompanying
neovascularization have been made, there exists a need to utilize
this understanding to develop further methods for treating
neovascular diseases disorders, including ocular neovascular
diseases and disorders such as the choroidal neovascularization
that occurs with AMD and diabetic retinopathy.
SUMMARY OF THE INVENTION
[0013] It has been discovered that the combination of anti-VEGF and
anti-PDGF agents surprisingly affords synergistic therapeutic
benefits for treating an ocular neovascular disease.
[0014] Accordingly, the invention features a method for treating a
patient diagnosed with or at risk for developing a neovascular
disorder. This method includes administering to the patient an
anti-VEGF agent and an anti-PDGF agent as a primary or adjunct
therapeutic treatment.
[0015] In one aspect, the invention provides a method for
suppressing a neovascular disorder in a patient in need thereof, by
administering to the patient a PDGF antagonist and a VEGF
antagonist, simultaneously, or within about 90 days of each other,
in amounts sufficient to suppress the neovascular disorder in the
patient.
[0016] In another aspect, the invention provides a method for
treating a patient diagnosed with, or at risk for developing, a
neovascular disorder in a patient in need thereof, by administering
to the patient a PDGF antagonist and a VEGF antagonist,
simultaneously or within 90 days of each other, in amounts
sufficient to treat the patient.
[0017] In particular embodiments of these aspects, the method of
the invention involves administering the PDGF antagonist and the
VEGF antagonist within about 10 days of each other. In another
embodiment of the method of the invention, the PDGF antagonist and
the VEGF antagonist are administered within 5 days of each other.
In yet another embodiment of the method of the invention, the PDGF
antagonist and the VEGF antagonist are administered within about 24
hours of each other. In a particular embodiment of the method of
the invention, the PDGF antagonist and said VEGF antagonist are
administered simultaneously.
[0018] In another embodiment, the method of the invention involves
administration of a PDGF antagonist that is a PDGF-B antagonist. In
still another embodiment, the method of the invention involves
administration of a VEGF antagonist that is a VEGF-A
antagonist.
[0019] In certain embodiments, the method of the invention involves
administration of a PDGF antagonist that is a nucleic acid
molecule, an aptamer, an antisense RNA molecule, a ribozyme, an
RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody,
a binding fragment of an antibody fragment, a sugar, a polymer, or
a small organic compound. In another embodiment, the method of the
invention involves administration of a VEGF antagonist that is a
nucleic acid molecule, an aptamer, an antisense RNA molecule, a
ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide,
an antibody, a binding fragment of an antibody fragment, a sugar, a
polymer, or a small organic compound.
[0020] In a particular embodiment, the method of the invention
involves administration of a VEGF antagonist that is an aptamer,
such as an EYE001 aptamer. In another embodiment, the method of the
invention involves administration of a VEGF antagonist that is an
antibody or binding fragment thereof.
[0021] In a particular embodiment, the method of the invention
involves administration of a PDGF antagonist that is an aptamer, an
antibody or a binding fragment thereof. In another particular
embodiment, the method of the invention involves administration of
a PDGF antagonist that is an antisense oligonucleotide.
[0022] In yet another embodiment of this aspect of the invention,
the PDGF antagonist and/or the VEGF antagonist are pro-drugs.
[0023] In one embodiment, the method of the invention provides a
means for suppressing or treating an ocular neovascular disorder.
In some embodiments, ocular neovascular disorders amenable to
treatment or suppression by the method of the invention include
ischemic retinopathy, iris neovascularization, intraocular
neovascularization, age-related macular degeneration, corneal
neovascularization, retinal neovascularization, choroidal
neovascularization, diabetic retinal ischemia, or proliferative
diabetic retinopathy. In still another embodiment, the method of
the invention provides a means for suppressing or treating
psoriasis or rheumatoid arthritis in a patient in need thereof or a
patient diagnosed with or at risk for developing such a
disorder.
[0024] The invention also provides a pharmaceutical composition
that includes both a PDGF antagonist and a VEGF antagonist, as well
a pharmaceutically acceptable carrier. In this aspect, the PDGF and
VEGF antagonists are present both in amounts sufficient to suppress
the neovascular disorder in the patient.
[0025] In one embodiment of this aspect, the pharmaceutical
composition includes a PDGF antagonist that is a PDGF-B antagonist.
In another embodiment, the pharmaceutical composition includes a
VEGF antagonist that is a VEGF-A antagonist.
[0026] In certain embodiments, the pharmaceutical composition of
the invention includes a PDGF antagonist that is a nucleic acid
molecule, an aptamer, an antisense RNA molecule, a ribozyme, an
RNAi molecule, a protein, a peptide, a cyclic peptide, an antibody,
a binding fragment of an antibody fragment, a sugar, a polymer or a
small organic compound. In another embodiment, the pharmaceutical
composition of the invention includes a VEGF antagonist that is a
nucleic acid molecule, an aptamer, an antisense RNA molecule, a
ribozyme, an RNAi molecule, a protein, a peptide, a cyclic peptide,
an antibody, a binding fragment of an antibody fragment, a sugar, a
polymer, or a small organic compound.
[0027] In other particular embodiments, the pharmaceutical
composition of the invention includes a VEGF antagonist that is an
aptamer, such as an EYE001 aptamer. In one embodiment, the
pharmaceutical composition of the invention includes a VEGF
antagonist that is an antibody or binding fragment thereof.
[0028] In a particular embodiment, the pharmaceutical composition
of the invention includes a PDGF antagonist that is an antibody or
binding fragment thereof. In another particular embodiment, the
pharmaceutical composition of the invention includes a PDGF
antagonist that is an antisense oligonucleotide.
[0029] The pharmaceutical composition the invention may include a
pharmaceutically acceptable carrier which includes a microsphere or
a hydrogel formulation.
[0030] In yet another embodiment, the PDGF antagonist and/or the
VEGF antagonist are pro-drugs.
[0031] In another embodiment, the pharmaceutical composition of the
invention provides a means for suppressing or treating an ocular
neovascular disorder. In some embodiments, ocular neovascular
disorders amenable to treatment or suppression by the
pharmaceutical composition of the invention include ischemic
retinopathy, iris neovascularization, intraocular
neovascularization, age-related macular degeneration, corneal
neovascularization, retinal neovascularization, choroidal
neovascularization, diabetic retinal ischemia, or proliferative
diabetic retinopathy. In still other embodiments, the
pharmaceutical composition of the invention provides a means for
suppressing or treating psoriasis or rheumatoid arthritis in a
patient in need thereof, or a patient diagnosed with or at risk for
developing such a disorder.
[0032] The invention also provides a pharmaceutical pack that
includes both a PDGF antagonist and a VEGF antagonist. In one
embodiment of this aspect, the pharmaceutical pack includes a PDGF
antagonist that is a PDGF-B antagonist. In another embodiment of
this aspect, the pharmaceutical pack includes a VEGF antagonist
that is a VEGF-A antagonist.
[0033] In another embodiment, the PDGF antagonist and VEGF
antagonist of the pharmaceutical pack are formulated separately and
in individual dosage amounts. In still another embodiment, the PDGF
antagonist and VEGF antagonist of the pharmaceutical pack are
formulated together.
[0034] In some particular embodiments, the pharmaceutical pack of
the invention includes a VEGF antagonist that is an aptamer, such
as an EYE001 aptamer. In other embodiments, the pharmaceutical pack
of the invention includes a VEGF antagonist that is an antibody or
binding fragment thereof.
[0035] In some embodiments, the pharmaceutical pack of the
invention includes a PDGF antagonist that is an antibody or binding
fragment thereof. In other particular embodiment, the
pharmaceutical pack of the invention includes a PDGF antagonist
that is an antisense oligonucleotide. In yet another embodiment of
this aspect, the PDGF antagonist and/or the VEGF antagonist are
pro-drugs.
BRIEF DESCRIPTION OF THE DRAWINGS
[0036] FIG. 1 (A) is a schematic representation of the nucleic acid
sequence of a human PDGF-B (GenBank Accession No. X02811) (SEQ ID
NO: 1).
[0037] FIG. 1 (B) is a schematic representation of the amino acid
sequence of a human PDGF-B (GenBank Accession No. CAA26579) (SEQ ID
NO: 2).
[0038] FIG. 1 (C) is a schematic representation of the nucleic acid
sequence of a human PDGF-A (GenBank Accession No. X06374) (SEQ ID
NO: 11).
[0039] FIG. 1 (D) is a schematic representation of the polypeptide
sequence of a human PDGF-A (GenBank Accession No. CAA29677) (SEQ ID
NO: 12).
[0040] FIG. 2 (A) is a schematic representation of the nucleic acid
sequence of a human VEGF (GenBank Accession No: NM.sub.--003376)
(SEQ ID NO: 3).
[0041] FIG. 2 (B) is a schematic representation of the amino acid
sequence of a human VEGF polypeptide (GenBank Accession No.
NP.sub.--003367) (SEQ ID NO: 4).
[0042] FIG. 3 (A) is a schematic representation of the nucleic acid
sequence of a human PDGFR-B (GenBank Accession No. NM.sub.--002609)
(SEQ ID NO: 5).
[0043] FIG. 3 (B) is a schematic representation of the polypeptide
sequence of a human PDGFR-B (GenBank Accession No. NP.sub.--002600)
(SEQ ID NO: 6).
[0044] FIG. 3 (C) is a schematic representation of the nucleic acid
sequence of a human PDGFR-A (GenBank Accession No. NM.sub.--006206)
(SEQ ID NO: 13).
[0045] FIG. 3 (D) is a schematic representation of the polypeptide
sequence of a human PDGFR-A (GenBank Accession No. NP.sub.--006197)
(SEQ ID NO: 14).
[0046] FIG. 4 (A) is a schematic representation of the nucleic acid
sequence of a human VEGFR-1 (Fit-1) (GenBank Accession No.
AF063657) (SEQ ID NO: 7).
[0047] FIG. 4 (B) is schematic a representation of the polypeptide
sequence of a human VEGFR-1 (Flt-1) (GenBank Accession No.) (SEQ ID
NO: 8).
[0048] FIG. 4 (C) is a schematic representation of the nucleic acid
sequence of a human VEGFR-2 (ICDR/Flk-1) (GenBank Accession No.
AF035121) (SEQ ID NO: 9).
[0049] FIG. 4 (D) is a schematic representation of the polypeptide
sequence of a human VEGFR-2 (KDR/Flk-1) (GenBank Accession No.
AAB88005) (SEQ ID NO: 10).
[0050] FIG. 5 is a graphical representation of the results of a
corneal neovascularization assay comparing a control treatment
(cont), Gleevec treatment (an anti-PDGF agent), and Macugen.TM.
treatment (i.e. pegaptanib treatment, an anti-VEGF agent), to the
results of a combination treatment with Macugen.TM. and Gleevec
(anti-PDGF/anti-VEGF combination therapy).
[0051] FIG. 6 (A) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in control (PEG-treated) mouse cornea.
[0052] FIG. 6 (B) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in a Gleevec-treated mouse cornea.
[0053] FIG. 6 (C) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in a Macugen.TM.-treated mouse cornea.
[0054] FIG. 6 (D) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in a mouse cornea treated with both Macugen.TM. and
Gleevec.
[0055] FIG. 7 (A) is a photographic representation of a
fluorescent-microscopic image showing that normal corneal
vasculature is unaffected by administration of APB5 (PDGFR
antibody, an anti-PDGF agent).
[0056] FIG. 7 (B) is a photographic representation of a
fluorescent-microscopic image showing that normal corneal
vasculature is unaffected by administration of Gleevec.
[0057] FIG. 7 (C) is a photographic representation of a
fluorescent-microscopic image showing that normal corneal
vasculature is unaffected by administration of Macugen.TM. (Mac)
and Gleevec together.
[0058] FIG. 7 (D) is a photographic representation of a
fluorescent-microscopic image showing that normal corneal
vasculature is unaffected by administration of PEG.
[0059] FIG. 8 is a graphical representation of the results of a
laser-induced choroidal neovascularization assay comparing a
control treatment (cont), Gleevec treatment (an anti-PDGF agent),
and Macugen.TM. treatment (i.e. pegaptanib treatment, an anti-VEGF
agent), to the results of a combination treatment with Macugen.TM.
and Gleevec (anti-PDGF/anti-VEGF combination therapy).
[0060] FIG. 9 is a graphical representation of the results of a
laser-induced choroidal neovascularization assay comparing a
control-treated (cant), APB5-treated (an anti-PGFR antibody, which
acts as an anti-PDGF agent), and Macugen treatment (i.e. pegaptanib
treatment, an anti-VEGF aptamer), to the results of a combination
treatment with Macugen and APB5 (Mac+APB5).
[0061] FIG. 10 is a graphical representation of the results of a
retinal developmental model comparing a control treatment (cont),
ARC-127 treatment (an anti-PDGF agent), and Macugen treatment (i.e.
pegaptanib treatment, an anti-VEGF agent), to the results of a
combination treatment with Macugen and ARC-127 (anti-PDGF/anti-VEGF
combination therapy).
[0062] FIG. 11 is a graphical representation of the results of a
corneal neovascularization assay comparing a control treatment
(cont), ARC-127 treatment (an anti-PDGF agent), and Macugen
treatment (i.e. pegaptanib treatment, an anti-VEGF agent), to the
results of a combination treatment with Macugen and ARC-127
(anti-PDGF/anti-VEGF combination therapy).
[0063] FIG. 12 (A) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in control mouse cornea.
[0064] FIG. 12 (B) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in a ARC-127-treated mouse cornea.
[0065] FIG. 12 (C) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in a Macugen-treated mouse cornea.
[0066] FIG. 12 (D) is a photographic representation of a
fluorescent-microscopic image of corneal neovascularization
occurring in a mouse cornea treated with both Macugen and
ARC-127.
[0067] FIG. 13 is a graphical representation of the results of a
corneal neovascularization assay comparing a control treatment
(cont), APB-5 treatment (an anti-PDGF agent), and Macugen treatment
(i.e. pegaptanib treatment, an anti-VEGF agent), to the results of
a combination treatment with Macugen and APB-5 (anti-PDGF/anti-VEGF
combination therapy).
[0068] FIG. 14 is a graphical representation of the results of a
corneal neovascularization assay comparing a control treatment
(cont), APB-5 treatment (an anti-PDGF agent), and Macugen treatment
(i.e. pegaptanib treatment, an anti-VEGF agent), to the results of
a combination treatment with Macugen and APB-5 (anti-PDGF/anti-VEGF
combination therapy).
DETAILED DESCRIPTION OF THE INVENTION
[0069] All publications, patents, and patent applications mentioned
in this specification are herein incorporated by reference.
Definitions
[0070] As used herein, the following terms and phrases shall have
the meanings set forth below. Unless defined otherwise, all
technical and scientific terms used herein have the same meaning as
commonly understood to one of ordinary skill in the art to which
this invention belongs.
[0071] By "antagonist" is meant an agent that inhibits, either
partially or fully, the activity or production of a target
molecule. In particular, the term "antagonist," as applied
selectively herein, means an agent capable of decreasing levels of
PDGF, PDGFR, VEGF or VEGFR gene expression, mRNA levels, protein
levels or protein activity. Exemplary forms of antagonists include,
for example, proteins, polypeptides, peptides (such as cyclic
peptides), antibodies or antibody fragments, peptide mimetics,
nucleic acid molecules, antisense molecules, ribozymes, aptamers,
RNAi molecules, and small organic molecules. Exemplary non-limiting
mechanisms of antagonist inhibition of the VEGF/VEGFR and
PDGF/PDGFR ligand/receptor targets include repression of ligand
synthesis and/or stability (e.g., using, antisense, ribozymes or
RNAi compositions targeting the ligand gene/nucleic acid), blocking
of binding of the ligand to its cognate receptor (e.g., using
anti-ligand aptamers, antibodies or a soluble, decoy cognate
receptor), repression of receptor synthesis and/or stability (e.g.,
using, antisense, ribozymes or RNAi compositions targeting the
ligand receptor gene/nucleic acid), blocking of the binding of the
receptor to its cognate receptor (e.g., using receptor antibodies)
and blocking of the activation of the receptor by its cognate
ligand (e.g., using receptor tyrosine kinase inhibitors). In
addition, the antagonist may directly or indirectly inhibit the
target molecule.
[0072] The term "antibody" as used herein is intended to include
whole antibodies, e.g., of any isotype (IgG, IgA, IgM, IgE, etc.),
and includes fragments thereof which recognize and are also
specifically reactive with vertebrate (e.g., mammalian) protein,
carbohydrates, etc. Antibodies can be fragmented using conventional
techniques and the fragments screened for utility in the same
manner as described above for whole antibodies. Thus, the term
includes segments of proteolytically cleaved or
recombinantly-prepared portions of an antibody molecule that are
capable of selectively reacting with a certain protein.
Non-limiting examples of such proteolytic and/or recombinant
fragments include Fab, F(ab').sub.2, Fab', Fv, and single chain
antibodies (scFv) containing a V[L] and/or V[H] domain joined by a
peptide linker. The scFv's may be covalently or noncovalently
linked to form antibodies having two or more binding sites. The
subject invention includes polyclonal, monoclonal, or other
purified preparations of antibodies and recombinant antibodies.
[0073] The term "aptamer," used herein interchangeably with the
term "nucleic acid ligand," means a nucleic acid that, through its
ability to adopt a specific three dimensional conformation, binds
to and has an antagonizing (i.e., inhibitory) effect on a target.
The target of the present invention is PDGF or VEGF (or one of
their cognate receptors PDGFR or VEGFR), and hence the term PDGF
aptamer or nucleic acid ligand or VEGF aptamer or nucleic acid
ligand (or PDGFR aptamer or nucleic acid ligand or VEGFR aptamer or
nucleic acid ligand) is used. Inhibition of the target by the
aptamer may occur by binding of the target, by catalytically
altering the target, by reacting with the target in a way which
modifies/alters the target or the functional activity of the
target, by covalently attaching to the target as in a suicide
inhibitor, by facilitating the reaction between the target and
another molecule. Aptamers may be comprised of multiple
ribonucleotide units, deoxyribonucleotide units, or a mixture of
both types of nucleotide residues. Aptamers may further comprise
one or more modified bases, sugars or phosphate backbone units as
described in further detail herein.
[0074] By "antibody antagonist" is meant an antibody molecule as
herein defined which is able to block or significantly reduce one
or more activities of a target PDGF or VEGF. For example, an VEGF
inhibitory antibody may inhibit or reduce the ability of VEGF to
stimulate angiogenesis.
[0075] A nucleotide sequence is "complementary" to another
nucleotide sequence if each of the bases of the two sequences
matches, i.e., are capable of forming Watson Crick base pairs. The
term "complementary strand" is used herein interchangeably with the
term "complement." The complement of a nucleic acid strand can be
the complement of a coding strand or the complement of a non-coding
strand.
[0076] The phrases "conserved residue" "or conservative amino acid
substitution" refer to grouping of amino acids on the basis of
certain common properties. A functional way to define common
properties between individual amino acids is to analyze the
normalized frequencies of amino acid changes between corresponding
proteins of homologous organisms. According to such analyses,
groups of amino acids may be defined where amino acids within a
group exchange preferentially with each other, and therefore
resemble each other most in their impact on the overall protein
structure (Schulz, G. E. and R. H. Schirmer, Principles of Protein
Structure, Springer-Verlag). Examples of amino acid groups defined
in this manner include:
(i) a charged group, consisting of Glu and Asp, Lys, Arg and His,
(ii) a positively-charged group, consisting of Lys, Arg and His,
(iii) a negatively-charged group, consisting of Glu and Asp, (iv)
an aromatic group, consisting of Phe, Tyr and Trp, (v) a nitrogen
ring group, consisting of His and Trp, (vi) a large aliphatic
nonpolar group, consisting of Val, Leu and lie, (vii) a
slightly-polar group, consisting of Met and Cys, (viii) a
small-residue group, consisting of Ser, Thr, Asp, Asn, Gly, Ala,
Glu, Gln and Pro, (ix) an aliphatic group consisting of Val, Leu,
Ile, Met and Cys, and (x) a small hydroxyl group consisting of Ser
and Thr.
[0077] In addition to the groups presented above, each amino acid
residue may form its own group, and the group formed by an
individual amino acid may be referred to simply by the one and/or
three letter abbreviation for that amino acid commonly used in the
art.
[0078] The term "interact" as used herein is meant to include
detectable relationships or association (e.g., biochemical
interactions) between molecules, such as interaction between
protein-protein, protein-nucleic acid, nucleic acid-nucleic acid,
and protein-small molecule or nucleic acid-small molecule in
nature.
[0079] The term "interacting protein" refers to protein capable of
interacting, binding, and/or otherwise associating to a protein of
interest, such as for example a PDGF or a VEGF protein, or their
corresponding cognate receptors.
[0080] The term "isolated" as used herein with respect to nucleic
acids, such as DNA or RNA, refers to molecules separated from other
DNAs, or RNAs, respectively that are present in the natural source
of the macromolecule. Similarly the term "isolated" as used herein
with respect to polypeptides refers to protein molecules separated
from other proteins that are present in the source of the
polypeptide. The term isolated as used herein also refers to a
nucleic acid or peptide that is substantially free of cellular
material, viral material, or culture medium when produced by
recombinant DNA techniques, or chemical precursors or other
chemicals when chemically synthesized.
[0081] "Isolated nucleic acid" is meant to include nucleic acid
fragments, which are not naturally occurring as fragments and would
not be found in the natural state. The term "isolated" is also used
herein to refer to polypeptides, which are isolated from other
cellular proteins and is meant to encompass both purified and
recombinant polypeptides.
[0082] As used herein, the terms "label" and "detectable label"
refer to a molecule capable of detection, including, but not
limited to, radioactive isotopes, fluorophores, chemiluminescent
moieties, enzymes, enzyme substrates, enzyme cofactors, enzyme
inhibitors, dyes, metal ions, ligands (e.g., biotin or haptens) and
the like. The term "fluorescer" refers to a substance or a portion
thereof, which is capable of exhibiting fluorescence in the
detectable range. Particular examples of labels which may be used
under the invention include fluorescein, rhodamine, dansyl,
umbelliferone, Texas red, luminol, NADPH, alpha-beta-galactosidase
and horseradish peroxidase.
[0083] The "level of expression of a gene in a cell" refers to the
level of mRNA, as well as pre-mRNA nascent transcript(s),
transcript processing intermediates, mature mRNA(s) and degradation
products, encoded by the gene in the cell, as well as the level of
protein translated from that gene.
[0084] As used herein, the term "nucleic acid" refers to
polynucleotides such as deoxyribonucleic acid (DNA), and, where
appropriate, ribonucleic acid (RNA). The term should also be
understood to include, as equivalents, analogs of either RNA or DNA
made from nucleotide analogs, and, as applicable to the embodiment
being described, single (sense or antisense) and double-stranded
polynucleotides, ESTs, chromosomes, cDNAs, mRNAs, and rRNAs are
representative examples of molecules that may be referred to as
nucleic acids.
[0085] The term "oligonucleotide" refers to an oligomer or polymer
of nucleotide or nucleoside monomers consisting of naturally
occurring bases, sugars and intersugar (backbone) linkages. The
term also includes modified or substituted oligomers comprising
non-naturally occurring monomers or portions thereof, which
function similarly. Incorporation of substituted oligomers is based
on factors including enhanced cellular uptake, or increased
nuclease resistance and are chosen as is known in the art. The
entire oligonucleotide or only portions thereof may contain the
substituted oligomers.
[0086] The term "percent identical" refers to sequence identity
between two amino acid sequences or between two nucleotide
sequences. Identity can each be determined by comparing a position
in each sequence, which may be aligned for purposes of comparison.
When an equivalent position in the compared sequences is occupied
by the same base or amino acid, then the molecules are identical at
that position; when the equivalent site occupied by the same or a
similar amino acid residue (e.g., similar in steric and/or
electronic nature), then the molecules can be referred to as
homologous (similar) at that position. Expression as a percentage
of homology, similarity, or identity refers to a function of the
number of identical or similar amino acids at positions shared by
the compared sequences. Various alignment algorithms and/or
programs may be used, including Hidden Markov Model (HMM), FASTA
and BLAST, HNiM, FASTA and BLAST are available through the National
Center for Biotechnology Information, National Library of Medicine,
National Institutes of Health, Bethesda, Md. and the European
Bioinformatic Institute EBI. In one embodiment, the percent
identity of two sequences that can be determined by these GCG
programs with a gap weight of 1, e.g., each amino acid gap is
weighted as if it were a single amino acid or nucleotide mismatch
between the two sequences. Other techniques for alignment are
described in Methods in Enzymology, vol. 266: Computer Methods for
Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic
Press, Inc., a division of Harcourt Brace & Co., San Diego,
Calif., USA. Where desirable, an alignment program that permits
gaps in the sequence is utilized to align the sequences. The Smith
Waterman is one type of algorithm that permits gaps in sequence
alignments (see (1997) Meth. Mol. Biol. 70: 173-187). Also, the GAP
program using the Needleman and Wunsch alignment method can be
utilized to align sequences. More techniques and algorithms
including use of the HMM are described in Sequence Structure and
Databanks: A Practical Approach (2000), ed. Oxford University
Press, Incorporated and in Bioinformatics: Databases and Systems
(1999) ed. Kluwer Academic Publishers. An alternative search
strategy uses MPSRCH software, which runs on a MASPAR computer.
MPSRCH uses a Smith-Watermnan algorithm to score sequences on a
massively parallel computer. This approach improves ability to pick
up distantly related matches, and is especially tolerant of small
gaps and nucleotide sequence errors. Nucleic acid-encoded amino
acid sequences can be used to search both protein and DNA
databases. Databases with individual sequences are described in
Methods in Enzymology, ed. Doolittle, supra. Databases include
Genbank, EMBL, and DNA Database of Japan (DDBJ).
[0087] "Perfectly matched" in reference to a duplex means that the
poly- or oligonucleotide strands making up the duplex form a double
stranded structure with one other such that every nucleotide in
each strand undergoes Watson-Crick basepairing with a nucleotide in
the other strand. The term also comprehends the pairing of
nucleoside analogs, such as deoxyinosine, nucleosides with
2-aminopurine bases, and the like, that may be employed. A mismatch
in a duplex between a target polynucleotide and an oligonucleotide
or polynucleotide means that a pair of nucleotides in the duplex
fails to undergo Watson-Crick bonding. In reference to a triplex,
the term means that the triplex consists of a perfectly matched
duplex and a third strand in which every nucleotide undergoes
Hoogsteen or reverse Hoogsteen association with a base pair of the
perfectly matched duplex.
[0088] The term "RNA interference," "RNAi," or "siRNA" all refer to
any method by which expression of a gene or gene product is
decreased by introducing into a target cell one or more
double-stranded RNAs, which are homologous to the gene of interest
(particularly to the messenger RNA of the gene of interest, e.g.,
PDGF or VEGF).
[0089] Polymorphic variants also may encompass "single nucleotide
polymorphisms" (SNPs) in which the polynucleotide sequence varies
by one base (e.g., a one base variation in PDGF or VEGF). The
presence of SNPs may be indicative of, for example, a certain
population, a disease state, or a propensity for a disease
state.
[0090] The "profile" of an aberrant, e.g., tumor cell's biological
state refers to the levels of various constituents of a cell that
change in response to the disease state. Constituents of a cell
include levels of RNA, levels of protein abundances, or protein
activity levels.
[0091] The term "protein" is used interchangeably herein with the
terms "peptide" and "polypeptide." The term "recombinant protein"
refers to a protein of the present invention which is produced by
recombinant DNA techniques, wherein generally DNA encoding the
expressed protein or RNA is inserted into a suitable expression
vector which is in turn used to transform a host cell to produce
the heterologous protein or RNA. Moreover, the phrase "derived
from." with respect to a recombinant gene encoding the recombinant
protein is meant to include within the meaning of "recombinant
protein" those proteins having an amino acid sequence of a native
protein, or an amino acid sequence similar thereto which is
generated by mutations, including substitutions and deletions, of a
naturally occurring protein.
[0092] As used herein, the term "transgene" means a nucleic acid
sequence (encoding, e.g., one of the target nucleic acids, or an
antisense transcript thereto), which has been introduced into a
cell. A transgene could be partly or entirely heterologous, i.e.,
foreign, to the transgenic animal or cell into which it is
introduced, or, is homologous to an endogenous gene of the
transgenic animal or cell into which it is introduced, but which is
designed to be inserted, or is inserted, into the animal's genome
in such a way as to alter the genome of the cell into which it is
inserted (e.g., it is inserted at a location which differs from
that of the natural gene or its insertion results in a knockout). A
transgene can also be present in a cell in the form of an episome.
A transgene can include one or more transcriptional regulatory
sequences and any other nucleic acid, such as introns, that may be
necessary for optimal expression of a selected nucleic acid.
[0093] By "neovascular disorder" is meant a disorder characterized
by altered or unregulated angiogenesis other than one accompanying
oncogenic or neoplastic transformation, i.e., cancer. Examples of
neovascular disorders include psoriasis, rheumatoid arthritis, and
ocular neovascular disorders including diabetic retinopathy and
age-related macular degeneration.
[0094] As used herein, the terms "neovascularization" and
"angiogenesis" are used interchangeably. Neovascularization and
angiogenesis refer to the generation of new blood vessels into
cells, tissue, or organs. The control of angiogenesis is typically
altered in certain disease states and, in many cases, the
pathological damage associated with the disease is related to
altered, unregulated, or uncontrolled angiogenesis. Persistent,
unregulated angiogenesis occurs in a multiplicity of disease
states, including those characterized by the abnormal growth by
endothelial cells, and supports the pathological damage seen in
these conditions including leakage and permeability of blood
vessels.
[0095] By "ocular neovascular disorder" is meant a disorder
characterized by altered or unregulated angiogenesis in the eye of
a patient. Exemplary ocular neovascular disorders include optic
disc neovascularization, iris neovascularization, retinal
neovascularization, choroidal neovascularization, corneal
neovascularization, vitreal neovascularization, glaucoma, pannus,
pterygium, macular edema, diabetic retinopathy, diabetic macular
edema, vascular retinopathy, retinal degeneration, uveitis,
inflammatory diseases of the retina, and proliferative
vitreoretinopathy.
[0096] The term "treating" a neovascular disease in a subject or
"treating" a subject having a neovascular disease refers to
subjecting the subject to a pharmaceutical treatment, e.g., the
administration of a drug, such that at least one symptom of the
neovascular disease is decreased. Accordingly, the term "treating"
as used herein is intended to encompass curing as well as
ameliorating at least one symptom of the neovascular condition or
disease. Accordingly, "treating" as used herein, includes
administering or prescribing a pharmaceutical composition for the
treatment or prevention of an ocular neovascular disorder.
[0097] By "patient" is meant any animal. The term "animal" includes
mammals, including, but is not limited to, humans and other
primates. The term also includes domesticated animals, such as
cows, hogs, sheep, horses, dogs, and cats.
[0098] By "PDGF" or "platelet-derived growth factor" is meant a
mammalian platelet-derived growth factor that affects angiogenesis
or an angiogenic process. As used herein, the term "PDGF" includes
the various subtypes of PDGF including PDGF-B (see FIGS. 1(A) and
(B)), and PDGF-A (see FIGS. 1(C) and (D)). Further, as used herein,
the term "PDGF" refers to PDGF-related angiogenic factors such as
PDGF-C and PDGF-D that act through a cognate PDGF receptor to
stimulate angiogenesis or an angiogenic process. In particular, the
term "PDGF" means any member of the class of growth factors that
(i) bind to a PDGF receptor such as PDGFR-B (see FIGS. 3 (A) and
(B)), or PDGFR-A (see FIGS. 3 (C) and (D)); (ii) activates a
tyrosine kinase activity associated with the VEGF receptor; and
(iii) thereby affects angiogenesis or an angiogenic process. As
used herein, the term "PDGF" generally refers to those members of
the class of growth factors that induce DNA synthesis and
mitogenesis through the binding and activation of a
platelet-derived growth factor cell surface receptor (i.e., PDGFR)
on a responsive cell type. PDGFs effect specific biological effects
including, for example: directed cell migration (chemotaxis) and
cell activation; phospholipase activation; increased
phosphatidylinositol turnover and prostaglandin metabolism;
stimulation of both collagen and collagenase synthesis by
responsive cells; alteration of cellular metabolic activities,
including matrix synthesis, cytokine production, and lipoprotein
uptake; induction, indirectly, of a proliferative response in cells
lacking PDGF receptors; and potent vasoconstrictor activity. The
term "PDGF" is meant to include both a "PDGF" polypeptide and its
corresponding "PDGF" encoding gene or nucleic acid.
[0099] By "PDGF-A" is meant an A chain polypeptide of PDGF and its
corresponding encoding gene or nucleic acid.
[0100] By "PDGF-B" is meant a B chain polypeptide of PDGF and its
corresponding encoding gene or nucleic acid.
[0101] By "VEGF," or "vascular endothelial growth factor," is meant
a mammalian vascular endothelial growth factor that affects
angiogenesis or an angiogenic process. As used herein, the term
"VEGF" includes the various subtypes of VEGF (also known as
vascular permeability factor (VPF) and VEGF-A) (see FIGS. 2(A) and
(B)) that arise by, e.g., alternative splicing of the VEGF-A/VPF
gene including VEGF.sub.121, VEGF.sub.165 and VEGF.sub.189.
Further, as used herein, the term "VEGF" refers to VEGF-related
angiogenic factors such as PIGF (placenta growth factor), VEGF-B,
VEGF-C, VEGF-D and VEGF-E that act through a cognate VEFG receptor
to stimulate angiogenesis or an angiogenic process. In particular,
the term "VEGF" means any member of the class of growth factors
that (i) bind to a VEGF receptor such as VEGFR-1 (Flt-1) (see FIGS.
4(A) and (B)). VEGFR-2 (KDR/Flk-1) (see FIGS. 4(C) and (D)), or
VEGFR-3 (FLT-4); (ii) activates a tyrosine kinase activity
associated with the VEGF receptor; and (iii) thereby affects
angiogenesis or an angiogenic process. The term "VEGF" is meant to
include both a "VEGF" polypeptide and its corresponding "VEGF"
encoding gene or nucleic acid.
[0102] By "PDGF antagonist" is meant an agent that reduces, or
inhibits, either partially or fully, the activity or production of
a PDGF. A PDGF antagonist may directly or indirectly reduce or
inhibit a specific PDGF such as PDGF-B. Furthermore, "PDGF
antagonists" consistent with the above definition of"antagonist,"
may include agents that act on either a PDGF ligand or its cognate
receptor so as to reduce or inhibit a PDGF-associated receptor
signal. Examples of such "PDGF antagonists" thus include, for
example: antisense, ribozymes or RNAi compositions targeting a PDGF
nucleic acid; anti-PDGF aptamers, anti-PDGF antibodies or soluble
PDGF receptor decoys that prevent binding of a PDGF to its cognate
receptor; antisense, ribozymes or RNAi compositions targeting a
cognate PDGF receptor (PDGFR) nucleic acid; anti-PDGFR aptamers or
anti-PDGFR antibodies that bind to a cognate PDGFR receptor; and
PDGFR tyrosine kinase inhibitors.
[0103] By "VEGF antagonist" is meant an agent that reduces, or
inhibits, either partially or fully, the activity or production of
a VEGF. A VEGF antagonist may directly or indirectly reduce or
inhibit a specific VEGF such as VEGF.sub.165. Furthermore, "VEGF
antagonists" consistent with the above definition of"antagonist,"
may include agents that act on either a VEGF ligand or its cognate
receptor so as to reduce or inhibit a VEGF-associated receptor
signal. Examples of such "VEGF antagonists" thus include, for
example: antisense, ribozymes or RNAi compositions targeting a VEGF
nucleic acid; anti-VEGF aptamers, anti-VEGF antibodies or soluble
VEGF receptor decoys that prevent binding of a VEGF to its cognate
receptor, antisense, ribozymes, or RNAi compositions targeting a
cognate VEGF receptor (VEGFR) nucleic acid; anti-VEGFR aptamers or
anti-VEGFR antibodies that bind to a cognate VEGFR receptor; and
VEGFR tyrosine kinase inhibitors.
[0104] By "an amount sufficient to suppress a neovascular disorder"
is meant the effective amount of an antagonist, in a combination of
the invention, required to treat or prevent a neovascular disorder
or symptom thereof. The "effective amount" of active antagonists
used to practice the present invention for therapeutic treatment of
conditions caused by or contributing to the neovascular disorder
varies depending upon the manner of administration, anatomical
location of the neovascular disorder, the age, body weight, and
general health of the patient. Ultimately, a physician or
veterinarian will decide the appropriate amount and dosage regimen.
Such amount is referred to as an amount sufficient to suppress a
neovascular disorder.
[0105] Other features and advantages of the invention will be
apparent from the following detailed description, and from the
claims.
[0106] A "variant" of polypeptide X refers to a polypeptide having
the amino acid sequence of peptide X in which is altered in one or
more amino acid residues. The variant may have "conservative"
changes, wherein a substituted amino acid has similar structural or
chemical properties (e.g., replacement of leucine, with
isoleucine). More rarely, a variant may have "nonconservative"
changes (e.g., replacement of glycine with tryptophan). Analogous
minor variations may also include amino acid deletions or
insertions, or both. Guidance in determining which amino acid
residues may be substituted, inserted, or deleted without
abolishing biological or immunological activity may be found using
computer programs well known in the art, for example, LASERGENE
software (DNASTAR).
[0107] The term "variant," when used in the context of a
polynucleotide sequence, may encompass a polynucleotide sequence
related to that of gene or the coding sequence thereof. This
definition may also include, for example, "allelic," "splice,"
"species," or "polymorphic" variants. A splice variant may have
significant identity to a reference molecule, but will generally
have a greater or lesser number of polynucleotides due to
alternative splicing of exons during mRNA processing. The
corresponding polypeptide may possess additional functional domains
or an absence of domains. Species variants are polynucleotide
sequences that vary from one species to another. The resulting
polypeptides generally will have significant amino acid identity
relative to each other. A polymorphic variant is a variation in the
polynucleotide sequence of a particular gene between individuals of
a given species.
[0108] The term "vector" refers to a nucleic acid molecule capable
of transporting another nucleic acid to which it has been linked.
One type of useful vector is an episome, i.e., a nucleic acid
capable of extra-chromosomal replication. Useful vectors are those
capable of autonomous replication and/or expression of nucleic
acids to which they are linked. Vectors capable of directing the
expression of genes to which they are operatively linked are
referred to herein as "expression vectors". In general, expression
vectors of utility in recombinant DNA techniques are often in the
form of "plasmids" which refer generally to circular double
stranded DNA loops which, in their vector form are not bound to the
chromosome. In the present specification, "plasmid" and "vector"
are used interchangeably as the plasmid is the most commonly used
form of vector. However, the invention is intended to include such
other forms of expression vectors which serve equivalent functions
and which become known in the art subsequently hereto.
[0109] Combination Therapy
[0110] The invention is based, in part, upon the specific
inhibition of both VEGF and PDGF activities using appropriate
growth factor antagonists as a potent treatment for patients having
a neovascular disorder. The administration of a combination of a
PDGF antagonist and a VEGF antagonist affords greater therapeutic
benefits for treating an ocular neovascular disorder than either
antagonist administered alone. The combined action of anti-VEGF and
anti-PDGF agents is unexpected in light of studies evidencing no
apparent cooperation between the two factors in stimulating
angiogenesis in a retinal endothelial cell system (see Castellon et
al., (2001) Exp. Eye Res. 74: 523-35).
[0111] PDGF and VEGF are important stimuli for the growth of new
blood vessels throughout the body, especially in the eye.
Combination therapy directed at inhibiting both PDGF and VEGF
biological activities provides a method for treating or preventing
the neovascular disorder.
[0112] Accordingly, the invention features methods and compositions
for suppressing a neovascular disorder using combination therapy.
In particular, the present invention utilizes two distinct
intercellular communication signaling pathways operative in
vascular cells, namely PDGF and VEGF signaling, as therapeutic
targets in the treatment of a neovascular disorder, such as an
ocular neovascular disorder. This combination method is especially
useful for treating any number of ophthamalogical diseases and
disorders marked by the development of ocular neovascularization,
including, but not limited to, optic disc neovascularization, iris
neovascularization, retinal neovascularization, choroidal
neovascularization, corneal neovascularization, vitreal
neovascularization, glaucoma, pannus, pterygium, macular edema,
diabetic macular edema, vascular retinopathy, retinal degeneration,
macular degeneration, uveitis, inflammatory diseases of the retina,
and proliferative vitreoretinopathy. The combination therapy,
consisting of antagonists that inhibit PDGF (such as PDGF-B) and
VEGF (such as VEGF-A) signaling results in an increased treatment
efficacy compared to either of the two therapies being used
independently. While the examples discussed below describe the
combination of a single PDGF antagonist and a single VEGF
antagonist, it is understood that the combination of multiple
antagonistic agents may be desirable.
[0113] Anti-PDGF and anti-VEGF combination therapy according to the
invention may be performed alone or in conjunction with another
therapy and may be provided at home, the doctor's office, a clinic,
a hospital's outpatient department, or a hospital. Treatment
generally begins at a hospital so that the doctor can observe the
therapy's effects closely and make any adjustments that are needed.
The duration of the combination therapy depends on the type of
neovascular disorder being treated, the age and condition of the
patient, the stage and type of the patient's disease, and how the
patient responds to the treatment. Additionally, a person having a
greater risk of developing a neovascular disorder (e.g., a diabetic
patient) may receive treatment to inhibit or delay the onset of
symptoms. One significant advantage provided by the present
invention is that the combination of a PDGF antagonist and a VEGF
antagonist for the treatment of a neovascular disorder allows for
the administration of a low dose of each antagonist and less total
active antagonist, thus providing similar efficacy with less
toxicity and side effects, and reduced costs.
[0114] The dosage and frequency of administration of each component
of the combination can be controlled independently. For example,
one antagonist may be administered three times per day, while the
second antagonist may be administered once per day. Combination
therapy may be given in on-and-off cycles that include rest periods
so that the patient's body has a chance to recover from any as yet
unforeseen side-effects. The antagonists may also be formulated
together such that one administration delivers both
antagonists.
[0115] PDGF and VEGF Antagonist Targets
[0116] PDGF was originally isolated from platelet lysates and
identified as the major growth-promoting activity present in serum
but not in plasma. The mitogenic activity of PDGF was first shown
to act on connective tissue cells, such as fibroblasts and smooth
muscle cells, and in glial cells in culture. Two homologous PDGF
isoforms have been identified, PDGF A and B, which are encoded by
separate genes (on chromosomes 7 and 22). The most abundant species
from platelets is the AB heterodimer, although all three possible
dimers (AA, AB and BB) occur naturally. Following translation, PDGF
dimers are processed into approximately 30 kDa secreted
proteins.
[0117] Two cell surface proteins that bind PDGF with high affinity
have been identified, alpha. and beta. (Heldin et al., (1981) Proc.
Natl. Acad. Sci. (USA) 78: 3664; Williams et al., (1981) Proc.
Natl. Acad. Sci. (USA) 79: 5867). Both species contain five
immunoglobulin-like extracellular domains, a single transmembrane
domain and an intracellular tyrosine kinase domain separated by a
kinase insert domain. In the last several years, the specificities
of the three PDGF isoforms for the three receptor dimers
(alpha/alpha, alpha/beta, and beta/beta.) have been elucidated. The
alpha-receptor homodimer binds all three PDGF isoforms with high
affinity, the beta-receptor homodimer binds only PDGF BB with high
affinity and PDGF AB with approximately 10-fold lower affinity, and
the alpha/beta.-receptor heterodimer binds PDGF BB and PDGF AB with
high affinity (Westermark & Heldin (1993) Acta Oncologica
32:101). The specificity pattern appears to result from the ability
of the A-chain to bind only to the alpha-receptor and of the
B-chain to bind to both alpha and beta-receptor subunits with high
affinity.
[0118] In general, the invention provides for agents that inhibit
one or more PDGF activities. These PDGF-inhibitory agents, or PDGF
antagonists may act on one or more forms of the PDGF ligand.
Platelet derived growth factors includes homo- or heterodimers of
A-chain (PDGF-A) and B-chain (PDGF-B) that exert their action via
binding to and dimerization of two related receptor tyrosine
kinases, [alpha]-receptors (PDGFR-[alpha]) and [beta]-receptors
(PDGFR-[beta]). In addition, PDGF-C and PDGF-D, two new
protease-activated ligands for the PDGFR complexes, have been
identified (see Li et al., (2000) Nat. Cell. Biol. 2: 302-9;
Bergsten et al., (2001) Nat. Cell. Biol. 3: 512-6; and Uutele et
al., (2001) Circulation 103: 2242-47). Due to the different ligand
binding specificities of the PDGFRs it is known that
PDGFR-[alpha][alpha] binds PDGF-AA, PDGF-BB, PDGF-AB, and PDGF-CC;
PDGFR-[beta][beta] binds PDGF-BB and PDGF-DD; whereas
PDGFR-[alpha][beta] binds PDGF-AB, PDGF-BB, PDGF-CC, and PDGF-DD
(see Betsholtz et al., (2001) BioEssays 23: 494-507).
[0119] VEGF is a secreted disulfide-linked homodimer that
selectively stimulates endothelial cells to proliferate, migrate,
and produce matrix-degrading enzymes (Conn et al., (1990) Proc.
Natl. Acad. Sci. (USA) 87:1323-1327); Ferrara and Henzel (1989)
Biochem. Biophys. Res. Commun. 161: 851-858); Pepper et al., (1991)
Biochem. Biophys. Res. Commun. 181:902-906; Unemori et al., (1992)
J. Cell. Physiol. 153:557-562), all of which are processes required
for the formation of new vessels. VEGF occurs in four forms
(VEGF-121, VEGF-165, VEGF-189, VEGF-206) as a result of alternative
splicing of the VEGF gene (Houck et al., (1991) Mol. Endocrinol.
5:1806-1814; Tischer et al., (1991) J. Biol. Chem.
266:11947-11954). The two smaller forms are diffusible whereas the
larger two forms remain predominantly localized to the cell
membrane as a consequence of their high affinity for heparin.
VEGF-165 also binds to heparin and is the most abundant form.
VEGF-121, the only form that does not bind to heparin, appears to
have a lower affinity for VEGF receptors (Gitay-Goren et al.,
(1996) J. Biol. Chem. 271:5519-5523) as well as lower mitogenic
potency (Keyt et al., (1996) J. Biol. Chem. 271:7788-7795). The
biological effects of VEGF are mediated by two tyrosine kinase
receptors (Flt-1 and Flk-1/KDR) whose expression is highly
restricted to cells of endothelial origin (de Vries et al., (1992)
Science 255:989-991; Millauer et al., (1993) Cell 72:835-846;
Terman et al., (1991) Oncogene 6:519-524). While the expression of
both functional receptors is required for high affinity binding,
the chemotactic and mitogenic signaling in endothelial cells
appears to occur primarily through the KDR receptor (Park et al.,
(1994) J. Biol. Chem. 269:25646-25654; Seetharam et al., (1995)
Oncogene 10:135-147; Waltenberger et al., (1994) J. Biol. Chem.
26988-26995). The importance of VEGF and VEGF receptors for the
development of blood vessels has recently been demonstrated in mice
lacking a single allele for the VEGF gene (Carmeliet et al., (1996)
Nature 380:435-439; Ferrara et al., (1996) Nature 380:439-442) or
both alleles of the Flt-1 (Fong et al., (1995) Nature 376:66-70) or
Flk-1 genes (Shalaby et al., (1995) Nature 376:62-66). In each
case, distinct abnormalities in vessel formation were observed
resulting in embryonic lethality.
[0120] Compensatory angiogenesis induced by tissue hypoxia is now
known to be mediated by VEGF (Levy et al., (1996) J. Biol. Chem.
2746-2753); Shweiki et al., (1992) Nature 359:843-845). Studies in
humans have shown that high concentrations of VEGF are present in
the vitreous in angiogenic retinal disorders but not in inactive or
non-neovascularization disease states. Human choroidal tissue
excised after experimental submacular surgery have also shown high
VEGF levels.
[0121] In addition to being the only known endothelial cell
specific mitogen. VEGF is unique among angiogenic growth factors in
its ability to induce a transient increase in blood vessel
permeability to macromolecules (hence its original and alternative
name, vascular permeability factor, VPF) (see Dvorak et al., (1979)
J. Immunol. 122:166-174; Senger et al., (1983) Science 219:983-985;
Senger et al., (1986) Cancer Res. 46:5629-5632). Increased vascular
permeability and the resulting deposition of plasma proteins in the
extravascular space assists the new vessel formation by providing a
provisional matrix for the migration of endothelial cells (Dvorak
et al., (1995) Am. J. Pathol. 146:1029-1039). Hyperpermeability is
indeed a characteristic feature of new vessels, including those
associated with tumors.
[0122] PDGF and VEGF Antagonists
[0123] General
[0124] The invention provides antagonists (i.e., inhibitors) of
PDGF and VEGF for use together in combination therapy for
neovascular disorders. Specific PDGF antagonists and VEGF
antagonists are known in the art and are described briefly in the
sections that follow. Still other PDGF antagonists and VEGF
antagonists that are now, or that have become, available to the
skilled artisan include the antibodies, aptamers, antisense
oligomers, ribozymes, and RNAi compositions that may be identified
and produced using practices that are routine in the art in
conjunction with the teachings and guidance of the specification,
including the further-provided sections appearing below.
[0125] PDGF Antagonists
[0126] Generally, inhibition of PDGF (for example, PDGF-B) may be
accomplished in a variety of ways. For example, a variety of PDGF
antagonists that inhibit the activity or production of PDGF are
available and can be used in the methods of the present invention.
Exemplary PDGF antagonists include nucleic acid ligands or aptamers
of PDGF, such as those described below. Alternatively, the PDGF
antagonist may be, for example, an anti-PDGF antibody or antibody
fragment. Accordingly, the PDGF molecule is rendered inactive by
inhibiting its binding to a receptor. In addition, nucleic acid
molecules such as antisense RNA, ribozymes, and RNAi molecules that
inhibit PDGF expression at the nucleic acid level are useful as
antagonists in the invention. Other PDGF antagonists include
peptides, proteins, cyclic peptides, or small organic compounds.
Furthermore, the signaling activity of PDGF may be inhibited by
disrupting its downstream signaling, for example, by using a number
of small molecule tyrosine kinase inhibitory antagonists including
those described below. The ability of a compound or agent to serve
as a PDGF antagonist may be determined according to the methods
known in art and, further, as set forth in, e.g., Dai et al.,
(2001) Genes & Dev. 15: 1913-25; Zippel, et al., (1989) Eur. J.
Cell Biol. 50(2):428-34; and Zwiller, et al., (1991) Oncogene 6:
219-21.
[0127] The invention further includes PDGF antagonists known in the
art as well as those supported below and any and all equivalents
that are within the scope of ordinary skill to create. For example,
inhibitory antibodies directed against PDGF are known in the art,
e.g., those described in U.S. Pat. Nos. 5,976,534, 5,833,986,
5,817,310, 5,882,644, 5,662,904, 5,620,687, 5,468,468, and PCT WO
2003/025019, the contents of which are incorporated by reference in
their entirety. In addition, the invention include
N-phenyl-2-pyrimidine-amine derivatives that are PDGF antagonists,
such as those disclosed in U.S. Pat. No. 5,521,184, as well as
WO2003/013541, WO2003/078404, WO2003/099771, WO2003/015282, and
WO2004/05282 which are hereby incorporated in their entirety by
reference.
[0128] Small molecules that block the action of PDGF are known in
the art, e.g., those described in U.S. Pat. No. 6,528,526 (PDGFR
tyrosine kinase inhibitors), U.S. Pat. No. 6,524,347 (PDGFR
tyrosine kinase inhibitors), U.S. Pat. No. 6,482,834 (PDGFR
tyrosine kinase inhibitors), U.S. Pat. No. 6,472,391 (PDGFR
tyrosine kinase inhibitors), U.S. Pat. Nos. 6,696,434, 6,331,555,
6,251,905, 6,245,760, 6,207,667, 5,990,141, 5,700,822, 5,618,837
and 5,731,326, the contents of which are incorporated by reference
in their entirety.
[0129] Proteins and polypeptides that block the action of PDGF are
known in the art, e.g., those described in U.S. Pat. No. 6,350,731
(PDGF peptide analogs), U.S. Pat. No. 5,952,304, the contents of
which are incorporated by reference in their entirety.
[0130] Bis mono- and bicyclic aryl and heteroaryl compounds which
inhibit EGF and/or PDGF receptor tyrosine kinase are known in the
art, e.g., those described in, e.g. U.S. Pat. Nos. 5,476,851,
5,480,883, 5,656,643, 5,795,889, and 6,057,320, the contents of
which are incorporated by reference in their entirety.
[0131] Antisense oligonucleotides for the inhibition of PDGF are
known in the art, e.g., those described in U.S. Pat. Nos.
5,869,462, and 5,821,234, the contents of each of which are
incorporated by reference in their entirety.
[0132] Aptamers (also known as nucleic acid ligands) for the
inhibition of PDGF are known in the art, e.g., those described in,
e.g., U.S. Pat. Nos. 6,582,918, 6,229,002, 6,207,816, 5,668,264,
5,674,685, and 5,723,594, the contents of each of which are
incorporated by reference in their entirety.
[0133] Other compounds for inhibiting PDGF known in the art include
those described in U.S. Pat. Nos. 5,238,950, 5,418,135, 5,674,892,
5,693,610, 5,700,822, 5,700,823, 5,728,726, 5,795,910, 5,817,310,
5,872,218, 5,932,580, 5,932,602, 5,958,959, 5,990,141, 6,358,954,
6,537,988 and 6,673,798, the contents of each of which are
incorporated by reference in their entirety.
[0134] VEGF Antagonists
[0135] Inhibition of VEGF (for example, VEGF-A) is accomplished in
a variety of ways. For example, a variety of VEGF antagonists that
inhibit the activity or production of VEGF, including nucleic acid
molecules such as aptamers, antisense RNA, ribozymes, RNAi
molecules, and VEGF antibodies, are available and can be used in
the methods of the present invention. Exemplary VEGF antagonists
include nucleic acid ligands or aptamers of VEGF, such as those
described below. A particularly useful antagonist to VEGF-A is
EYE001 (previously referred to as NX1838), which is a modified,
PEGylated aptamer that binds with high and specific affinity to the
major soluble human VEGF isoform (see, U.S. Pat. Nos. 6,011,020;
6,051,698; and 6,147,204). The aptamer binds and inactivates VEGF
in a manner similar to that of a high-affinity antibody directed
towards VEGF. Another useful VEGF aptamer is EYE001 in its
non-pegylated form. Alternatively, the VEGF antagonist may be, for
example, an anti-VEGF antibody or antibody fragment. Accordingly,
the VEGF molecule is rendered inactive by inhibiting its binding to
a receptor. In addition, nucleic acid molecules such as antisense
RNA, ribozymes, and RNAi molecules that inhibit VEGF expression or
RNA stability at the nucleic acid level are useful antagonists in
the methods and compositions of the invention. Other VEGF
antagonists include peptides, proteins, cyclic peptides, and small
organic compound. For example, soluble truncated forms of VEGF that
bind to the VEGF receptor without concomitant signaling activity
also serve as antagonists. Furthermore, the signaling activity of
VEGF may be inhibited by disrupting its downstream signaling, for
example, by using a number of antagonists including small molecule
inhibitors of a VEGF receptor tyrosine kinase activity, as
described further below.
[0136] The ability of a compound or agent to serve as a VEGF
antagonist may be determined according to any number of standard
methods well known in the art. For example, one of the biological
activities of VEGF is to increase vascular permeability through
specific binding to receptors on vascular endothelial cells. The
interaction results in relaxation of the tight endothelial
junctions with subsequent leakage of vascular fluid. Vascular
leakage induced by VEGF can be measured in vivo by following the
leakage of Evans Blue Dye from the vasculature of the guinea pig as
a consequence of an intradermal injection of VEGF (Dvorak et al.,
in Vascular Permeability Factor/Vascular Endothelial Growth Factor
Microvascular Hyperpermeability and Angiogenesis; and (1995) Am. J.
Pathol. 146:1029). Similarly, the assay can be used to measure the
ability of an antagonist to block this biological activity of
VEGF.
[0137] In one useful example of a vascular permeability assay,
VEGF.sub.165 (20-30 nM) is premixed ex vivo with EYE001 (30 nM to 1
.mu.M) or a candidate VEGF antagonist and subsequently administered
by intradermal injection into the shaved skin on the dorsum of
guinea pigs. Thirty minutes following injection, the Evans Blue dye
leakage around the injection sites is quantified according to
standard methods by use of a computerized morphometric analysis
system. A compound that inhibits VEGF-induced leakage of the
indicator dye from the vasculature is taken as being a useful
antagonist in the methods and compositions of the invention.
[0138] Another assay for determining whether a compound is a VEGF
antagonist is the so-called corneal angiogenesis assay. In this
assay, methacyrate polymer pellets containing VEGF.sub.65 (3 pmol)
are implanted into the corneal stroma of rats to induce blood
vessel growth into the normally avascular cornea. A candidate VEGF
antagonist is then administered intravenously to the rats at doses
of 1 mg/kg, 3 mg/kg, and 10 mg/kg either once or twice daily for 5
days. At the end of the treatment period, all of the individual
corneas are photomicrographed. The extent to which new blood
vessels develop in the corneal tissue, and their inhibition by the
candidate compound, are then quantified by standardized
morphometric analysis of the photomicrographs. A compound that
inhibits VEGF-dependent angiogenesis in the cornea when compared to
treatment with phosphate buffered saline (PBS) is taken as being a
useful antagonist in the methods and compositions of the
invention.
[0139] Candidate VEGF antagonists are also identified using the
mouse model of retinopathy of prematurity. In one useful example,
litters of 9, 8, 8, 7, and 7 mice, respectively, are left in room
air or made hyperoxic and are treated intraperitoneally with
phosphate buffered saline (PBS) or a candidate VEGF antagonist (for
example, at 1 mg/kg, 3 mg/kg, or 10 mg/kg/day). The endpoint of the
assay, outgrowth of new capillaries through the inner limiting
membrane of the retina into the vitreous humor, is then assessed by
microscopic identification and counting of the neovascular buds in
20 histologic sections of each eye from all of the treated and
control mice. A reduction in retinal neovasculature in the treated
mice relative to the untreated control is taken as identifying a
useful VEGF antagonist.
[0140] In still another exemplary screening assay, candidate VEGF
antagonists are identified using an in vivo human tumor xenograft
assay. In this screening assay, in vivo efficacy of a candidate
VEGF antagonist is tested in human tumor xenografts (A673
rhabdomyosarcoma and Wilms tumor) implanted in nude mice. Mice are
then treated with the candidate VEGF antagonist (e.g., 10 mg/kg
given intraperitoneally once a day following development of
established tumors (200 mg)). Control groups are treated with a
control agent. Candidate compounds identified as inhibiting A673
rhabdomyosarcorna tumor growth and Wilms tumor relative to the
control are taken as being useful antagonists in the methods and
compositions of the invention.
[0141] Additional methods of assaying for a VEGF antagonist
activity are known in the art and described in further detail
below.
[0142] The invention further includes VEGF antagonists known in the
art as well as those supported below and any and all equivalents
that are within the scope of ordinary skill to create. For example,
inhibitory antibodies directed against VEGF are known in the art,
e.g., those described in U.S. Pat. Nos. 6,524,583, 6,451,764 (VRP
antibodies), U.S. Pat. Nos. 6,448,077, 6,416,758, 6,403,088 (to
VEGF-C), U.S. Pat. No. 6,383,484 (to VEGF-D), U.S. Pat. No.
6,342,221 (anti-VEGF antibodies), U.S. Pat. Nos. 6,342,219
6,331,301 (VEGF-B antibodies), and U.S. Pat. No. 5,730,977, and PCT
publications WO96/30046, WO 97/44453, and WO 98/45331, the contents
of which are incorporated by reference in their entirety. The
invention further provides an anti-VEGF antibody heavy chain
variable domain comprising the amino acid sequence:
EVQLVESGGGLVQPGGSLRLSCAASGYX.sub.1FTX.sub.2YGMNWVRQAPGKGLEWVGWINTYTG
EPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPX.sub.3YYGX.sub.4SHWYFDV
WGQGTLVTVSS (SEQ ID NO: 125 of WO 98/45331) (SEQ ID NO: 28),
wherein X.sub.1 is T or D; X.sub.2, is N or H; X.sub.3 is Y or H
and X.sub.4 is S or T. One particularly useful heavy chain variable
domain sequence is that of the F(ab)-12 humanized antibody of
Example 1 of WO 98/45331 and comprises the heavy chain variable
domain sequence of SEQ ID NO: 7 of WO 98/45331, i.e.,
EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGW
INTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHW
YFDVWGQGTL (SEQ ID NO: 26). Such preferred heavy chain variable
domain sequences may be combined with the following preferred light
chain variable domain sequences or with other light chain variable
domain sequences, provided that the antibody so produced binds
human VEGF. The invention also provides preferred light chain
variable domain sequences which may be combined with the
above-identified heavy chain variable domain sequences or with
other heavy chain variable domain sequences, provided that the
antibody so produced retains the ability to bind to human VEGF. For
example, the light chain variable domain may comprise hypervariable
regions with the following amino acid sequences: CDRL1
(SASQDISNYLN; SEQ ID NO: 4 of WO 98/45331)(SEQ ID NO: 29), CDRL2
(FTSSLHS; SEQ ID NO: 5 of WO 98/45331)(SEQ ID NO: 30) and CDRL3
(QQYSTVPWT; SEQ ID NO: 6 of WO 98/45331)(SEQ ID NO: 31).
Preferably, the three light chain hypervariable regions are
provided in a human framework region, e.g., as a contiguous
sequence represented by the following formula:
FR1-CDRL1-FR2-CDRL2-FR3-CDRL3-FR4. In one embodiment, the invention
provides a humanized anti-VEGF antibody light chain variable domain
comprising the amino acid sequence:
DIQX.sub.1TQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPS
RFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKR (SEQ ID NO: 124 of
WO 98/45331) (SEQ ID NO: 32), wherein X.sub.1 is M or L. One
particularly useful light chain variable domain sequence is that of
the F(ab)-12 humanized antibody of Example 1 of WO98/45331 and
comprises the light chain variable domain sequence of SEQ ID NO: 8
of WO 98/45331, i.e., DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP
GKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQ
GTKVEIKRTV (SEQ ID NO: 27). The invention also provides a variant
of a parent anti-VEGF antibody (which parent antibody is preferably
a humanized or human anti-VEGF antibody), wherein the variant binds
human VEGF and comprises an amino acid substitution in a
hypervariable region of the heavy or light chain variable domain of
the parent anti-VEGF antibody. The variant preferably has one or
more substitution(s) in one or more hypervariable region(s) of the
anti-VEGF antibody. Preferably, the substitution(s) are in the
heavy chain variable domain of the parent antibody. For example,
the amino acid substitution(s) may be in the CDRH1 and/or CDRH3 of
the heavy chain variable domain. Preferably, there are
substitutions in both these hypervariable regions. Such "affinity
matured" variants are demonstrated in WO 98/45331 to bind human
VEGF more strongly than the parent anti-VEGF antibody from which
they are generated, i.e., they have a K.sub.d value which is
significantly less than that of the parent anti-VEGF antibody.
Preferably, the variant has an ED50 value for inhibiting
VEGF-induced proliferation of endothelial cells in vitro which is
at least about 10 fold lower, preferably at least about 20 fold
lower, and most preferably at least about 50 fold lower, than that
of the parent anti-VEGF antibody. One particularly preferred
variant is the Y0317 variant of Example 3 of WO 98/45331, which has
a CDRH1 comprising the amino acid sequence: GYDFTHYGMN (SEQ ID NO:
126 of WO 98/45331) (SEQ ID NO: 33) and a CDRH3 comprising the
amino acid sequence: YPYYYGTSHWYFDV (SEQ ID NO: 127 of WO 98/45331)
(SEQ ID NO: 34). These hypervariable regions and CDRH2 are
generally provided in a human framework region, e.g., resulting in
a heavy chain variable domain comprising the amino acid sequence of
SEQ ID NO: 116 of WO 98/45331, i.e.,
EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGE
PTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWG QGTL (SEQ
ID NO: 24). Such heavy chain variable domain sequences are
optionally combined with a light chain variable domain comprising
the amino acid sequence of SEQ ID NO: 124 of WO 98/45331 (SEQ ID
NO: 32), and preferably the light chain variable domain amino acid
sequence of SEQ ID NO: 115 of WO 98/45331, i.e.,
DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSR
FSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIKRTV (SEQ ID NO:
25).
[0143] Antibodies to VEGF receptors are also known in the art, such
as those described in, for example, U.S. Pat. Nos. 5,840,301,
5,874,542, 5,955,311, 6,365,157, and PCT publication WO 04/003211,
the contents of which are incorporated by reference in their
entirety.
[0144] Small molecules that block the action of VEGF by, e.g.,
inhibiting a VEGFR-associated tyrosine kinase activity, are known
in the art, e.g., those described in U.S. Pat. Nos. 6,514,971,
6,448,277, 6,414,148, 6,362,336, 6,291,455, 6,284,751, 6,177,401,
6,071,921, and 6001,885 (retinoid inhibitors of VEGF expression),
the contents of each of which are incorporated by reference in
their entirety.
[0145] Proteins and polypeptides that block the action of VEGF are
known in the art, e.g., those described in U.S. Pat. Nos.
6,576,608, 6,559,126, 6,541,008, 6,515,105, 6,383,486 (VEGF decoy
receptor), U.S. Pat. No. 6,375,929 (VEGF decoy receptor), U.S. Pat.
No. 6,361,946 (VEFG peptide analog inhibitors), U.S. Pat. No.
6,348,333 (VEGF decoy receptor), U.S. Pat. No. 6,559,126
(polypeptides that bind VEGF and block binding to VEGFR), U.S. Pat.
No. 6,100,071 (VEGF decoy receptor), and U.S. Pat. No. 5,952,199,
the contents of each of which are incorporated by reference in
their entirety.
[0146] Short interfering nucleic acids (siNA), short interfering
RNA (siRNA), double stranded RNA (dsRNA), microRNA (miRNA) and
short hairpin RNA (shRNA) capable of mediating RNA interference
(RNAi) against VEGF and/or VEGFR gene expression and/or activity
are known in the art, for example, as disclosed in PCT publication
WO 03/070910, the contents of which is incorporated by reference in
its entirety.
[0147] Antisense oligonucleotides for the inhibition of VEGF are
known in the art, e.g., those described in, e.g., U.S. Pat. Nos.
5,611,135, 5,814,620, 6,399,586, 6,410,322, and 6,291,667, the
contents of each of which are incorporated by reference in their
entirety.
[0148] Aptamers (also known as nucleic acid ligands) for the
inhibition of VEGF are known in the art, e.g., those described in,
e.g., U.S. Pat. Nos. 6,762,290, 6,426,335, 6,168,778, 6,051,698,
and 5,859,228, the contents of each of which are incorporated by
reference in their entirety.
[0149] Antibody Antagonists
[0150] The invention includes antagonist antibodies directed
against PDGF and VEGF as well as their cognate receptors PDGFR and
VEGFR. The antibody antagonists of the invention block binding of a
ligand with its cognate receptor. Accordingly, a PDGF antagonist
antibody of the invention includes antibodies directed against a
PDGF as well as a PDGFR target.
[0151] The antagonist antibodies of the invention include
monoclonal inhibitory antibodies. Monoclonal antibodies, or
fragments thereof, encompass all immunoglobulin classes such as
IgM, IgG, IgD, IgE, IgA, or their subclasses, such as the IgG
subclasses or mixtures thereof. IgG and its subclasses are useful,
such as IgG.sub.1, IgG.sub.2, IgG.sub.2a, IgG.sub.2b, IgG.sub.3 or
IgG.sub.M. The IgG subtypes IgG.sub.1/kappa, and IgG.sub.2b/kapp
are included as useful embodiments. Fragments which may be
mentioned are all truncated or modified antibody fragments with one
or two antigen-complementary binding sites which show high binding
and neutralizing activity toward mammalian PDGF or VEGF (or their
cognate receptors), such as parts of antibodies having a binding
site which corresponds to the antibody and is formed by light and
heavy chains, such as Fv, Fab or F(ab').sub.2 fragments, or
single-stranded fragments. Truncated double-stranded fragments such
as Fv, Fab or F(ab').sub.2 are particularly useful. These fragments
can be obtained, for example, by enzymatic means by eliminating the
Fc part of the antibody with enzymes such as papain or pepsin, by
chemical oxidation or by genetic manipulation of the antibody
genes. It is also possible and advantageous to use genetically
manipulated, non-truncated fragments. The anti-PDGF or VEGF
antibodies or fragments thereof can be used alone or in
mixtures.
[0152] The novel antibodies, antibody fragments, mixtures or
derivatives thereof advantageously have a binding affinity for PDGF
or VEGF (or their cognate receptors) in a range from
1.times.10.sup.7 M to 1.times.10.sup.-12 M, or from
1.times.10.sup.-8 M to 1.times.10.sup.-11 M, or from 1.times.10-9 M
to 5.times.10.sup.-10 M.
[0153] The antibody genes for the genetic manipulations can be
isolated, for example from hybridoma cells, in a manner known to
the skilled worker. For this purpose, antibody-producing cells are
cultured and, when the optical density of the cells is sufficient,
the mRNA is isolated from the cells in a known manner by lysing the
cells with guanidinium thiocyanate, acidifying with sodium acetate,
extracting with phenol, chloroform/isoamyl alcohol, precipitating
with isopropanol and washing with ethanol. cDNA is then synthesized
from the mRNA using reverse transcriptase. The synthesized cDNA can
be inserted, directly or after genetic manipulation, for example,
by site-directed mutagenesis, introduction of insertions,
inversions, deletions, or base exchanges, into suitable animal,
fungal, bacterial or viral vectors and be expressed in appropriate
host organisms. Useful bacterial or yeast vectors are pBR322,
pUC18/19, pACYC184, lambda or yeast mu vectors for the cloning of
the genes and expression in bacteria such as E. coli or in yeasts
such as Saccharomyces cerevisiae.
[0154] The invention furthermore relates to cells that synthesize
PDGF or VEGF antibodies. These include animal, fungal, bacterial
cells or yeast cells after transformation as mentioned above. They
are advantageously hybridoma cells or trionoma cells, typically
hybridoma cells. These hybridoma cells can be produced, for
example, in a known manner from animals immunized with PDGF or VEGF
(or their cognate receptors) and isolation of their
antibody-producing B cells, selecting these cells for PDGF or
VEGF-binding antibodies and subsequently fusing these cells to, for
example, human or animal, for example, mouse myeloma cells, human
lymphoblastoid cells or heterohybridoma cells (see, e.g., Koehler
et al., (1975) Nature 256: 496) or by infecting these cells with
appropriate viruses to produce immortalized cell lines. Hybridoma
cell lines produced by fusion are useful and mouse hybridoma cell
lines are particularly useful. The hybridoma cell lines of the
invention secrete useful antibodies of the IgG type. The binding of
the mAb antibodies of the invention bind with high affinity and
reduce or neutralize the biological (e.g., angiogenic) activity of
PDGF or VEGF.
[0155] The invention further includes derivatives of these
anti-PDGF or VEGF antibodies which retain their PDGF or
VEGF-inhibiting activity while altering one or more other
properties related to their use as a pharmaceutical agent, e.g.,
serum stability or efficiency of production. Examples of such
anti-PDGF or VEGF antibody derivatives include peptides,
peptidomimetics derived from the antigen-binding regions of the
antibodies, and antibodies, antibody fragments or peptides bound to
solid or liquid carriers such as polyethylene glycol, glass,
synthetic polymers such as polyacrylamide, polystyrene,
polypropylene, polyethylene or natural polymers such as cellulose,
Sepharose or agarose, or conjugates with enzymes, toxins or
radioactive or nonradioactive markers such as .sup.3H, .sup.123I,
.sup.125I, .sup.131I, .sup.32P, .sup.35S, .sup.14C, .sup.51Cr,
.sup.36Cl, .sup.57Co, .sup.55Fe, .sup.59Fe, .sup.90Y, .sup.90mTc,
.sup.75Se, or antibodies, fragments, or peptides covalently bonded
to fluorescent/chemiluminescent labels such as rhodamine,
fluorescein, isothiocyanate, phycoerythrin, phycocyanin,
fluorescamine, metal chelates, avidin, streptavidin or biotin.
[0156] The novel antibodies, antibody fragments, mixtures, and
derivatives thereof can be used directly, after drying, for example
freeze drying, after attachment to the abovementioned carriers or
after formulation with other pharmaceutical active and ancillary
substances for producing pharmaceutical preparations. Examples of
active and ancillary substances which may be mentioned are other
antibodies, antimicrobial active substances with a microbiocidal or
microbiostatic action such as antibiotics in general or
sulfonamides, antitumor agents, water, buffers, salines, alcohols,
fats, waxes, inert vehicles or other substances customary for
parenteral products, such as amino acids, thickeners or sugars.
These pharmaceutical preparations are used to control diseases, and
are useful to control ocular neovascular disorders and diseases
including AMD and diabetic retinopathy.
[0157] The novel antibodies, antibody fragments, mixtures or
derivatives thereof can be used in therapy or diagnosis directly or
after coupling to solid or liquid carriers, enzymes, toxins,
radioactive or nonradioactive labels or to
fluorescent/chemiluminescent labels as described above.
[0158] The human PDGF or VEGF monoclonal antibodies of the present
invention may be obtained by any means known in the art. For
example, a mammal is immunized with human PDGF or VEGF (or their
cognate receptors). Purified human PDGF and VEGF is commercially
available (e.g., from Cell Sciences. Norwood, Mass., as well as
other commercial vendors). Alternatively, human PDGF or VEGF (or
their cognate receptors) may be readily purified from human
placental tissue. The mammal used for raising anti-human PDGF or
VEGF antibody is not restricted and may be a primate, a rodent
(such as mouse, rat or rabbit), bovine, sheep, goat or dog.
[0159] Next, antibody-producing cells such as spleen cells are
removed from the immunized animal and are fused with myeloma cells.
The myeloma cells are well-known in the art (e.g., p3x63-Ag8-653,
NS-0, NS-1 or P3U1 cells may be used). The cell fusion operation
may be carried out by any conventional method known in the art.
[0160] The cells, after being subjected to the cell fusion
operation, are then cultured in HAT selection medium so as to
select hybridomas. Hybridomas which produce antihuman monoclonal
antibodies are then screened. This screening may be carried out by,
for example, sandwich enzyme-linked immunosorbent assay (ELISA) or
the like in which the produced monoclonal antibodies are bound to
the wells to which human PDGF or VEGF (or their cognate receptor)
is immobilized. In this case, as the secondary antibody, an
antibody specific to the immunoglobulin of the immunized animal,
which is labeled with an enzyme such as peroxidase, alkaline
phosphatase, glucose oxidase, beta-D-galactosidase, or the like,
may be employed. The label may be detected by reacting the labeling
enzyme with its substrate and measuring the generated color. As the
substrate, 3,3-diaminobenzidine, 2,2-diaminobis-o-dianisidine,
4-chloronaphthol, 4-aminoantipyrine, o-phenylenediamine or the like
may be produced.
[0161] By the above-described operation, hybridomas which produce
anti-human PDGF or VEGF antibodies can be selected. The selected
hybridomas are then cloned by the conventional limiting dilution
method or soft agar method. If desired, the cloned hybridomas may
be cultured on a large scale using a serum-containing or a serum
free medium, or may be inoculated into the abdominal cavity of mice
and recovered from ascites, thereby a large number of the cloned
hybridomas may be obtained.
[0162] From among the selected anti-human PDGF or VEGF monoclonal
antibodies, those that have an ability to prevent binding and
activation of the corresponding ligand/receptor pair (e.g., in a
cell-based PDGF or VEGF assay system (see above)) are then chosen
for further analysis and manipulation. If the antibody blocks
receptor/ligand binding and/or activation, it means that the
monoclonal antibody tested has an ability to reduce or neutralize
the PDGF or VEGF activity of human PDGF or VEGF. That is, the
monoclonal antibody specifically recognizes and/or interferes with
the critical binding site of human PDGF or VEGF (or their cognate
receptors).
[0163] The monoclonal antibodies herein further include hybrid and
recombinant antibodies produced by splicing a variable (including
hypervariable) domain of an anti-PDGF or VEGF antibody with a
constant domain (e.g., "humanized" antibodies), or a light chain
with a heavy chain, or a chain from one species with a chain from
another species, or fusions with heterologous proteins, regardless
of species of origin or immunoglobulin class or subclass
designation, as well as antibody fragments, [e.g., Fab,
F(ab).sub.2, and Fv], so long as they exhibit the desired
biological activity. [See, e.g., U.S. Pat. No. 4,816,567 and Mage
& Lamoyi, in Monoclonal Antibody Production Techniques and
Applications, pp. 79-97 (Marcel Dekker, Inc.), New York
(1987)].
[0164] Thus, the term "monoclonal" indicates that the character of
the antibody obtained is from a substantially homogeneous
population of antibodies, and is not to be construed as requiring
production of the antibody by any particular method. For example,
the monoclonal antibodies to be used in accordance with the present
invention may be made by the hybridoma method first described by
Kohler & Milstein, Nature 256:495 (1975), or may be made by
recombinant DNA methods (U.S. Pat. No. 4,816,567). The "monoclonal
antibodies" may also be isolated from phage libraries generated
using the techniques described in McCafferty et al., Nature
348:552-554 (1990), for example.
[0165] "Humanized" forms of non-human (e.g., murine) antibodies are
specific chimeric immunoglobulins, immunoglobulin chains or
fragments thereof (such as Fv, Fab, Fab', F(ab).sub.2 or other
antigen-binding subsequences of antibodies) which contain minimal
sequence derived from non-human immunoglobulin. For the most part,
humanized antibodies are human immunoglobulins (recipient antibody)
in which residues from the complementary determining regions (CDRs)
of the recipient antibody are replaced by residues from the CDRs of
a non-human species (donor antibody) such as mouse, rat or rabbit
having the desired specificity, affinity and capacity. In some
instances, Fv framework region (FR) residues of the human
immunoglobulin are replaced by corresponding non-human FR residues.
Furthermore, the humanized antibody may comprise residues that are
found neither in the recipient antibody nor in the impelled CDR or
FR sequences. These modifications are made to further refine and
optimize antibody performance. In general, the humanized antibody
will comprise substantially all of at least one, and typically two,
variable domains, in which all or substantially all of the CDR
regions correspond to those of a non-human immunoglobulin and all
or substantially all of the FR residues are those of a human
immunoglobulin consensus sequence. The humanized antibody optimally
also will comprise at least a portion of an immunoglobulin constant
region (Fc), typically that of a human immunoglobulin.
[0166] Methods for humanizing non-human antibodies are well known
in the art. Generally, a humanized antibody has one or more amino
acid residues introduced into it from a source which is non-human.
These non-human amino acid residues are often referred to as
"import" residues, which are typically taken from an "import"
variable domain. Humanization can be essentially performed
following the method of Winter and co-workers (Jones et al., (1986)
Nature 321: 522-525; Riechmann et al., (1988) Nature 332: 323-327;
and Verhoeyen et al., (1988) Science 239: 1534-1536), by
substituting rodent CDRs or CDR sequences for the corresponding
sequences of a human antibody. Accordingly, such "humanized"
antibodies are chimeric antibodies, wherein substantially less than
an intact human variable domain has been substituted by the
corresponding sequence from a non-human species. In practice,
humanized antibodies are typically human antibodies in which some
CDR residues and possibly some FR residues are substituted by
residues from analogous sites in rodent antibodies.
[0167] The choice of human variable domains, both light and heavy,
to be used in making the humanized antibodies is very important to
reduce antigenicity. According to the so-called "best-fit" method,
the sequence of the variable domain of a rodent antibody is
screened against the entire library of known human variable-domain
sequences. The human sequence which is closest to that of the
rodent is then accepted as the human framework (FR) for the
humanized antibody (Sims et al., (1993) J. Immunol., 151:2296; and
Chothia and Lesk (1987) J. Mol. Biol., 196:901). Another method
uses a particular framework derived from the consensus sequence of
all human antibodies of a particular subgroup of light or heavy
chains. The same framework may be used for several different
humanized antibodies (Carter et al., (1992) Proc. Natl. Acad. Sci.
(USA), 89: 4285; and Presta et al., (1993) J. Immnol.,
151:2623).
[0168] It is further important that antibodies be humanized with
retention of high affinity for the antigen and other favorable
biological properties. To achieve this goal, according to one
useful method, humanized antibodies are prepared by a process of
analysis of the parental sequences and various conceptual humanized
products using three-dimensional models of the parental and
humanized sequences. Three-dimensional immunoglobulin models are
commonly available and are familiar to those skilled in the art.
Computer programs are available which illustrate and display
probable three-dimensional conformational structures of selected
candidate immunoglobulin sequences. Inspection of these displays
permits analysis of the likely role of the residues in the
functioning of the candidate immunoglobulin sequence, i.e., the
analysis of residues that influence the ability of the candidate
immunoglobulin to bind its antigen. In this way, FR residues can be
selected and combined from the consensus and import sequences so
that the desired antibody characteristic, such as increased
affinity for the target antigen(s), is achieved. In general, the
CDR residues are directly and most substantially involved in
influencing antigen binding.
[0169] Human monoclonal antibodies directed against PDGF or VEGF
are also included in the invention. Such antibodies can be made by
the hybridoma method. Human myeloma and mouse-human heteromyeloma
cell lines for the production of human monoclonal antibodies have
been described, for example, by Kozbor (1984) J. Immunol., 133,
3001; Brodeur, et al., Monoclonal Antibody Production Techniques
and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987);
and Boerner et al., (1991) J. Immunol., 147:86-95.
[0170] It is now possible to produce transgenic animals (e.g.,
mice) that are capable, upon immunization, of producing a full
repertoire of human antibodies in the absence of endogenous
immunoglobulin production. For example, it has been described that
the homozygous deletion of the antibody heavy-chain joining region
(J.sub.H) gene in chimeric and germ-line mutant mice results in
complete inhibition of endogenous antibody production. Transfer of
the human germ-line immunoglobulin gene array in such gem-line
mutant mice will result in the production of human antibodies upon
antigen challenge (see, e.g., Jakobovits et al., (1993) Proc. Natl.
Acad. Sci. (USA), 90: 2551; Jakobovits et al., (1993) Nature,
362:255-258; and Bruggermann et al., (1993) Year in Immuno.,
7:33).
[0171] Alternatively, phage display technology (McCafferty et al.,
(1990) Nature, 348: 552-553) can be used to produce human
antibodies and antibody fragments in vitro, from immunoglobulin
variable (V) domain gene repertoires from unimmunized donors (for
review see, e.g., Johnson et al., (1993) Current Opinion in
Structural Biology, 3:564-571). Several sources of V-gene segments
can be used for phage display. For example, Clackson et al.,
((1991) Nature, 352: 624-628) isolated a diverse array of
anti-oxazolone antibodies from a small random combinatorial library
of V genes derived from the spleens of immunized mice. A repertoire
of V genes from unimmunized human donors can be constructed and
antibodies to a diverse array of antigens (including self-antigens)
can be isolated essentially following the techniques described by
Marks et al., ((1991) J. Mol. Biol., 222:581-597, or Griffith et
al., (1993) EMBO J., 12:725-734).
[0172] In a natural immune response, antibody genes accumulate
mutations at a high rate (somatic hypermutation). Some of the
changes introduced will confer higher affinity, and B cells
displaying high-affinity surface immunoglobulin are preferentially
replicated and differentiated during subsequent antigen challenge.
This natural process can be mimicked by employing the technique
known as "chain shuffling" (see Marks et al., (1992) Bio. Technol.,
10:779-783). In this method, the affinity of "primary" human
antibodies obtained by phage display can be improved by
sequentially replacing the heavy and light chain V region genes
with repertoires of naturally occurring variants (repertoires) of V
domain genes obtained from unimmunized donors. This technique
allows the production of antibodies and antibody fragments with
affinities in the nM range. A strategy for making very large phage
antibody repertoires has been described by Waterhouse et al.,
((1993) Nucl. Acids Res., 21:2265-2266).
[0173] Gene shuffling can also be used to derive human antibodies
from rodent antibodies, where the human antibody has similar
affinities and specificities to the starting rodent antibody.
According to this method, which is also referred to as "epitope
imprinting", the heavy or light chain V domain gene of rodent
antibodies obtained by phage display technique is replaced with a
repertoire of human V domain genes, creating rodent-human chimeras.
Selection on antigen results in isolation of human variable capable
of restoring a functional antigen-binding site, i.e., the epitope
governs (imprints) the choice of partner. When the process is
repeated in order to replace the remaining rodent V domain, a human
antibody is obtained (see PCT WO 93/06213, published 1 Apr. 1993).
Unlike traditional humanization of rodent antibodies by CDR
grafting, this technique provides completely human antibodies,
which have no framework or CDR residues of rodent origin.
[0174] Aptamer Antagonists
[0175] The invention provides aptamer antagonists directed against
PDGF and/or VEGF (or their cognate receptors). Aptamers, also known
as nucleic acid ligands, are non-naturally occurring nucleic acids
that bind to and, generally, antagonize (i.e., inhibit) a
pre-selected target.
[0176] Aptamers can be made by any known method of producing
oligomers or oligonucleotides. Many synthesis methods are known in
the art. For example, 2'-O-allyl modified oligomers that contain
residual purine ribonucleotides, and bearing a suitable 3'-terminus
such as an inverted thymidine residue (Ortigao et al., Antisense
Research and Development, 2:129-146 (1992)) or two phosphorothioate
linkages at the 3'-terminus to prevent eventual degradation by
3'-exonucleases, can be synthesized by solid phase beta-cyanoethyl
phosphoramidite chemistry (Sinha et al., Nucleic Acids Res.,
12:4539-4557 (1984)) on any commercially available DNA/RNA
synthesizer. One method is the 2'-O-tert-butyldimethylsilyl (TBDMS)
protection strategy for the ribonucleotides (Usman et al., J. Am.
Chem. Soc., 109:7845-7854 (1987)), and all the required
3'-O-phosphoramidites are commercially available. In addition,
aminomethylpolystyrene may be used as the support material due to
its advantageous properties (McCollum and Andrus (1991) Tetrahedron
Lett., 32:4069-4072). Fluorescein can be added to the 5'-end of a
substrate RNA during the synthesis by using commercially available
fluorescein phosphoramidites. In general, an aptamer oligomer can
be synthesized using a standard RNA cycle. Upon completion of the
assembly, all base labile protecting groups are removed by an eight
hour treatment at 55.degree. C., with concentrated aqueous
ammonia/ethanol (3:1 v/v) in a sealed vial. The ethanol suppresses
premature removal of the 2'-O-TBDMS groups that would otherwise
lead to appreciable strand cleavage at the resulting ribonucleotide
positions under the basic conditions of the deprotection (Usman et
al., (1987) J. Am. Chem. Soc., 109:7845-7854). After
lyophilization, the TBDMS protected oligomer is treated with a
mixture of triethylamine
trihydrofluoride/triethylamine/N-methylpyrrolidinone for 2 hours at
60.degree. C. to afford fast and efficient removal of the silyl
protecting groups under neutral conditions (see Wincott et al.,
(1995) Nucleic Acids Res., 23:2677-2684). The fully deprotected
oligomer can then be precipitated with butanol according to the
procedure of Cathala and Brunel ((1990) Nucleic Acids Res.,
18:201). Purification can be performed either by denaturing
polyacrylamide gel electrophoresis or by a combination of
ion-exchange HPLC (Sproat et al., (1995) Nucleosides and
Nucleotides, 14:255-273) and reversed phase HPLC. For use in cells,
synthesized oligomers are converted to their sodium salts by
precipitation with sodium perchlorate in acetone. Traces of
residual salts may then be removed using small disposable gel
filtration columns that are commercially available. As a final step
the authenticity of the isolated oligomers may be checked by matrix
assisted laser desorption mass spectrometry (Pieles et al., (1993)
Nucleic Acids Res., 21:3191-3196) and by nucleoside base
composition analysis.
[0177] The disclosed aptamers can also be produced through
enzymatic methods, when the nucleotide subunits are available for
enzymatic manipulation. For example, the RNA molecules can be made
through in vitro RNA polymerase T7 reactions. They can also be made
by strains of bacteria or cell lines expressing T7, and then
subsequently isolated from these cells. As discussed below, the
disclosed aptamers can also be expressed in cells directly using
vectors and promoters.
[0178] The aptamers, like other nucleic acid molecules of the
invention, may further contain chemically modified nucleotides. One
issue to be addressed in the diagnostic or therapeutic use of
nucleic acids is the potential rapid degration of oligonucleotides
in their phosphodiester form in body fluids by intracellular and
extracellular enzymes such as endonucleases and exonucleases before
the desired effect is manifest. Certain chemical modifications of
the nucleic acid ligand can be made to increase the in vivo
stability of the nucleic acid ligand or to enhance or to mediate
the delivery of the nucleic acid ligand (see, e.g., U.S. Pat. No.
5,660,985, entitled "High Affinity Nucleic Acid Ligands Containing
Modified Nucleotides") which is specifically incorporated herein by
reference.
[0179] Modifications of the nucleic acid ligands contemplated in
this invention include, but are not limited to, those which provide
other chemical groups that incorporate additional charge,
polarizability, hydrophobicity, hydrogen bonding, electrostatic
interaction, and fluxionality to the nucleic acid ligand bases or
to the nucleic acid ligand as a whole. Such modifications include,
but are not limited to, 2'-position sugar modifications, 5-position
pyrimidine modifications, 8-position purine modifications,
modifications at exocyclic amines, substitution of 4-thiouridine,
substitution of 5-bromo or 5-iodo-uracil; backbone modifications,
phosphorothioate or alkyl phosphate modifications, methylations,
unusual base-pairing combinations such as the isobases isocytidine
and isoguanidine and the like. Modifications can also include 3'
and 5' modifications such as capping or modification with sugar
moieties. In some embodiments of the instant invention, the nucleic
acid ligands are RNA molecules that are 2'-fluoro (2'-F) modified
on the sugar moiety of pyrimidine residues.
[0180] The stability of the aptamer can be greatly increased by the
introduction of such modifications and as well as by modifications
and substitutions along the phosphate backbone of the RNA. In
addition, a variety of modifications can be made on the nucleobases
themselves which both inhibit degradation and which can increase
desired nucleotide interactions or decrease undesired nucleotide
interactions. Accordingly, once the sequence of an aptamer is
known, modifications or substitutions can be made by the synthetic
procedures described below or by procedures known to those of skill
in the art.
[0181] Other modifications include the incorporation of modified
bases (or modified nucleoside or modified nucleotides) that are
variations of standard bases, sugars and/or phosphate backbone
chemical structures occurring in ribonucleic (i.e., A, C, G and U)
and deoxyribonucleic (i.e., A, C, G and T) acids. Included within
this scope are, for example: Gm (2'-methoxyguanylic acid), Am
(2'-methoxyadenylic acid), Cf(2'-fluorocytidylic acid),
Uf(2'-fluorouridylic acid), Ar (riboadenylic acid). The aptamers
may also include cytosine or any cytosine-related base including
5-methylcytosine, 4-acetylcytosine, 3-methylcytosine,
5-hydroxymethyl cytosine, 2-thiocytosine, 5-halocytosine (e.g.,
5-fluorocytosine, 5-bromocytosine, 5-chlorocytosine, and
5-iodocytosine), 5-propynyl cytosine, 6-azocytosine,
5-trifluoromethylcytosine, N4,N4-ethanocytosine, phenoxazine
cytidine, phenothiazine cytidine, carbazole cytidine or
pyridoindole cytidine. The aptamer may further include guanine or
any guanine-related base including 6-methylguanine,
1-methylguanine, 2,2-dimethylguanine, 2-methylguanine,
7-methylguanine, 2-propylguanine, 6-propylguanine, 8-haloguanine
(e.g., 8-fluoroguanine, 8-bromoguanine, 8-chloroguanine, and
8-iodoguanine), 8-aminoguanine, 8-sulfhydrylguanine,
8-thioalkylguanine, 8-hydroxylguanine, 7-methylguanine,
8-azaguanine, 7-deazaguanine or 3-deazaguanine. The aptamer may
still further include adenine or any adenine-related base including
6-methyladenine, N6-isopentenyladenine, N6-methyladenine,
-methyladenine, 2-methyladenine,
2-methylthio-N6-isopentenyladenine, 8-haloadenine (e.g.,
8-fluoroadenine, 8-bromoadenine, 8-chloroadenine, and
8-iodoadenine), 8-aminoadenine, 8-sulfhydryladenine,
8-thioalkyladenine, 8-hydroxyladenine, 7-methyladenine,
2-haloadenine (e.g., 2-fluoroadenine, 2-bromoadenine,
2-chloroadenine, and 2-iodoadenine), 2-aminoadenine, 8-azaadenine,
7-deazaadenine or 3-deazaadenine. Also included are uracil or any
uracil-related base including 5-halouracil (e.g., 5-fluorouracil,
5-bromouracil, 5-chlorouracil, 5-iodouracil),
5-(carboxyhydroxylmethyl)uracil,
5-carboxymethylaminomethyl-2-thiouracil,
5-carboxymethylaminomethyluracil, dihydrouracil,
1-methylpseudouracil, 5-methoxyaminomethyl-2-thiouracil,
5'-methoxycarbonylmethyluracil, 5-methoxyuracil,
5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid,
pseudouracil, 5-methyl-2-thiouracil, 2-thiouracil,
3-(3-amino-3-N-2-carboxypropyl)uracil, 5-methylaminomethyluracil,
5-propynyl uracil, 6-azouracil, or 4-thiouracil.
[0182] Examples of other modified base variants known in the art
include, without limitation, those listed at 37 C.F.R.
.sctn.1.822(p) (1), e.g., 4-acetylcytidine,
5-(carboxyhydroxylmethyl) uridine, 2'-methoxycytidine,
5-carboxymethylaminomethyl-2-thioridine,
5-carboxymethylaminomethyluridine, dihydrouridine,
2'-O-methylpseudouridine, b-D-galactosylqueosine, inosine,
N6-isopentenyladenosine, 1-methyladenosine, 1-methylpseudouridine,
1-methylguanosine, 1-methylinosine, 2,2-dimethylguanosine,
2-methyladenosine, 2-methylguanosine, 3-methylcytidine,
5-methylcytidine, N6-methyladenosine, 7-methylguanosine,
5-methylaminomethyluridine, 5-methoxyaminomethyl-2-thiouridine,
b-D-mannosylqueosine, 5-methoxycarbonylmethyluridine,
5-methoxyuridine, 2-methylthio-N6-isopentenyladenosine,
N-((9-b-D-ribofuranosyl-2-methylthiopurine-6-yl)carbamoyl)threonine,
N-((9-b-D-ribofuranosylpurine-6-yl)N-methyl-carbamoyl)threonine,
urdine-5-oxyacetic acid methylester, uridine-5-oxyacetic acid (v),
wybutoxosine, pseudouridine, queosine, 2-thiocytidine,
5-methyl-2-thiouridine, 2-thiouridine, 4-thiouridine,
5-methyluridine,
N-((9-b-D-ribofuranosylpurine-6-yl)carbamoyl)threonine,
2'-O-methyl-5-methyluridine, 2'-O-methyluridine, wybutosine,
3-(3-amino-3-carboxypropyl)uridine.
[0183] Also included are the modified nucleobases described in U.S.
Pat. Nos. 3,687,808, 3,687,808, 4,845,205, 5,130,302, 5,134,066,
5,175,273, 5,367,066, 5,432,272, 5,457,187, 5,459,255, 5,484,908,
5,502,177, 5,525,711, 5,552,540, 5,587,469, 5,594,121, 5,596,091,
5,614,617, 5,645,985, 5,830,653, 5,763,588, 6,005,096, and
5,681,941. Examples of modified nucleoside and nucleotide sugar
backbone variants known in the art include, without limitation,
those having, e.g., 2' ribosyl substituents such as F, SH, SCH3,
OCN, Cl, Br, CN, CF3, OCF3, SOCH3, SO2, CH3, ONO2, NO2, N3, NH2,
OCH2CH2OCH3, O(CH2)2ON(CH3)2, OCH2OCH2N(CH3)2, O(C1-10 alkyl),
O(C2-10 alkenyl), O(C2-10 alkynyl), S(C1-10 alkyl), S(C2-10
alkenyl), S(C2-10 alkynyl), NH(C1-10 alkyl), NH(C2-10 alkenyl),
NH(C2-10 alkynyl), and O-alkyl-O-alkyl. Desirable 2' ribosyl
substituents include 2'-methoxy (2'-OCH3), 2'-aminopropoxy (2'
OCH2CH2CH2NH2), 2'-allyl (2'-CH2-CH.dbd.CH2), 2'-O-allyl
(2'-O--CH2-CH.dbd.CH2), 2'-amino (2'-NH2), and 2'-fluoro (2'-F).
The 2'-substituent may be in the arabino (up) position or ribo
(down) position.
[0184] The aptamers of the invention may be made up of nucleotides
and/or nucleotide analogs such as described above, or a combination
of both, or are oligonucleotide analogs. The aptamers of the
invention may contain nucleotide analogs at positions which do not
effect the function of the oligomer to bind PDGF or VEGF (or their
cognate receptors).
[0185] There are several techniques that can be adapted for
refinement or strengthening of the nucleic acid Ligands binding to
a particular target molecule or the selection of additional
aptamers. One technique, generally referred to as "in vitro
genetics" (see Szostak (1992) TIBS. 19:89), involves isolation of
aptamer antagonists by selection from a pool of random sequences.
The pool of nucleic acid molecules from which the disclosed
aptamers may be isolated may include invariant sequences flanking a
variable sequence of approximately twenty to forty nucleotides.
This method has been termed Selective Evolution of Ligands by
EXponential Enrichment (SELEX). Compositions and methods for
generating aptamer antagonists of the invention by SELEX and
related methods are known in the art and taught in, for example,
U.S. Pat. No. 5,475,096 entitled "Nucleic Acid Ligands," and U.S.
Pat. No. 5,270,163, entitled "Methods for Identifying Nucleic Acid
Ligands," each of which is specifically incorporated by reference
herein in its entirety. The SELEX process in general, and VEGF and
PDGF aptamers and formulations in particular, are further described
in, e.g., U.S. Pat. Nos. 5,668,264, 5,696,249, 5,670,637,
5,674,685, 5,723,594, 5,756,291, 5,811,533, 5,817,785, 5,958,691,
6,011,020, 6,051,698, 6,147,204, 6,168,778, 6,207,816, 6,229,002,
6,426,335, 6,582,918, the contents of each of which is specifically
incorporated by reference herein.
[0186] Briefly, the SELEX method involves selection from a mixture
of candidate oligonucleotides and step-wise iterations of binding
to a selected target, partitioning and amplification, using the
same general selection scheme, to achieve virtually any desired
criterion of binding affinity and selectivity. Starting from a
mixture of nucleic acids, typically comprising a segment of
randomized sequence, the SELEX method includes steps of contacting
the mixture with the target under conditions favorable for binding,
partitioning unbound nucleic acids from those nucleic acids which
have bound specifically to target molecules, dissociating the
nucleic acid-target complexes, amplifying the nucleic acids
dissociated from the nucleic acid-target complexes to yield a
ligand-enriched mixture of nucleic acids, then reiterating the
steps of binding, partitioning, dissociating and amplifying through
as many cycles as desired to yield highly specific high affinity
nucleic acid ligands to the target molecule.
[0187] The basic SELEX method has been modified to achieve a number
of specific objectives. For example, U.S. Pat. No. 5,707,796,
entitled "Method for Selecting Nucleic Acids on the Basis of
Structure," describes the use of the SELEX process in conjunction
with gel electrophoresis to select nucleic acid molecules with
specific structural characteristics, such as bent DNA. U.S. Pat.
No. 5,763,177 entitled "Systematic Evolution of Ligands by
Exponential Enrichment: Photoselection of Nucleic Acid Ligands and
Solution SELEX" describe a SELEX based method for selecting nucleic
acid ligands containing photoreactive groups capable of binding
and/or photocrosslinking to and/or photoinactivating a target
molecule. U.S. Pat. No. 5,580,737 entitled "High-Affinity Nucleic
Acid Ligands That Discriminate Between Theophylline and Caffeine,"
describes a method for identifying highly specific nucleic acid
ligands able to discriminate between closely related molecules,
which can be non-peptidic, termed Counter-SELEX. U.S. Pat. No.
5,567,588 entitled "Systematic Evolution of Ligands by EXponential
Enrichment: Solution SELEX," describes a SELEX-based method which
achieves highly efficient partitioning between oligonucleotides
having high and low affinity for a target molecule.
[0188] The SELEX method encompasses the identification of
high-affinity nucleic acid ligands containing modified nucleotides
conferring improved characteristics on the ligand, such as improved
in vivo stability or improved delivery characteristics. Examples of
such modifications include chemical substitutions at the ribose
and/or phosphate and/or base positions. SELEX process-identified
nucleic acid ligands containing modified nucleotides are described
in U.S. Pat. No. 5,660,985 entitled "High Affinity Nucleic Acid
Ligands Containing Modified Nucleotides," that describes
oligonucleotides containing nucleotide derivatives chemically
modified at the 5- and 2'-positions of pyrimidines. U.S. Pat. No.
5,580,737, supra, describes highly specific nucleic acid ligands
containing one or more nucleotides modified with 2'-amino (2'-NH2),
2'-fluoro (2'-F), and/or 2'-O-methyl (2'-OMe). U.S. patent
application Ser. No. 08/264,029, filed Jun. 22, 1994, entitled
"Novel Method of Preparation of Known and Novel 2' Modified
Nucleosides by Intramolecular Nucleophilic Displacement," now
abandoned, describes oligonucleotides containing various
2'-modified pyrimidines.
[0189] The SELEX method encompasses combining selected
oligonucleotides with other selected oligonucleotides and
non-oligonucleotide functional units as described in U.S. Pat. No.
5,637,459 entitled "Systematic Evolution of Ligands by EXponential
Enrichment: Chimeric SELEX," and U.S. Pat. No. 5,683,867 entitled
"Systematic Evolution of Ligands by EXponential Enrichment: Blended
SELEX," respectively. These patents allow for the combination of
the broad array of shapes and other properties, and the efficient
amplification and replication properties, of oligonucleotides with
the desirable properties of other molecules.
[0190] The SELEX method further encompasses combining selected
nucleic acid ligands with lipophilic compounds or non-immunogenic,
high molecular weight compounds in a diagnostic or therapeutic
complex as described in U.S. Pat. No. 6,011,020, entitled "Nucleic
Acid Ligand Complexes," which is specifically incorporated by
reference herein in their entirety.
[0191] The aptamer antagonists can also be refined through the use
of computer modeling techniques. Examples of molecular modeling
systems are the CHARMm and QUANTA programs, Polygen Corporation
(Waltham, Mass.). CHARMm performs the energy minimization and
molecular dynamics functions. QUANTA performs the construction,
graphic modeling and analysis of molecular structure. QUANTA allows
interactive construction, modification, visualization, and analysis
of the behavior of molecules with each other. These applications
can be adapted to define and display the secondary structure of RNA
and DNA molecules.
[0192] Aptamers with these various modifications can then be tested
for function using any suitable assay for the PDGF or VEGF function
of interest, such as a PDGF cell-based proliferation activity
assay.
[0193] The modifications can be pre- or post-SELEX process
modifications. Pre-SELEX process modifications yield nucleic acid
ligands with both specificity for their SELEX target and improved
in vivo stability. Post-SELEX process modifications made to 2'-OH
nucleic acid ligands can result in improved in vivo stability
without adversely affecting the binding capacity of the nucleic
acid ligand.
[0194] Other modifications useful for producing aptamers of the
invention are known to one of ordinary skill in the art. Such
modifications may be made post-SELEX process (modification of
previously identified unmodified ligands) or by incorporation into
the SELEX process.
[0195] It has been observed that aptamers, or nucleic acid ligands,
in general, and VEGF aptamers in particular, are most stable, and
therefore efficacious when 5'-capped and 3'-capped in a manner
which decreases susceptibility to exonucleases and increases
overall stability. Accordingly, the invention is based in one
embodiment, upon the capping of aptamers in general, and anti-VEGF
aptamers in particular, with a 5'-5' inverted nucleoside cap
structure at the 5' end and a 3'-3' inverted nucleoside cap
structure at the 3' end. Accordingly, the invention provides
anti-VEGF and/or anti-PDGF aptamers, i.e., nucleic acid ligands,
that are capped at the 5' end with a 5'-5-inverted nucleoside cap
and at the 3' end with a 3'-3' inverted nucleoside cap.
[0196] Certain particularly useful aptamers of the invention are
anti-VEGF aptamer compositions, including, but not limited to,
those having both 5'-5' and 3'-3' inverted nucleotide cap
structures at their ends. Such anti-VEGF capped aptamers may be RNA
aptamers, DNA aptamers or aptamers having a mixed (i.e., both RNA
and DNA) composition. Suitable anti-VEGF aptamer sequences of the
invention include the nucleotide sequence GAAGAAUUGG (SEQ ID NO:
15); or the nucleotide sequence UUGGACGC (SEQ ID NO: 16); or the
nucleotide sequence GUGAAUGC (SEQ ID NO: 17). Particularly useful
are capped anti-VEGF aptamers of the invention have the
sequence:
TABLE-US-00001 (SEQ ID NO: 18)
X-5'-5'-CGGAAUCAGUGAAUGCUUAUACAUCCG-3'-3'-X
[0197] where each C, G, A, and U represents, respectively, the
naturally-occurring nucleotides cytidine, guanidine, adenine, and
uridine, or modified nucleotides corresponding thereto; X-5'-5' is
an inverted nucleotide capping the 5' terminus of the aptamer;
3'-3'-X is an inverted nucleotide capping the 3' terminus of the
aptamer; and the remaining nucleotides or modified nucleotides are
sequentially linked via 5'-3' phosphodiester linkages. In some
embodiments, each of the nucleotides of the capped anti-VEGF
aptamer, individually carries a 2' ribosyl substitution, such as
--OH (which is standard for ribonucleic acids (RNAs)), or --H
(which is standard for deoxyribonucleic acids (DNAs)). In other
embodiments the 2' ribosyl position is substituted with an
O(C.sub.1-10 alkyl), an O(C.sub.1-10 alkenyl), a F, an N3, or an
NH2 substituent.
[0198] In a still more particular non-limiting example, the 5'-5'
capped anti-VEGF aptamer may have the structure:
TABLE-US-00002 (SEQ ID NO: 19)
T.sub.d-5'-5'C.sub.fG.sub.mG.sub.mA.sub.rA.sub.rU.sub.fC.sub.fA.sub.mG.sub-
.mU.sub.fG.sub.mA.sub.mA.sub.mU.sub.fG.sub.mC.sub.fU.sub.fU.sub.fA.sub.mU.-
sub.fA.sub.mC.sub.fA.sub.mU.sub.fC.sub.f
C.sub.fG.sub.m3'-3'-T.sub.d
where "G.sub.m" represents 2'-methoxyguanylic acid, "A.sub.m"
represents 2'-methoxyadenylic acid, "C.sub.f" represents
2'-fluorocytidylic acid. "U.sub.f" represents 2'-fluorouridylic
acid, "Ar" represents riboadenylic acid, and "T.sub.d" represents
deoxyribothymidylic acid.
[0199] Antisense, Ribozymes, and DNA Enzyme Antagonists
[0200] Antisense oligonucleotides and ribozymes that are targeted
to PDGF and VEGF effect PDGF/VEGF inhibition by inhibiting protein
translation from these messenger RNAs or by targeting degradation
of the corresponding PDGF or VEGF mRNs, respectively. These PDGF-
and VEGF-targeted nucleic acids described above provide useful
sequences for the design and synthesis of these PDGF and VEGF
ribozymes and antisense oligonucleotides. Methods of design and
synthesis of antisense oligonucleotides and ribozymes are known in
the art. Additional guidance is provided herein.
[0201] One issue in designing specific and effective mRNA-targeted
oligonucleotides (antisense ODNs) and ribozymes and antisense is
that of identifying accessible sites of antisense pairing within
the target mRNA (which is itself folded into a partially
self-paired secondary structure). A combination of computer-aided
algorithms for predicting RNA pairing accessibility and molecular
screening allow for the creation of specific and effective
ribozymes and/or antisense oligonucleotides directed against most
mRNA targets. Indeed several approaches have been described to
determine the accessibility of a target RNA molecule to antisense
or ribozyme inhibitors. One approach uses an in vitro screening
assay applying as many antisense oligodeoxynucleotides as possible
(see Monia et al., (1996) Nature Med., 2:668-675; and Milner et
al., (1997) Nature Biotechnol., 15:537-541). Another utilizes
random libraries of ODNs (Ho et al., (1996) Nucleic Acids Res.,
24:1901-1907; Birikh et al., (1997) RNA 3:429-437; and Lima et al.,
(1997) J. Biol. Chem., 272:626-638). The accessible sites can be
monitored by RNase H cleavage (see Birikh et al., supra; and Ho et
al., (1998) Nature Biotechnol., 16:59-63). RNase H catalyzes the
hydrolytic cleavage of the phosphodiester backbone of the RNA
strand of a DNA-RNA duplex.
[0202] In another approach, involving the use of a pool of
semi-random, chimeric chemically synthesized ODNs, is used to
identify accessible sites cleaved by RNase H on an in vitro
synthesized RNA target. Primer extension analyses are then used to
identify these sites in the target molecule (see Lima et al.,
supra). Other approaches for designing antisense targets in RNA are
based upon computer assisted folding models for RNA. Several
reports have been published on the use of random ribozyme libraries
to screen effective cleavage (see Campbell et al., (1995) RNA
1:598-609; Lieber et al., (1995) Mol. Cell Biol., 15: 540-551; and
Vaish et al., (1997) Biochem., 36:6459-6501).
[0203] Other in vitro approaches, which utilize random or
semi-random libraries of ODNs and RNase H may be more useful than
computer simulations (Lima et al., supra). However, use of in vitro
synthesized RNA does not predict the accessibility of antisense
ODNs in vivo because recent observations suggest that annealing
interactions of polynucleotides are influenced by RNA-binding
proteins (see Tsuchihashi et al., (1993) Science, 267:99-102;
Portman et al., (1994) EMBO J., 13:213-221; and Bertrand and Rossi
(1994) EMBO J., 13:2904-2912). U.S. Pat. No. 6,562,570, the
contents of which are incorporated herein by reference, provides
compositions and methods for determining accessible sites within an
mRNA in the presence of a cell extract, which mimics in vivo
conditions.
[0204] Briefly, this method involves incubation of native or in
vitro-synthesized RNAs with defined antisense ODNs, ribozymes, or
DNAzymes, or with a random or semi-random ODN, ribozyme or DNAzyme
library, under hybridization conditions in a reaction medium which
includes a cell extract containing endogenous RNA-binding proteins,
or which mimics a cell extract due to presence of one or more
RNA-binding proteins. Any antisense ODN, Ribozyme, or DNAzyme,
which is complementary to an accessible site in the target RNA will
hybridize to that site. When defined ODNs or an ODN library is
used, RNase H is present during hybridization or is added after
hybridization to cleave the RNA where hybridization has occurred.
RNase H can be present when ribozymes or DNAzymes are used, but is
not required, since the ribozymes and DNAzymes cleave RNA where
hybridization has occurred. In some instances, a random or
semi-random ODN library in cell extracts containing endogenous
mRNA, RNA-binding proteins and RNase H is used.
[0205] Next, various methods can be used to identify those sites on
target RNA to which antisense ODNs, ribozymes or DNAzymes have
bound and cleavage has occurred. For example, terminal
deoxynucleotidyl transferase-dependent polymerase chain reaction
(TDPCR) may be used for this purpose (see Komura and Riggs (1998)
Nucleic Acids Res., 26:1807-11). A reverse transcription step is
used to convert the RNA template to DNA, followed by TDPCR. In this
invention, the 3' termini needed for the TDPCR method is created by
reverse transcribing the target RNA of interest with any suitable
RNA dependent DNA polymerase (e.g., reverse transcriptase). This is
achieved by hybridizing a first ODN primer (P1) to the RNA in a
region which is downstream (i.e., in the 5' to 3' direction on the
RNA molecule) from the portion of the target RNA molecule which is
under study. The polymerase in the presence of dNTPs copies the RNA
into DNA from the 3' end of P1 and terminates copying at the site
of cleavage created by either an antisense ODN/RNase H, a ribozyme
or a DNAzyme. The new DNA molecule (referred to as the first strand
DNA) serves as first template for the PCR portion of the TDPCR
method, which is used to identify the corresponding accessible
target sequence present on the RNA.
[0206] For example, the TDPCR procedure may then be used, i.e., the
reverse-transcribed DNA with guanosine triphosphate (rGTP) is
reacted in the presence of terminal deoxynucleotidyl transferase
(TdT) to add an (rG)2-4 tail on the 3' termini of the DNA
molecules. Next is ligated a double-stranded ODN linker having a
3'2-4 overhang on one strand that base-pairs with the (rG)2-4 tail.
Then two PCR primers are added. The first is a linker primer (LP)
that is complementary to the strand of the TDPCR linker which is
ligated to the (rG)2-4 tail (sometimes referred to as the lower
strand). The other primer (P2) can be the same as P1, but may be
nested with respect to P1, i.e., it is complementary to the target
RNA in a region which is at least partially upstream (i.e., in the
3' to 5' direction on the RNA molecule) from the region which is
bound by P1, but it is downstream of the portion of the target RNA
molecule which is under study. That is, the portion of the target
RNA molecule, which is under study to determine whether it has
accessible binding sites is that portion which is upstream of the
region that is complementary to P2. Then PCR is carried out in the
known manner in presence of a DNA polymerase and dNTPs to amplify
DNA segments defined by primers LP and P2. The amplified product
can then be captured by any of various known methods and
subsequently sequenced on an automated DNA sequencer, providing
precise identification of the cleavage site. Once this identity has
been determined, defined sequence antisense DNA or ribozymes can be
synthesized for use in vitro or in vivo.
[0207] Antisense intervention in the expression of specific genes
can be achieved by the use of synthetic antisense oligonucleotide
sequences (see, e.g., Lefebvre-d'Hellencourt et al., (1995) Eur.
Cyokine Netw., 6:7; Agrawal (1996) TIBTECH, 14: 376; and Lev-Lehman
et al., (1997) Antisense Therap. Cohen and Smicek, eds. (Plenum
Press, New York)). Briefly, antisense oligonucleotide sequences may
be short sequences of DNA, typically 15-30 mer but may be as small
as 7 mer (see Wagner et al., (1994) Nature, 372: 333) designed to
complement a target mRNA of interest and form an RNA:AS duplex.
This duplex formation can prevent processing, splicing, transport
or translation of the relevant mRNA. Moreover, certain AS
nucleotide sequences can elicit cellular RNase H activity when
hybridized with their target mRNA, resulting in mRNA degradation
(see Calabretta et al., (1996) Semin. Oncol., 23:78). In that case,
RNase H will cleave the RNA component of the duplex and can
potentially release the AS to further hybridize with additional
molecules of the target RNA. An additional mode of action results
from the interaction of AS with genomic DNA to form a triple helix
that may be transcriptionally inactive.
[0208] In as a non-limiting example of, addition to, or substituted
for, an antisense sequence as discussed herein above, ribozymes may
be utilized for suppression of gene function. This is particularly
necessary in cases where antisense therapy is limited by
stoichiometric considerations. Ribozymes can then be used that will
target the same sequence. Ribozymes are RNA molecules that possess
RNA catalytic ability that cleave a specific site in a target RNA.
The number of RNA molecules that are cleaved by a ribozyme is
greater than the number predicted by a 1:1 stoichiometry (see
Hampel and Tritz (1989) Biochem., 28: 4929-33; and Uhlenbeck (1987)
Nature, 328: 596-600). Therefore, the present invention also allows
for the use of the ribozyme sequences targeted to an accessible
domain of an PDGF or VEGF mRNA species and containing the
appropriate catalytic center. The ribozymes are made and delivered
as known in the art and discussed further herein. The ribozymes may
be used in combination with the antisense sequences.
[0209] Ribozymes catalyze the phosphodiester bond cleavage of RNA.
Several ribozyme structural families have been identified including
Group I introns, RNase P, the hepatitis delta virus ribozyme,
hammerhead ribozymes and the hairpin ribozyme originally derived
from the negative strand of the tobacco ringspot virus satellite
RNA (sTRSV) (see Sullivan (1994) Investig. Dermatolog., (Suppl.)
103: 95S; and U.S. Pat. No. 5,225,347). The latter two families are
derived from viroids and virusoids, in which the ribozyme is
believed to separate monomers from oligomers created during rolling
circle replication (see Symons (1989) TIBS, 14: 445-50; Symons
(1992) Ann. Rev. Biochem., 61: 641-71). Hammerhead and hairpin
ribozyme motifs are most commonly adapted for trans-cleavage of
mRNAs for gene therapy. The ribozyme type utilized in the present
invention is selected as is known in the art. Hairpin ribozymes are
now in clinical trial and are a particularly useful type. In
general the ribozyme is from 30-100 nucleotides in length.
[0210] Ribozyme molecules designed to catalytically cleave a target
mRNA transcript are known in the art (e.g., PDGF (SEQ ID NO: 1) or
VEGF (SEQ ID NO: 3) and can also be used to prevent translation of
mRNA (see, e.g., PCT International Pub. W090/11364; Sarver et al.,
(1990) Science, 247:1222-1225 and U.S. Pat. No. 5,093,246). While
ribozymes that cleave mRNA at site specific recognition sequences
can be used to destroy particular mRNAs, the use of hammerhead
ribozymes is particularly useful. Hammerhead ribozymes cleave mRNAs
at locations dictated by flanking regions that form complementary
base pairs with the target mRNA. The sole requirement is that the
target mRNA have the following sequence of two bases: 5'-UG-3'. The
construction and production of hammerhead ribozymes is well known
in the art and is described more fully in Haseloff and Gerlach
((1988) Nature, 334: 585).
[0211] The ribozymes of the present invention also include RNA
endoribonucleases (hereinafter "Cech-type ribozymes") such as the
one which occurs naturally in Tetrahymena thermophila (known as the
IVS, or L-19 IVS RNA), and which has been extensively described by
Thomas Cech and collaborators (see Zaug et al., (1984) Science,
224:574-578; Zaug and Cech (1986) Science, 231:470-475; Zaug, et
al., (1986) Nature, 324:429-433; International patent application
No. WO88/04300; Been and Cech (1986) Cell, 47:207-216). The
Cech-type ribozymes have an eight base pair active site, which
hybridizes to a target RNA sequence where after cleavage of the
target RNA takes place. The invention encompasses those Cech-type
ribozymes, which target eight base-pair active site sequences.
While the invention is not limited to a particular theory of
operative mechanism, the use of hammerhead ribozymes in the
invention may have an advantage over the use of PDGF/VEGF-directed
antisense, as recent reports indicate that hammerhead ribozymes
operate by blocking RNA translation and/or specific cleavage of the
mRNA target.
[0212] As in the antisense approach, the ribozymes can be composed
of modified oligonucleotides (e.g., for improved stability,
targeting, etc.) and are delivered to cells expressing the target
mRNA. A useful method of delivery involves using a DNA construct
"encoding" the ribozyme under the control of a strong constitutive
pol III or pol II promoter, so that transfected cells will produce
sufficient quantities of the ribozyme to destroy targeted messages
and inhibit translation. Because ribozymes, unlike antisense
molecules, are catalytic, a lower intracellular concentration is
required for efficiency.
[0213] As described above, nuclease resistance, where needed, is
provided by any method known in the art that does not substantially
interfere with biological activity of the antisense
oligodeoxynucleotides or ribozymes as needed for the method of use
and delivery (Iyer et al., (1990) J. Org. Chem., 55: 4693-99;
Eckstein (1985) Ann. Rev. Biochem., 54: 367-402; Spitzer and
Eckstein (1988) Nucleic Acids Res., 18: 11691-704; Woolf et al.,
(1990) Nucleic Acids Res., 18: 1763-69; and Shaw et al., (1991)
Nucleic Acids Res., 18: 11691-704). As described above for
aptamers, non-limiting representative modifications that can be
made to antisense oligonucleotides or ribozymes in order to enhance
nuclease resistance include modifying the phosphorous or oxygen
heteroatom in the phosphate backbone, short chain alkyl or
cycloalkyl intersugar linkages or short chain heteroatomic or
heterocyclic intersugar linkages. These include, e.g., preparing
2'-fluoridated, O-methylated, methyl phosphonates,
phosphorothioates, phosphorodithioates and morpholino oligomers.
For example, the antisense oligonucleotide or ribozyme may have
phosphorothioate bonds linking between four to six 3'-terminus
nucleotide bases. Alternatively, phosphorothioate bonds may link
all the nucleotide bases.
[0214] Phosphorothioate antisense oligonucleotides do not normally
show significant toxicity at concentrations that are effective and
exhibit sufficient pharmacodynamic half-lives in animals (see
Agarwal et al., (1996) TIBTECH, 14: 376) and are nuclease
resistant. Alternatively the nuclease resistance for the AS-ODN can
be provided by having a 9 nucleotide loop forming sequence at the
3'-terminus having the nucleotide sequence CGCGAAGCG. The use of
avidin-biotin conjugation reaction can also be used for improved
protection of AS-ODNs against serum nuclease degradation (see Boado
and Pardridge (1992) Bioconj. Chem., 3: 519-23). According to this
concept the AS-ODN agents are monobiotinylated at their 3'-end.
When reacted with avidin, they form tight, nuclease-resistant
complexes with 6-fold improved stability over non-conjugated
ODNs.
[0215] Other studies have shown extension in vivo of antisense
oligodeoxynuclcotides (Agarwal et al., (1991) Proc. Natl. Acad.
Sci. (USA) 88: 7595). This process, presumably useful as a
scavenging mechanism to remove alien AS-oligonucleotides from the
circulation, depends upon the existence of free 3'-termini in the
attached oligonucleotides on which the extension occurs. Therefore
partial phosphorothioate, loop protection or biotin-avidin at this
important position should be sufficient to ensure stability of
these AS-oligodeoxynucleotides.
[0216] In addition to using modified bases as described above,
analogs of nucleotides can be prepared wherein the structure of the
nucleotide is fundamentally altered and that are better suited as
therapeutic or experimental reagents. An example of a nucleotide
analog is a peptide nucleic acid (PNA) wherein the deoxyribose (or
ribose) phosphate backbone in DNA (or RNA) is replaced with a
polyamide backbone, which is similar to that found in peptides. PNA
analogs have been shown to be resistant to degradation by enzymes
and to have extended lives in vivo and in vitro. Further, PNAs have
been shown to bind stronger to a complementary DNA sequence than a
DNA molecule. This observation is attributed to the lack of charge
repulsion between the PNA strand and the DNA strand. Other
modifications that can be made to oligonucleotides include polymer
backbones, morpholino polymer backbones (see, e.g., U.S. Pat. No.
5,034,506, the contents of which are incorporated herein by
reference), cyclic backbones, or acyclic backbones, sugar mimetics
or any other modification including which can improve the
pharmacodynamics properties of the oligonucleotide.
[0217] A further aspect of the invention relates to the use of DNA
enzymes to decrease expression of the target mRNA as, e.g., PDGF or
VEGF. DNA enzymes incorporate some of the mechanistic features of
both antisense and ribozyme technologies. DNA enzymes axe designed
so that they recognize a particular target nucleic acid sequence,
much like an antisense oligonucleotide, however much like a
ribozyme they are catalytic and specifically cleave the target
nucleic acid.
[0218] There are currently two basic types of DNA enzymes, and both
of these were identified by Santoro and Joyce (see, for example,
U.S. Pat. No. 6,110,462). The 10-23 DNA enzyme comprises a loop
structure which connect two arms. The two arms provide specificity
by recognizing the particular target nucleic acid sequence while
the loop structure provides catalytic function under physiological
conditions.
[0219] Briefly, to design DNA enzyme that specifically recognizes
and cleaves a target nucleic acid, one of skill in the art must
first identify the unique target sequence. This can be done using
the same approach as outlined for antisense oligonucleotides. In
certain instances, the unique or substantially sequence is a G/C
rich of approximately 18 to 22 nucleotides. High G/C content helps
insure a stronger interaction between the DNA enzyme and the target
sequence.
[0220] When synthesizing the DNA enzyme, the specific antisense
recognition sequence that targets the enzyme to the message is
divided so that it comprises the two arms of the DNA enzyme, and
the DNA enzyme loop is placed between the two specific arms.
[0221] Methods of making and administering DNA enzymes can be
found, for example, in U.S. Pat. No. 6,110,462. Similarly, methods
of delivery DNA ribozymes in vitro or in vivo include methods of
delivery RNA ribozyme, as outlined herein. Additionally, one of
skill in the art will recognize that, like antisense
oligonucleotides, DNA enzymes can be optionally modified to improve
stability and improve resistance to degradation.
[0222] RNAi antagonists
[0223] Some embodiments of the invention make use of materials and
methods for effecting repression of VEGF and PDGF by means of RNA
interference (RNAi). RNAi is a process of sequence-specific
post-transcriptional gene repression that can occur in eukaryotic
cells. In general, this process involves degradation of an mRNA of
a particular sequence induced by double-stranded RNA (dsRNA) that
is homologous to that sequence. For example, the expression of a
long dsRNA corresponding to the sequence of a particular
single-stranded mRNA (ss mRNA) will labilize that message, thereby
"interfering" with expression of the corresponding gene.
Accordingly, any selected gene may be repressed by introducing a
dsRNA which corresponds to all or a substantial part of the mRNA
for that gene. It appears that when a long dsRNA is expressed, it
is initially processed by a ribonuclease III into shorter dsRNA
oligonucleotides of as few as 21 to 22 base pairs in length.
Accordingly, RNAi may be effected by introduction or expression of
relatively short homologous dsRNAs. Indeed the use of relatively
short homologous dsRNAs may have certain advantages as discussed
below.
[0224] Mammalian cells have at least two pathways that are affected
by double-stranded RNA (dsRNA). In the RNAi (sequence-specific)
pathway, the initiating dsRNA is first broken into short
interfering (si) RNAs, as described above. The siRNAs have sense
and antisense strands of about 21 nucleotides that form
approximately 19 nucleotide si RNAs with overhangs of two
nucleotides at each 3' end. Short interfering RNAs are thought to
provide the sequence information that allows a specific messenger
RNA to be targeted for degradation. In contrast, the nonspecific
pathway is triggered by dsRNA of any sequence, as long as it is at
least about 30 base pairs in length. The nonspecific effects occur
because dsRNA activates two enzymes: PKR (double-stranded
RNA-activated protein kinase), which in its active form
phosphorylates the translation initiation factor eIF2 to shut down
all protein synthesis, and 2',5' oligoadenylate synthetase
(2',5'-AS), which synthesizes a molecule that activates RNase L, a
nonspecific enzyme that targets all mRNAs. The nonspecific pathway
may represent a host response to stress or viral infection, and, in
general, the effects of the nonspecific pathway are minimized in
particularly useful methods of the present invention.
Significantly, longer dsRNAs appear to be required to induce the
nonspecific pathway and, accordingly, dsRNAs shorter than about 30
bases pairs are particular useful to effect gene repression by RNAi
(see, e.g., Hunter et al., (1975) J. Biol. Chem., 250: 409-17;
Manche et al., (1992) Mol. Cell Biol., 12: 5239-48; Minks et al.,
(1979) J. Biol. Chem., 254: 10180-3; and Elbashir et al., (2001)
Nature, 411: 494-8).
[0225] Certain double stranded oligonucleotides used to effect RNAi
are less than 30 base pairs in length and may comprise about 25,
24, 23, 22, 21, 20, 19, 18 or 17 base pairs of ribonucleic acid.
Optionally, the dsRNA oligonucleotides of the invention may include
3' overhang ends. Non-limiting exemplary 2-nucleotide 3' overhangs
may be composed of ribonucleotide residues of any type and may even
be composed of 2'-deoxythymidine resides, which lowers the cost of
RNA synthesis and may enhance nuclease resistance of siRNAs in the
cell culture medium and within transfected cells (see Elbashi et
al., (2001) Nature, 411: 494-8).
[0226] Longer dsRNAs of 50, 75, 100 or even 500 base pairs or more
may also be utilized in certain embodiments of the invention.
Exemplary concentrations of dsRNAs for effecting RNAi are about
0.05 nM, 0.1 nM, 0.5 nM, 1.0 nM, 1.5 nM, 25 nM or 100 nM, although
other concentrations may be utilized depending upon the nature of
the cells treated, the gene target and other factors readily
discernable the skilled artisan. Exemplary dsRNAs may be
synthesized chemically or produced in vitro or in vivo using
appropriate expression vectors. Exemplary synthetic RNAs include 21
nucleotide RNAs chemically synthesized using methods known in the
art (e.g., Expedite RNA phophoramidites and thymidine
phosphoramidite (Proligo, Germany)). Synthetic oligonucleotides may
be deprotected and gel-purified using methods known in the art (see
e.g., Elbashir et al., (2001) Genes Dev., 15: 188-200). Longer RNAs
may be transcribed from promoters, such as T7 RNA polymerase
promoters, known in the art. A single RNA target, placed in both
possible orientations downstream of an in vitro promoter, will
transcribe both strands of the target to create a dsRNA
oligonucleotide of the desired target sequence.
[0227] The specific sequence utilized in design of the
oligonucleotides may be any contiguous sequence of nucleotides
contained within the expressed gene message of the target (e.g., of
PDGF (e.g., SEQ ID NO:2) or VEGF (e.g., SEQ ID NO: 4). Programs and
algorithms, known in the art, may be used to select appropriate
target sequences. In addition, optimal sequences may be selected,
as described additionally above, utilizing programs designed to
predict the secondary structure of a specified single stranded
nucleic acid sequence and allow selection of those sequences likely
to occur in exposed single stranded regions of a folded mRNA.
Methods and compositions for designing appropriate oligonucleotides
may be found in, for example, U.S. Pat. No. 6,251,588, the contents
of which are incorporated herein by reference. mRNA is generally
thought of as a linear molecule that contains the information for
directing protein synthesis within the sequence of ribonucleotides.
However, studies have revealed a number of secondary and tertiary
structures exist in most mRNAs. Secondary structure elements in RNA
are formed largely by Watson-Crick type interactions between
different regions of the same RNA molecule. Important secondary
structural elements include intramolecular double stranded regions,
hairpin loops, bulges in duplex RNA and internal loops. Tertiary
structural elements are formed when secondary structural elements
come in contact with each other or with single stranded regions to
produce a more complex three-dimensional structure. A number of
researchers have measured the binding energies of a large number of
RNA duplex structures and have derived a set of rules which can be
used to predict the secondary structure of RNA (see e.g., Jaeger et
al., (1989) Proc. Natl. Acad. Sci. (USA) 86:7706 (1989); and Turner
et al., (1988) Ann. Rev. Biophys. Biophys. Chem., 17:167). The
rules are useful in identification of RNA structural elements and,
in particular, for identifying single stranded RNA regions, which
may represent particularly useful segments of the mRNA to target
for silencing RNAi, ribozyme or antisense technologies.
Accordingly, particular segments of the mRNA target can be
identified for design of the RNAi mediating dsRNA oligonucleotides
as well as for design of appropriate ribozyme and
hammerheadribozyme compositions of the invention.
[0228] The dsRNA oligonucleotides may be introduced into the cell
by transfection with an heterologous target gene using carrier
compositions such as liposomes, which are known in the art, e.g.,
Lipofectamine 2000 (Life Technologies, Rockville Md.) as described
by the manufacturer for adherent cell lines. Transfection of dsRNA
oligonucleotides for targeting endogenous genes may be carried out
using Oligofectamine (Life Technologies). Transfection efficiency
may be checked using fluorescence microscopy for mammalian cell
lines after co-transfection of hGFP encoding pAD3 (Kehlenback et
al., (1998) J. Cell. Biol., 141: 863-74). The effectiveness of the
RNAi may be assessed by any of a number of assays following
introduction of the dsRNAs. These include, but are not limited to,
Western blot analysis using antibodies which recognize the targeted
gene product following sufficient time for turnover of the
endogenous pool after new protein synthesis is repressed, and
Northern blot analysis to determine the level of existing target
mRNA.
[0229] Still further compositions, methods and applications of RNAi
technology for use in the invention are provided in U.S. Pat. Nos.
6,278,039, 5,723,750 and 5,244,805, which are incorporated herein
by reference.
[0230] Receptor Tyrosine Kinase Inhibitor Antagonists
[0231] Also included in the invention are tyrosine kinase
antagonists known in the art and variants and alternatives thereto
that may be obtained using routine skill in the art and the
teachings of the art incorporated herein by reference. The
extracellular signal of PDGF (and VEGF) is communicated to other
parts of the cell via a tyrosine kinase mediated phosphorylation
event effected by the PDGF receptor (and VEGF receptor) and which
affects substrate proteins downstream of the cell membrane bound
signaling complex. Accordingly, antagonists acting at the receptor
kinase stage of PDGF (and/or VEGF) signaling are also effective in
the method of the invention.
[0232] A number of types of tyrosine kinase inhibitors that are
selective for tyrosine kinase receptor enzymes such as PDGFR or
VEGFR, are known (see, e.g., Spada and Myers ((1995) Exp. Opin.
Ther. Patents, 5: 805) and Bridges ((1995) Exp. Opin. Ther.
Patents, 5: 1245). Additionally Law and Lydon have summarized the
anticancer potential of tyrosine kinase inhibitors ((1996) Emerging
Drugs: The Prospect For Improved Medicines, 241-260). For example,
U.S. Pat. No. 6,528,526 describes substituted quinoxaline compounds
that exhibit selectively inhibit platelet-derived growth
factor-receptor (PDGFR) tyrosine kinase activity. The known
inhibitors of PDGFR tyrosine kinase activity includes
quinoline-based inhibitors reported by Maguire et al., ((1994) J.
Med. Chem., 37: 2129), and by Dolle, et al., ((1994) J. Med. Chem.,
37: 2627). A class of phenylamino-pyrimidine-based inhibitors was
recently reported by Traxler, et al., in EP 564409 and by Zimmerman
et al., ((1996) Biorg. Med. Chem. Lett., 6: 1221-1226) and by
Buchdunger, et al., ((1995) Proc. Nat. Acad. Sci. (USA), 92: 2558).
Quinazoline derivatives that are useful in inhibiting PDGF receptor
tyrosine kinase activity include bismono- and bicyclic aryl
compounds and heteroaryl compounds (see, e.g., WO 92/20642),
quinoxaline derivatives (see (1994) Cancer Res., 54: 6106-6114),
pyrimidine derivatives (Japanese Published Patent Application No.
87834/94) and dimethoxyquinoline derivatives (see Abstracts of the
116th Annual Meeting of the Pharmaceutical Society of Japan
(Kanazawa), (1996), 2, p. 275, 29(C2) 15-2).
[0233] Examples of VEGFR tyrosine kinase inhibitors include
cinnoline derivatives, e.g., those described in U.S. Pat. No.
6,514,971, the contents of which are incorporated herein in their
entirety. Other such cinnoline derivatives are also known. For
example, (1995) J. Med Chem., 38: 3482-7 discloses
4-(3-bromoanilino)cinnoline; (1968) J. Chem. Soc. C, (9):1 152-5
discloses 6-chloro-4-phenoxycinnoline; (1984) J. Karnatak Univ.,
Sci., 29: 82-6 discloses certain 4-anilinocinnolines; and (1973)
Indian J. Chem., 11: 211-13 discloses certain
4-phenylthiocinnolines. Furthermore, (1973) J. Karnatak Univ., 18:
25-30 discloses certain 4-phenoxycinnolines, (1984) J. Karnatak
Univ. Sci., 29: 82-6 discloses two compounds:
4-(4-methoxyanilino)-6,7-dimethoxycinnoline and
4-(3-chloroanilino)-6,7-dimethoxycinnoline. Furthermore, certain
cinnolines with a phenyl ring linked via a group selected from
--O--, --S--, --NH-- and --CH2- at the 4-position are described in
U.S. Pat. No. 5,017,579, U.S. Pat. No. 4,957,925, U.S. Pat. No.
4,994,474, and EP 0302793 A2.
[0234] Still other related compounds for inhibition of VEGFR and/or
PDGFR are available by screening novel compounds for their effect
on the receptor tyrosine kinase activity of interest using a
convention assay. Effective inhibition by a candidate PDGFR or
VEGFR small molecule organic inhibitor can be monitored using a
cell-based assay system as well as other assay systems known in the
art.
[0235] For example, one test for activity against VEGF-receptor
tyrosine kinase is as follows. The test is conducted using Fit-1
VEGF-receptor tyrosine kinase. The detailed procedure is as
follows: 30 .mu.l kinase solution (10 ng of the kinase domain of
Fit-1 (see Shibuya, et al., (1990) Oncogene. 5: 519-24) in 20 mM
Tris.HCl pH 7.5, 3 mM manganese dichloride (MnCl.sub.2), 3 mM
magnesium chloride (MgCl.sub.2), 10 uM sodium vanadate, 0.25 mg/ml
polyethylenglycol (PEG) 20000, 1 mM dithiothreitol and 3 ug/.mu.l
poly(Glu,Tyr) 4:1 (Sigma, Buchs, Switzerland). 8 uM [.sup.33P]-ATP
(0.2 uCi), 1% dimethyl sulfoxide, and 0 to 100 .mu.M of the
compound to be tested are incubated together for 10 minutes at room
temperature. The reaction is then terminated by the addition of 10
.mu.l 0.25 M ethylenediaminetetraacetate (EDTA) pH 7. Using a
multichannel dispenser (LAB SYSTEMS, USA), an aliquot of 20 .mu.l
is applied to a PVDF (=polyvinyl difluoride) Immobilon P membrane
(Millipore, USA), through a microtiter filter manifold and
connected to a vacuum. Following complete elimination of the
liquid, the membrane is washed 4 times successively in a bath
containing 0.5% phosphoric acid (H.sub.3PO.sub.4) and once with
ethanol, incubated for 10 minutes each time while shaking, then
mounted in a Hewlett Packard TopCount Manifold and the
radioactivity measured after the addition of 10 .mu.l
Microscint.RTM. (beta-scintillation counter liquid).
IC.sub.50-values are determined by linear regression analysis of
the percentages for the inhibition of each compound in three
concentrations (as a rule 0.01 .mu.mol, 0.1 .mu.mol, and 1
.mu.mol). The IC.sub.50-values of active tyrosine inhibitor
compounds may be in the range of 0.01 .mu.M to 100 .mu.M.
[0236] Furthermore, inhibition of a VEGF-induced VEGFR tyrosine
kinase/autophosphorylation activity can be confirmed with a further
experiment on cells. Briefly, transfected CHO cells, which
permanently express human VEGF receptor (VEGFR/KDR), are seeded in
complete culture medium (with 10% fetal call serum (FCS) in 6-well
cell-culture plates and incubated at 37.degree. C. under 5%
CO.sub.2 until they show about 80% confluency. The compounds to be
tested are then diluted in culture medium (without FCS, with 0.1%
bovine serum albumin) and added to the cells. (Controls comprise
medium without test compounds). After a two hour incubation at
37.degree. C., recombinant VEGF is added; the final VEGF
concentration is 20 ng/ml). After a further five minutes incubation
at 37.degree. C., the cells are washed twice with ice-cold PBS) and
immediately lysed in 100 .mu.l lysis buffer per well. The lysates
are then centrifuged to remove the cell nuclei, and the protein
concentrations of the supernatants are determined using a
commercial protein assay (BIORAD). The lysates can then either be
immediately used or, if necessary, stored at -200.degree. C.
[0237] A sandwich ELISA is then carried out to measure the
KDR-receptor phosphorylation: a monoclonal antibody to KDR is
immobilized on black ELISA plates (OptiPlate.TM., HTRF-96 from
Packard). The plates are then washed and the remaining free
protein-binding sites are saturated with 1% BSA in PBS. The cell
lysates (20 .mu.g protein per well) are then incubated in these
plates overnight at 4.degree. C. together with an
antiphosphotyrosine antibody coupled with alkaline phosphatase
(e.g., PY20:AP from Transduction Laboratories, Lexington, Ky.). The
plates are washed again and the binding of the antiphosphotyrosine
antibody to the captured phosphorylated receptor is then
demonstrated using a luminescent AP substrate (CDP-Star, ready to
use, with Emerald II; Applied-Biosystems TROPIX Bedford, Mass.).
The luminescence is measured in a Packard Top Count Microplate
Scintillation Counter. The difference between the signal of the
positive control (stimulated with VEGF or PDGF) and that of the
negative control (not stimulated with VEGF or PDGF) corresponds to
VEGF-induced KDR-receptor phosphorylation (=100%). The activity of
the tested substances is calculated as % inhibition of VEGF-induced
KDR-receptor phosphorylation, wherein the concentration of
substance that induces half the maximum inhibition is defined as
the ED.sub.50 (effective dose for 50% inhibition). Active tyrosine
inhibitor compound have ED.sub.50 values in the range of 0.001
.mu.M to 6 .mu.M, typically 0.005 .mu.M to 0.5 .mu.M.
[0238] Pharmaceutical Formulations and Therapeutic
Administration
[0239] The anti-VEGF and anti-PDGF agents are useful in the
treatment of a neovascular disorder, including psoriasis,
rheumatoid arthritis, and ocular neovascular disorders. Of
particular interest are therapies using a PDGF-B antagonist
compound in combination with a VEGF-A antagonist to suppress an
ocular neovascular disorder such as macular degeneration or
diabetic retinopathy. Accordingly, once a patient has been
diagnosed to be at risk at developing or having a neovascular
disorder, the patient is treated by administration of a PDGF
antagonist in combination with a VEGF antagonist in order to block
respectively the negative effects of PDGF and VEGF, thereby
suppressing the development of a neovascular disorder and
alleviating deleterious effects associated with neovascularization.
The practice of the methods according to the present invention does
not result in corneal edema. As is discussed above, a wide variety
of PDGF and VEGF antagonists may be used in the present
invention.
[0240] Anti-PDGF and anti-VEGF combination therapy according to the
invention may be performed alone or in conjunction with another
therapy and may be provided at home, the doctor's office, a clinic,
a hospital's outpatient department, or a hospital. Treatment
generally begins at a hospital so that the doctor can observe the
therapy's effects closely and make any adjustments that are needed.
The duration of the combination therapy depends on the type of
neovascular disorder being treated, the age and condition of the
patient, the stage and type of the patient's disease, and how the
patient responds to the treatment. Additionally, a person having a
greater risk of developing a neovascular disorder (e.g., a diabetic
patient) may receive treatment to inhibit or delay the onset of
symptoms. One significant advantage provided by the present
invention is that the combination of a PDGF antagonist and a VEGF
antagonist for the treatment of a neovascular disorder allows for
the administration of a low dose of each antagonist and less total
active antagonist, thus providing similar efficacy with less
toxicity and side effects, and reduced costs.
[0241] Administration of each antagonist of the combination therapy
may be by any suitable means that results in a concentration of the
antagonist that, combined with the other antagonist, is effective
for the treatment of a neovascular disorder. Each antagonist, for
example, may be admixed with a suitable carrier substance, and is
generally present in an amount of 1-95% by weight of the total
weight of the composition. The composition may be provided in a
dosage form that is suitable for ophthalmic, oral, parenteral
(e.g., intravenous, intramuscular, subcutaneous), rectal,
transdermal, nasal, or inhalant administration. Accordingly, the
composition may be in form of, e.g., tablets, capsules, pills,
powders, granulates, suspensions, emulsions, solutions, gels
including hydrogels, pastes, ointments, creams, plasters, delivery
devices, suppositories, enemas, injectables, implants, sprays, or
aerosols. The pharmaceutical compositions containing a single
antagonist or two or more antagonists may be formulated according
to conventional pharmaceutical practice (see, e.g., Remington: The
Science and Practice of Pharmacy, (20th ed.) ed. A. R. Gennaro,
2000, Lippincott Williams & Wilkins, Philadelphia, Pa. and
Encyclopedia of Pharmaceutical Technology, eds., J. Swarbrick and
J. C. Boylan, 1988-2002, Marcel Dekker, New York).
[0242] Combinations of PDGF and VEGF antagonists are, in one useful
aspect, administered parenterally (e.g., by intramuscular,
intraperitoneal, intravenous, intraocular, intravitreal,
retro-bulbar, subconjunctival, subtenon or subcutaneous injection
or implant) or systemically. Formulations for parenteral or
systemic administration include sterile aqueous or non-aqueous
solutions, suspensions, or emulsions. A variety of aqueous carriers
can be used, e.g., water, buffered water, saline, and the like.
Examples of other suitable vehicles include polypropylene glycol,
polyethylene glycol, vegetable oils, gelatin, hydrogels,
hydrogenated naphalenes, and injectable organic esters, such as
ethyl oleate. Such formulations may also contain auxiliary
substances, such as preserving, wetting, buffering, emulsifying,
and/or dispersing agents. Biocompatible, biodegradable lactide
polymer, lactide/glycolide copolymer, or
polyoxyethylene-polyoxypropylene copolymers may be used to control
the release of the active ingredients.
[0243] Alternatively, combinations of PDGF and VEGF antagonists can
be administered by oral ingestion. Compositions intended for oral
use can be prepared in solid or liquid forms, according to any
method known to the art for the manufacture of pharmaceutical
compositions.
[0244] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. Generally, these
pharmaceutical preparations contain active ingredients (such as a
PDGF small organic molecule antagonist and a VEGF small organic
molecule antagonist) admixed with non-toxic pharmaceutically
acceptable excipients. These may include, for example, inert
diluents, such as calcium carbonate, sodium carbonate, lactose,
sucrose, glucose, mannitol, cellulose, starch, calcium phosphate,
sodium phosphate, kaolin and the like. Binding agents, buffering
agents, and/or lubricating agents (e.g., magnesium stearate) may
also be used. Tablets and pills can additionally be prepared with
enteric coatings. The compositions may optionally contain
sweetening, flavoring, coloring, perfuming, and preserving agents
in order to provide a more palatable preparation.
[0245] For example, the PDGF and VEGF antagonists may be administer
intraocullary by intravitreal injection into the eye as well as
subconjunctival and subtenon injections. Other routes of
administration include transcleral, retro bulbar, intraperoteneal,
intramuscular, and intravenous. Alternatively, a combination of
antagonists may be delivered using a drug delivery device or an
intraocular implant (see below).
[0246] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups, and soft gelatin capsules. These forms contain inert
diluents commonly used in the art, such as water or an oil medium,
and can also include adjuvants, such as wetting agents, emulsifying
agents, and suspending agents.
[0247] In some instances, the combination of PDGF and VEGF
antagonists can also be administered topically, for example, by
patch or by direct application to a region, such as the epidermis
or the eye, susceptible to or affected by a neovascular disorder,
or by iontophoresis.
[0248] Formulations for ophthalmic use include tablets containing
the active ingredient(s) in a mixture with non-toxic
pharmaceutically acceptable excipients. These excipients may be,
for example, inert diluents or fillers (e.g., sucrose and
sorbitol), lubricating agents, glidants, and antiadhesives (e.g.,
magnesium stearate, zinc stearate, stearic acid, silicas,
hydrogenated vegetable oils, or talc).
[0249] The PDGF and VEGF antagonists may be mixed together in a
tablet or other vehicle, or may be partitioned. In one example, the
first antagonist is contained on the inside of the tablet, and the
second antagonist is on the outside, such that a substantial
portion of the second antagonist is released prior to the release
of the first antagonist. If desired, antagonists in a tablet form
may be delivered using a drug delivery device (see below).
[0250] Generally, each of the antagonists should be administered in
an amount sufficient to suppress or reduce or eliminate a
deleterious effect or a symptom of a neovascular disorder. The
amount of an active antagonist ingredient that is combined with the
carrier materials to produce a single dosage will vary depending
upon the subject being treated and the particular mode of
administration.
[0251] The dosage of each antagonist of the claimed combinations
depends on several factors including the severity of the condition,
whether the condition is to be treated or prevented, and the age,
weight, and health of the person to be treated. Additionally,
pharmacogenomic (the effect of genotype on the pharmacokinetic,
pharmacodynamic or efficacy profile of a therapeutic) information
about a particular patient may affect dosage used. Furthermore, one
skilled in the art will appreciate that the exact individual
dosages may be adjusted somewhat depending on a variety of factors,
including the specific combination of PDGF and VEGF antagonists
being administered, the time of administration, the route of
administration, the nature of the formulation, the rate of
excretion, the particular neovascular disorder being treated, the
severity of the disorder, and the anatomical location of the
neovascular disorder (for example, the eye versus the body cavity).
Wide variations in the needed dosage are to be expected in view of
the differing efficiencies of the various routes of administration.
For instance, oral administration generally would be expected to
require higher dosage levels than administration by intravenous or
intravitreal injection. Variations in these dosage levels can be
adjusted using standard empirical routines for optimization, which
are well-known in the art. The precise therapeutically effective
dosage levels and patterns are typically determined by the
attending physician such as an ophthalmologist in consideration of
the above-identified factors.
[0252] Generally, when orally administered to a human, the dosage
of the PDGF antagonist or VEGF antagonist is normally about 0.001
mg to about 200 mg per day, desirably about 1 mg to 100 mg per day,
and more desirably about 5 mg to about 50 mg per day. Dosages up to
about 200 mg per day may be necessary. For administration of the
PDGF antagonist or VEGF antagonist by injection, the dosage is
normally about 0.1 mg to about 250 mg per day, desirably about 1 mg
to about 20 mg per day, or about 3 mg to about 5 mg per day.
Injections may be given up to about four times daily. Generally,
when parenterally or systemically administered to a human, the
dosage of the VEGF antagonist for use in combination with the PDGF
antagonist is normally about 0.1 mg to about 1500 mg per day, or
about 0.5 mg to 10 about mg per day, or about 0.5 mg to about 5 mg
per day. Dosages up to about 3000 mg per day may be necessary.
[0253] When ophthalmologically administered to a human, the dosage
of the VEGF antagonist for use in combination with the PDGF
antagonist is normally about 0.15 mg to about 3.0 mg per day, or at
about 0.3 mg to about 3.0 mg per day, or at about 0.1 mg to 1.0 mg
per day.
[0254] For example, for ophthalmic uses, PDGF-B and VEGF-A aptamer
drug substances are formulated in phosphate buffered saline at pH
5-7. Sodium hydroxide or hydrochloric acid may be added for pH
adjustment. In one working formulation, a PDGF-B aptamer and a
VEGF-A aptamer, such as EYE001, are individually formulated at
three different concentrations: 3 mg/100 .mu.l, 2 mg/100 .mu.l and
1 mg/100 .mu.l packaged in a sterile 1 ml, USP Type I graduated
glass syringe fitted with a sterile 27-gauge needle. The
combination drug product is preservative-free and intended for
single use by intravitreous injection only. The active ingredient
is PDGF-B and VEGF-A drug substances, at 30 mg/ml, 20 mg/ml and 10
mg/ml concentrations. The excipients are Sodium Chloride, USP;
Sodium Phosphate Monobasic, Monohydrate, USP; Sodium Phosphate
Dibasic, Heptahydrate, USP; Sodium Hydroxide, USP; Hydrochloric
acid, USP; and Water for injection, USP. In this form the PDGF-B
and VEGF-A aptamer drug products are in a ready-to-use sterile
solution provided in a single-use glass syringe. The syringe is
removed from refrigerated storage at least 30 minutes (but not
longer than 4 hours) prior to use to allow the solution to reach
room temperature. Administration of the syringe contents involves
attaching the threaded plastic plunger rod to the rubber stopper
inside the barrel of the syringe. The rubber end cap is then
removed to allow administration of the product. PDGF-B and VEGF-A
aptamers are administered as a 100 .mu.l intravitreal injections on
three occasions at 28 day intervals. Patients receive 3
mg/injection per visit. The dose is reduced to 2 mg or 1 mg, and
further to 0.1 mg if necessary.
[0255] The specific amounts of drugs administered depend on the
specific combination of components. In a desired dose combination,
the ratio of PDGF antagonist to VEGF antagonist is about 50:1 by
weight, about 20:1 by weight, about 10:1 by weight, or about 4:1,
about 2:1, or about 1:1 by weight.
[0256] A useful combination therapy includes a PDGF-B aptamer
antagonist and a VEGF-A aptamer antagonist. The antagonists are
used in combination in a weight ratio range from about 0.1 to about
5.0 to about 5.0 to 0.1 of the PDGF-B aptamer antagonist to VEGF-A
aptamer antagonist. A useful range of these two antagonists (PDGF-B
to VEGF-A antagonist) is from about 0.5 to about 2.0, or from about
2.0 to 0.5, while another useful ratio is from about 1.0 to about
1.0, depending ultimately on the selection of the PDGF-B aptamer
antagonist and the VEGF-A aptamer antagonist.
[0257] Administration of each drug in the combination therapy can,
independently, be one to four times daily for one day to one year,
and may even be for the life of the patient. Chronic, long-term
administration will be indicated in many cases. The dosage may be
administered as a single dose or divided into multiple doses. In
general, the desired dosage should be administered at set intervals
for a prolonged period, usually at least over several weeks,
although longer periods of administration of several months or more
may be needed.
[0258] In addition to treating pre-existing neovascular disorders,
the combination therapy that includes a PDGF antagonist and VEGF
antagonist can be administered prophylactically in order to prevent
or slow the onset of these disorders. In prophylactic applications,
the PDGF and VEGF antagonists are administered to a patient
susceptible to or otherwise at risk of a particular neovascular
disorder. Again, the precise timing of the administration and
amounts that are administered depend on various factors such as the
patient's state of health, weight, etc.
[0259] In one working example, the combination of the PDGF
antagonist and the VEGF antagonist is administered to a mammal in
need of treatment therewith, typically in the form of an injectable
pharmaceutical composition. In the combination aspect, for example,
a PDGF-B aptamer and a VEGF-A aptamer may be administered either
separately or in the pharmaceutical composition comprising both. It
is generally preferred that such administration be by injection or
by using a drug delivery device. Parenteral, systemic, or
transdermal administration is also acceptable.
[0260] As discussed above, when the PDGF antagonist and VEGF
antagonist are administered together, such administration can be
sequential in time or simultaneous with the sequential method being
one mode of administration. When the PDGF and VEGF antagonists are
administered sequentially, the administration of each can be by the
same or different methods. For sequential administration, however,
it is useful that the method employ administration of the PDGF
antagonist over about five seconds (up to about three injections)
followed by sustained administration every six weeks for up to
about nine injections per year of a VEGF antagonist. The PDGF
antagonist may be administered at the time of each VEGF antagonist
injection or may be given less often, as determined by the
physician. Sequential administration also includes a combination
where the individual antagonists may be administered at different
times or by different routes or both but which act in combination
to provide a beneficial effect, for example, to suppress a
neovascular disorder. It is also noted that administration by
injection is particularly useful.
[0261] Pharmaceutical compositions according to the invention may
be formulated to release the active PDGF and VEGF antagonists
substantially immediately upon administration or at any
predetermined time period after administration, using controlled
release formulations. For example, a pharmaceutical composition
that includes at least one of each of a PDGF antagonist and a VEGF
antagonist may be provided in sustained release compositions. The
use of immediate or sustained release compositions depends on the
nature of the condition being treated. If the condition consists of
an acute or over-acute disorder, treatment with an immediate
release form will be typically utilized over a prolonged release
composition. For certain preventative or long-term treatments, a
sustained released composition may also be appropriate.
[0262] Administration of each of the antagonists in controlled
release formulations is useful where the antagonist, either alone
or in combination, has (i) a narrow therapeutic index (e.g., the
difference between the plasma concentration leading to harmful side
effects or toxic reactions and the plasma concentration leading to
a therapeutic effect is small; generally, the therapeutic index,
TI, is defined as the ratio of median lethal dose (LD.sub.50) to
median effective dose (ED.sub.50)); (ii) a narrow absorption window
in the gastro-intestinal tract; or (iii) a short biological
half-life, so that frequent dosing during a day is required in
order to sustain the plasma level at a therapeutic level.
[0263] Many strategies can be pursued to obtain controlled release
in which the rate of release outweighs the rate of degradation or
metabolism of the therapeutic antagonist. For example, controlled
release can be obtained by the appropriate selection of formulation
parameters and ingredients, including, e.g., appropriate controlled
release compositions and coatings. Examples include single or
multiple unit tablet or capsule compositions, oil solutions,
suspensions, emulsions, microcapsules, microspheres, nanoparticles,
patches, and liposomes. Methods for preparing such sustained or
controlled release formulations are well known in the art.
[0264] Pharmaceutical compositions that include a PDGF antagonist
and/or a VEGF antagonist or both may also be delivered using a drug
delivery device such as an implant. Such implants may be
biodegradable and/or biocompatible implants, or may be
non-biodegradable implants. The implants may be permeable or
impermeable to the active agent. Ophthalmic drug delivery devices
may be inserted into a chamber of the eye, such as the anterior or
posterior chambers or may be implanted in or on the scelra,
choroidal space, or an avascularized region exterior to the
vitreous. In one embodiment, the implant may be positioned over an
avascular region, such as on the sclera, so as to allow for
transcleral diffusion of the drug to the desired site of treatment,
e.g., the intraocular space and macula of the eye. Furthermore, the
site of transcleral diffusion may be proximity to a site of
neovascularization such as a site proximal to the macula.
[0265] As noted above, the invention relates to combining separate
pharmaceutical compositions in a pharmaceutical pack. The
combination of the invention is therefore provided as components of
a pharmaceutical pack. At least two antagonists can be formulated
together or separately and in individual dosage amounts. The
antagonists of the invention are also useful when formulated as
salts.
[0266] The pharmaceutical pack, in general, includes (1) an amount
of a PDGF antagonist, and a pharmaceutically acceptable carrier,
vehicle, or diluent in a first unit dosage form; (2) an amount of a
VEGF antagonist, and a pharmaceutically acceptable carrier,
vehicle, or diluent in a second unit dosage form; and (3) a
container. The container is used to separate components and may
include, for example, a divided bottle or a divided foil packet.
The separate antagonist compositions may also, if desired, be
contained within a single, undivided container. The pharmaceutical
pack may also include directions for the administration of the
separate PDGF and VEGF antagonists. The pharmaceutical pack is
particularly advantageous when the separate components are
administered in different dosage forms, are administered at
different dosage levels, or when titration of the individual
components of the combination is desired by the prescribing
physician. In one embodiment, the pharmaceutical pack is designed
to dispense doses of the PDGF and VEGF antagonists one at a time in
the order of their intended use. In another example, a
pharmaceutical pack is designed to contain rows of a PDGF
antagonist and a VEGF antagonist placed side by side in the pack,
with instructions on the pack to convey to the user that one pair
of antagonists is to be administered. An exemplary pharmaceutical
pack is the so-called blister pack that is well known in the
pharmaceutical packaging industry.
[0267] Effectiveness
[0268] Suppression of a neovascular disorder is evaluated by any
accepted method of measuring whether angiogenesis is slowed or
diminished. This includes direct observation and indirect
evaluation such as by evaluating subjective symptoms or objective
physiological indicators. Treatment efficacy, for example, may be
evaluated based on the prevention or reversal of
neovascularization, microangiopathy, vascular leakage or vascular
edema or any combination thereof. Treatment efficacy for evaluating
suppression of an ocular neovascular disorder may also be defined
in terms of stabilizing or improving visual acuity.
[0269] In determining the effectiveness of a particular combination
therapy in treating or preventing an ocular neovascular disorder,
patients may also be clinically evaluated by an ophthalmologist
several days after injection and at least one-month later just
prior to the next injection. ETDRS visual acuities, kodachrome
photography, and fluorescein angiography are also performed monthly
for the first 4 months as required by the ophthalmologist.
[0270] For example, in order to assess the effectiveness of
combination PDGF antagonist and VEGF antagonist therapy to treat
ocular neovascularization, studies are conducted involving the
administration of either single or multiple intravitreal injections
of a PDGF-B aptamer in combination with a VEGF-A aptamer (for
example, a PEGylated form of EYE001) in patients suffering from
subfoveal choroidal neovascularization secondary to age-related
macular degeneration according to standard methods well known in
the ophthalmologic arts. In one working study, patients with
subfoveal choroidal neovascularization (CNV) secondary to
age-related macular degeneration (AMD) receive a single
intravitreal injection of a PDGF-B aptamer and a VEGF-A aptamer.
Effectiveness of the combination is monitored, for example, by
ophthalmic evaluation. Patients showing stable or improved vision
three months after treatment, for example, demonstrating a 3-line
or greater improvement in vision on the ETDRS chart, are taken as
receiving an effective dosage combination of the PDGF-B aptamer and
VEGF-A aptamer that suppresses an ocular neovascular disorder.
[0271] In a working study example, patients with subfoveal CNV
secondary to age-related macular degeneration and with a visual
acuity worse than 20/200 on the ETDRS chart receive a single
intravitreous injection of the PDGF-B aptamer and VEGF-A aptamer.
The starting dose is 0.25 mg of each antagonist injected once
intravitreously. Dosages of 0.5 mg, 1, 2 mg and 3 mg of each
antagonist are also tested. Complete ophthalmic examination with
fundus photography and fluorescein angiography is also performed.
The combination drug product is a ready-to-use sterile solution
composed of the PDGF-B aptamer and VEGF-A aptamer dissolved in 10
mM sodium phosphate and 0.9% sodium chloride buffer injection in a
sterile and pyrogen free 1 cc glass body syringe barrel, with a
coated stopper attached to a plastic plunger, and a rubber end cap
on the pre-attached 27 gauge needle. The PDGF-B and VEGF-A aptamers
are supplied at drug concentrations of 1 mg/ml, 2.5 mg/ml, 5 mg/ml,
10 mg/ml, 20 mg/ml, or 30 mg/ml for each aptamer (expressed as
oligonucleotide content) to provide a 100 .mu.l delivery volume. At
approximately 3 months after injection of the PDGF-B and VEGF-A
aptamers, acuity studies are performed to evaluate effectiveness of
the treatment. Patients showing stable or improved vision after
treatment, for example, those showing as a 3-line, or greater,
increase in vision on the ETDRS chart, are taken as receiving an
effective dosage combination of PDGF-B and VEGF-A aptamers that
suppresses an ocular neovascular disorder.
EXAMPLES
[0272] The following examples illustrate certain modes of making
and practicing the present invention, but are not meant to limit
the scope of the invention since alternative methods may be used to
obtain similar results.
Example 1
Corneal Neovascularization (Corneal NV)
[0273] Corneal Neovascularization is a widely used animal model
that allows clear visualization of abnormal vascular growth in the
eye. The vessels that grow into the normally avascular cornea, can
become well established, making this an attractive model to study
vessel regression. To induce experimental corneal NV, male C57BL/6
mice (18-20 g; Charles River, Wilmington, Mass.) were anesthetized
with intramuscular ketamine hydrochloride (25 mg/kg) and xylazine
(10 mg/kg). NaOH (2 ul of 0.2 mM) was applied topically. The
corneal and limbal epithelia were removed by applying a rotary
motion parallel to the limbus using #21 blade (Feather. Osaka,
Japan). After 7 days, mice were treated with intra-peritoneal
injections of 25 mg/kg of pegaptanib sodium (Macugen.TM. (Eyetech
Pharmaceuticals, New York, N.Y.), an anti-VEGF aptamer agent also
known as EYE001) twice a day or by oral administration of 50 mg/kg
of Gleevec.RTM./STI57 ((also known as CGP57148B) a
2-phenylaminopyrimidine-related, tyrosine kinase-inhibiting
anti-PDGF agent from Novartis Pharma AG, Basel, Switzerland) by
gavage twice a day or both for 7 days. At day 14 following corneal
NV induction, mice received 20 ug/g of fluorescein-isothiocyanate
coupled concanavalin A lectin (Vector Laboratories, Burlingame,
Calif.) intravenously whilst deeply anesthetized with xylazine
hydrochloride and ketamine hydrochloride. Thirty minutes later,
mice eyes were enucleated, and the corneas flat-mounted. Corneal NV
was visualized using fluorescence microscopy and quantified using
Openlab software. The percent of cornea covered by vessels was
calculated as a percentage of total corneal area.
[0274] The effects of pegaptanib sodium and Gleevec on
neovascularization of the cornea following NaOH application and
injury to the epithilia of the limbus and cornea were investigated.
Animals treated with pegaptanib sodium (Macugen) showed a 19.6%
(p=0.0014) decrease in vessel growth as compared to both untreated
and Gleevec treated eyes (FIG. 5).
[0275] Animals treated with pegaptanib sodium and Gleevec
(Mac+Glee) exhibited significantly less neovascular growth on the
cornea (35.6% p<0.0001) as compared to controls and animals
treated with Gleevec alone (FIG. 5). Combination treatment was also
more effective than pegaptanib sodium (Macugen) alone at reducing
vessel growth (16% p<0.0145).
[0276] The results of representative corneal neovascularization
experiments are also shown in FIGS. 6 and 7. FIG. 6(D) is a
photographic representation of a fluorescent-microscopic image
showing effective inhibition of new blood vessel formation in
combination (Mac+Gleevec)-treated corneas, as compared to
individual treatments with Macugen (FIG. 6(C)) or Gleevec (FIG.
6(B)). FIG. 6(A) is a photographic representation of a
fluorescent-microscopic image showing the extent of
neovascularization in a control (PEG-treated) cornea. FIG. 7 is a
photographic representation of a fluorescent-microscopic image
showing that the individual (FIG. 7(A) (APB5-treated) and FIG. 7(B)
(Gleevec-treated)) and combined treatments (FIG. 7(C)) inhibited
only new vessel growth, and did not affect established blood
vessels. FIG. 7(D) is a photographic representation of a
fluorescent-microscopic image showing the extent of
neovascularization in a control (PEG-treated) cornea.
Example 2
Choroidal Neovascularization (CNV)
[0277] Experimental CNV is often used as a model for Age-related
Macular degeneration (AMD). In this model, vessels of the choroid
grow through breaks in Bruch's membrane and into the retina,
similar to what is observed in AMD patients. To induce experimental
CNV, male C57BL/6 mice (18-20 g; Charles River, Wilmington, Mass.)
were anesthetized with intramuscular ketamine hydrochloride (25
mg/kg) and xylazine (10 mg/kg) and the pupils were dilated with 1%
tropicamide. Four burns were generated using diode laser
photocoagulation (75-.mu.m spot size, 0.1-second duration, 90 mW,
Oculight SL laser, IRIDEX, Mountain View, Calif.) and a hand-held
cover slide as a contact lens. Burns localized to the 3, 6, 9 and
12 o'clock positions of the posterior pole of the retina.
Production of a bubble at the time of laser, which indicates
rupture of Bruch's membrane, is an important factor in obtaining
choroidal neovascularization, so only mice in which a bubble was
produced for all four burns were included in the study. After 7
days, mice were treated with intraperitoneal injections of 25 mg/kg
of pegaptanib sodium twice a day or 50 mg/kg of Gleevec.RTM./STI57
(Novartis Pharma AG, Basel. Switzerland) by gavage twice a day or
both for 7 days. In experiments using APB5 (an anti-mouse PDGFRb
(CD140b) antibody (anti-PDGF agent) from eBioscience, San Diego,
Calif.), 5 mg/kg of antibody was administered using
intra-peritoneal injections of twice a day. The area of choroidal
NV lesions was measured in flat-mounted choroid stained with PECAM.
Flat-mounts were examined by fluorescence microscopy and quantified
using Openlab software.
[0278] Eyes treated with pegaptanib sodium (Macugen.TM.) showed a
24% (p=0.007) decrease in CNV area compared to untreated controls
(FIG. 8). In contrast, APB5-treated eyes were not significantly
different to controls (6.5% decrease in CNV area compared to
control). Eyes treated with both pegaptanib sodium and APB5 showed
significantly less (46% p=0.001) CNV area as compared to control
eyes or to eyes treated with either pegaptanib sodium (22% p=0.011)
or APBS (39.5% p<0.0001) alone (FIG. 8)
[0279] A similar trend was observed when using the PDGFR.beta.
inhibitor. Gleevec.RTM. treated eyes showed no significant
difference to control eyes (4.2%) (FIG. 9). The area of CNV in
pegaptanib sodium (Macugen.TM.) treated eyes, however, was
significantly different to that of controls (27% less p=0.0034).
Importantly, animals treated with both pegaptanib sodium and
Gleevec (Macugen+Gleevec) exhibited the least amount of CNV (46%
p<0.0001) compared to control eyes and a 19% decrease in the CNV
area as compared to pegaptanib sodium alone treated eyes (p=0.0407)
(FIG. 9).
Example 3
Neonatal Mouse Model
[0280] The effect of administering pegaptanib sodium (Macugen.TM.),
and ARC-127 (Archemix Corp., Cambridge, Mass.), a PEGylated,
anti-PDGF aptamer having the sequence CAGGCUACGN CGTAGAGCAU
CANTGATCCU GT (SEQ ID NO: 23, which corresponds to SEQ ID NO: 146
from U.S. Pat. No. 6,582,918, incorporated herein by reference in
its entirety) having 2'-fluoro-2'-deoxyuridine at positions 6, 20
and 30, 2'-fluoro-2'-deoxycytidine at positions 8, 21, 28, and 29,
2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31,
2'-O-Methyl-2'-deoxyadenosine at position 22, "N" in positions 10
and 23 from a hexaethylene-glycol phosphoramidite, and an inverted
orientation T (i.e., 3'-3'-linked) at position 32, or both on the
developing vessels of the retina was investigated. Neonatal C57BL/6
mice were injected daily (in the intra-peritoneal cavity) with 100
.mu.g of ARC-127 or 100 .mu.g of Macugen or both, starting on
postnatal day 0 (P0). Mice eyes were enucleated at P4. The retinal
vasculature was visualized in flatmounted retinas by immunostaining
with PECAM and NG-2 or by perfusion with ConA-FITC and analyzed by
fluorescence microscopy.
[0281] Injection of ARC-127 completely blocked mural cell
recruitment to the developing vessels of the retina. In addition,
less vessel growth was observed at P4 as compared to the control
non-treated retina. In contrast, Macugen did not interfere with
normal blood vessel development. However, mice treated with both
Macugen and ARC-127 exhibited similar but significantly more severe
defects than mice treated with ARC-127 alone.
[0282] These results, depicted in FIG. 10, show that Macugen has no
effect on the blood vessels of the developing retina. PDGFR-B
antagonist ARC-127 affects vessels outgrowth and morphology.
However, Macugen in combination with ARC-127 affects blood vessels
more severely than either of them alone.
Example 4
Combination Therapy with Anti-PDGF Aptamer and Anti-VEGF
Antibody
[0283] In this example, effectiveness of a combination therapy
using anti-PDGF aptamers and an anti-VEGF antibody is demonstrated
using the corneal neovascularization model described above. To
induce experimental corneal NV, male C57BL/6 mice (18-20 g; Charles
River, Wilmington, Mass.) are anesthetized with intramuscular
ketamine hydrochloride (25 mWkg) and xylazine (10 mg/kg). NaOH (2
ul of 0.2 mM) are applied topically. The corneal and limbal
epithelia are removed by applying a rotary motion parallel to the
limbus using #21 blade (Feather. Osaka, Japan). After 7 days, mice
are treated with intra-peritoneal injections of 25 mg/kg of an
anti-PDGF aptamer having the structure 40 Kd
PEG-5'-CAGGCTACGCGTAG-AGCATCATGATCCTG(iT)-3' (in which iT
represents that the final nucleotide is in the inverted orientation
(3'-3' linked)) in combination with 100 .mu.g of the anti-VEGF
antibody 2C3 described in U.S. Pat. No. 6,342,221 (incorporated
herein by reference). At day 14 following corneal NV induction,
mice receive 20 .mu.g/g of fluorescein-isothiocyanate coupled
concanavalin A lectin (Vector Laboratories, Burlingame, Calif.)
intravenously whilst deeply anesthetized with xylazine
hydrochloride and ketamine hydrochloride. Thirty minutes later,
mice eyes are enucleated, and the corneas flat-mounted. Corneal NV
is visualized using fluorescence microscopy and quantified using
Openlab software. The percent of cornea covered by vessels is
calculated as a percentage of total corneal area. The results
demonstrate the efficacy of the combination therapy over individual
treatments with the anti-PDGF aptamer or anti-VEGF antibody
alone.
[0284] In separate experiments, the effects of two related
anti-PDGF aptamers are tested in combination with 100 .mu.g of the
anti-VEGF antibody 2C3 described in U.S. Pat. No. 6,342,221.
PEGylated and un-PEGylated versions of the following two anti-PDGF
aptamers are tested: (i) CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (SEQ
ID NO: 23, which corresponds to SEQ ID NO: 146 from U.S. Pat. No.
6,582,918, incorporated herein by reference in its entirety) having
2'-fluoro-2'-deoxyuridine at positions 6, 20 and 30,
2'-fluoro-2'-deoxycytidine at positions 8, 21, 28, and 29,
2'-O-Methyl-2'-deoxyguanosine at positions 9, 15, 17, and 31,
2'-O-Methyl-2'-deoxyadenosine at position 22, "N" in positions 10
and 23 from a hexaethylene-glycol phosphoramidite, and an inverted
orientation T (i.e., 3'-3'-linked) at position 32; and (ii)
CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (see SEQ ID NO: 87 from U.S.
Pat. No. 5,723,594, incorporated herein by reference in its
entirety) having O-methyl-2-deoxycytidine at C at position 8,
2-O-methyl-2-deoxyguanosine at Gs at positions 9, 17 and 31,
2-O-methyl-2-deoxyadenine at A at position 22,
2-O-methyl-2-deoxyuridine at position 30, 2-fluoro-2 deoxyuridine
at U at positions 6 and 20, 2-fluoro-2-deoxycytidine at C at
positions 21, 28 and 29, a pentaethylene glycol phosphoramidite
spacer at N at positions 10 and 23, and an inverted orientation T
(i.e., 3'-3'-linked) at position 32. Appropriate controls are
provided to detect the improved anti-neovascular effect of the
combination therapy over individual anti-PDGF aptamer or anti-VEGF
antibody treatments. The results demonstrate the efficacy of the
combination therapy over individual treatments with the anti-PDGF
aptamer or anti-VEGF antibody alone.
Example 5
Combination of Anti-PDGF Aptamer and Anti-VEGF Aptamer Block
Choroidal Neovascularization (CNV)
[0285] In this example, effectiveness of a combination therapy
using anti-PDGF aptamers and anti-VEGF aptamers in blocking
chorodial neovascularization is demonstrated using the choroidal
neovascularization model described above. Experimental CNV is often
used as a model for Age-related Macular degeneration (AMD). In this
model, vessels of the choroid grow through breaks in Bruch's
membrane and into the retina, similar to what is observed in AMD
patients. To induce experimental CNV, male C57BLU6 mice (18-20 g;
Charles River, Wilmington, Mass.) are anesthetized with
intramuscular ketamine hydrochloride (25 mg/kg) and xylazine (10
mg/kg) and the pupils are dilated with 1% tropicamide. Four burns
are generated using diode laser photocoagulation (75-.mu.m spot
size, 0.1-second duration, 90 mW, Oculight SL laser, IRIDEX,
Mountain View, Calif.) and a hand-held cover slide as a contact
lens. Burns localized to the 3, 6, 9 and 12 o'clock positions of
the posterior pole of the retina. Production of a bubble at the
time of laser, which indicates rupture of Bruch's membrane, is an
important factor in obtaining choroidal neovascularization, so only
mice in which a bubble was produced for all four burns are included
in the study. After 7 days, mice are treated with intraperitoneal
injections of 25 mg/kg of pegaptanib sodium twice a day. In
experiments using anti-PDGF aptamer, 25 mg/kg of an anti-PDGF
aptamer having the structure 40 Kd
PEG-5'-CAGGCTACGCGTAGAGCATCATGA-TCCTG(iT)-3' (in which iT
represents that the final nucleotide is in the inverted orientation
(3'-3' linked)) is co-administered with pegaptanib sodium. The area
of choroidal NV lesions is measured in flat-mounted choroid stained
with PECAM. Flat-mounts are examined by fluorescence microscopy and
quantified using Openlab software. The results demonstrate that
eyes treated with the combination therapy showed significantly less
CNV area as compared to control eyes or to eyes treated with either
pegaptanib sodium or the anti-PDGF aptamer alone.
[0286] In separate experiments, the effects of two related
anti-PDGF aptamers are tested in combination with the anti-VEGF
treatment by intraperitoneal injections of 25 mg/kg of pegaptanib
sodium twice a day. PEGylated and un-PEGylated versions of the
following two anti-PDGF aptamers are tested: (i) CAGGCUACGN
CGTAGAGCAU CANTGATCCU GT (SEQ ID NO. 23, which corresponds to SEQ
ID NO: 146 from U.S. Pat. No. 6,582,918, incorporated herein by
reference in its entirety) having 2'-fluoro-2'-deoxyuridine at
positions 6, 20 and 30, 2'-fluoro-2'-deoxycytidine at positions 8,
21, 28, and 29, 2'-O-Methyl-2'-deoxyguanosine at positions 9, 15,
17, and 31, 2'-O-Methyl-2'-deoxyadenosine at position 22, "N" in
positions 10 and 23 from a hexaethylene-glycol phosphoramidite, and
an inverted orientation T (i.e., 3'-3'-linked) at position 32; and
(ii) CAGGCUACGN CGTAGAGCAU CANTGATCCU GT (see SEQ ID NO: 87 from
U.S. Pat. No. 5,723,594, incorporated herein by reference in its
entirety) having O-methyl-2-deoxycytidine at C at position 8,
2-O-methyl-2-deoxyguanosine at Gs at positions 9, 17 and 31,
2-O-methyl-2-deoxyadenine at A at position 22,
2-O-methyl-2-deoxyuridine at position 30, 2-fluoro-2-deoxyuridine
at U at positions 6 and 20, 2-fluoro-2-deoxycytidine at C at
positions 21, 28 and 29, a pentaethylene glycol phosphoramidite
spacer at N at positions 10 and 23, and an inverted orientation T
(i.e., 3'-3'-linked) at position 32. Appropriate controls are
provided to detect the improved anti-neovascular effect of the
combination therapy over individual anti-PDGF aptamer or anti-VEGF
aptamer treatments. The results demonstrate the efficacy of the
combination therapy in blocking choroidal neovascularization over
individual treatments with either of the anti-PDGF aptamers or the
anti-VEGF aptamer alone.
Example 6
Corneal Neovasclarization (Corneal NV)--Regression
[0287] The corneal NV model of Example 1 was used to investigate
the combination of an anti-VEGF aptamer and anti-PDGF aptamer.
After 10 days, mice were treated with intra-peritoneal injections
of 25 mg/kg of pegaptanib sodium (Macugen.TM., Eyetech
Pharmaceuticals, New York, N.Y.), an anti-VEGF aptamer agent) twice
a day and/or of 50 mg/kg of ARC-127 (Archemix Corp., Cambridge,
Mass., an anti-PDGF aptamer having the structure 40 Kd
PEG-5'-CAGGCTACGCGTAGAGCATCATGA-TCCTG(iT)-3' (in which iT
represents that the final nucleotide is in the inverted orientation
(3'-3' linked)) once a day for 10 days. At day 20 following corneal
NV induction, eyes were enucleated, and the corneas flat-mounted.
Corneal NV was visualized using CD31 staining (BD Biosciences
Pharmingen, San Diego, Calif.) and quantified using Metamorph
software. The percent of cornea covered by vessels was calculated
as a percentage of total corneal area.
[0288] The effects of pegaptanib sodium and/or ARC-127 on the
regression of neovascularization of the cornea following NaOH
application and injury to the epithilia of the limbus and cornea
are depicted in FIGS. 11 and 12. Animals treated with ARC-127 did
not show a significant decrease in vessel growth as compared to the
day 20 control. The day 20 controls showed a 12.92% increase in
corneal neovascularization when compared with the day 10 controls.
Animals treated with pegaptanib sodium (Macugen) alone showed a
13.81% (p.ltoreq.016) decrease in vessel growth as compared to day
20 controls. Animals treated with pegaptanib sodium and ARC-127
exhibited significantly less neovascular growth on the cornea
(26.85%, p.ltoreq.002) as compared to control.
Example 7
Corneal Neovasclarization (Corneal NV)--Regression
[0289] The corneal NV model of Example 1 was used to investigate
the combination of an anti-VEGF aptamer and an antibody against the
PDGFB receptor. After 14 days, mice were treated with
intra-peritoneal injections of 25 mg/kg of pegaptanib sodium
(Macugen, an anti-VEGF aptamer agent) twice a day and/or by oral
administration of 50 mg/kg of APB5 (a polyclonal antibody against
the PDGFB receptor) by gavage twice a day for 14 days. At day 28
following corneal NV induction, mice received 20 ug/g of
fluorescein-isothiocyanate coupled concanavalin A lectin (Vector
Laboratories, Burlingame, Calif.) intravenously whilst deeply
anesthetized with xylazine hydrochloride and ketamine
hydrochloride. Thirty minutes later, mice eyes were enucleated, and
the corneas flat-mounted. Corneal NV was visualized using
fluorescence microscopy and quantified using Openlab software. The
percent of cornea covered by vessels was calculated as a percentage
of total corneal area.
[0290] The effects of pegaptanib sodium and/or APB5 on the
regression of neovascularization of the cornea following NaOH
application and injury to the epithilia of the limbus and cornea
are depicted in FIG. 13. Animals treated with pegaptanib sodium
(Macugen) showed an 8.3% decrease in vessel growth as compared to
control. Animals treated with pegaptanib sodium and APB5 exhibited
significantly less neovascular growth on the cornea (21.4%) as
compared to control.
Example 8
Corneal Neovasclarization (Corneal NV)--Regression (Order of
Addition of Therapeutic Agent)
[0291] The corneal NV model of Example 1 was used to investigate
the effect of order of addition of the combination therapy using an
anti-VEGF aptamer and an antibody against the PDGFB receptor. After
14 days, mice were treated with intra-peritoneal injections of 25
mg/kg of pegaptanib sodium (Macugen, an anti-VEGF aptamer agent)
twice a day and/or by oral administration of 50 mg/kg of APB5
(eBioscience, San Diego, Calif.), a polyclonal antibody against the
PDGFB receptor, by gavage twice a day for 7 days at different
timepoints. At day 28 following corneal NV induction, mice received
20 ug/g of fluorescein-isothiocyanate coupled concanavalin A lectin
(Vector Laboratories, Burlingame, Calif.) intravenously whilst
deeply anesthetized with xylazine hydrochloride and ketamine
hydrochloride. Thirty minutes later, mice eyes were enucleated, and
the corneas flat-mounted. Corneal NV was visualized using
fluorescence microscopy and quantified using Openlab software. The
percent of cornea covered by vessels was calculated as a percentage
of total corneal area and the results are depicted in FIG. 14,
[0292] The effects of pegaptanib sodium alone from day 21-28 or
APB5 alone from day 14-21 followed by no treatment showed little
effect compared with control on the regression of
neovascularization of the cornea following NaOH application and
injury to the epithelia of the limbus and cornea. Animals treated
with APB5 from day 14-21 and pegaptanib sodium from day 21-28
exhibited less neovascular growth on the cornea (13.4%) as compared
to control.
EQUIVALENTS
[0293] Various modifications and variations of the described method
and system of the invention will be apparent to those skilled in
the art without departing from the scope and spirit of the
invention. Although the invention has been described in connection
with specific desired embodiments, it should be understood that the
invention as claimed should not be unduly limited to such specific
embodiments. Those skilled in the art will recognize or be able to
ascertain using no more than routine experimentation, many
equivalents to the specific embodiments of the invention described
herein. Such equivalents are intended to be encompassed in the
scope of the present invention.
Sequence CWU 1
1
3412137DNAHomo sapiens 1ccctgcctgc ctccctgcgc acccgcagcc tcccccgctg
cctccctagg gctcccctcc 60ggccgccagc gcccattttt cattccctag atagagatac
tttgcgcgca cacacataca 120tacgcgcgca aaaaggaaaa aaaaaaaaaa
aagcccaccc tccagcctcg ctgcaaagag 180aaaaccggag cagccgcagc
tcgcagctcg cagcccgcag cccgcagagg acgcccagag 240cggcgagcgg
gcgggcagac ggaccgacgg actcgcgccg cgtccacctg tcggccgggc
300ccagccgagc gcgcagcggg cacgccgcgc gcgcggagca gccgtgcccg
ccgcccgggc 360ccgccgccag ggcgcacacg ctcccgcccc cctacccggc
ccgggcggga gtttgcacct 420ctccctgccc gggtgctcga gctgccgttg
caaagccaac tttggaaaaa gttttttggg 480ggagacttgg gccttgaggt
gcccagctcc gcgctttccg attttggggg cctttccaga 540aaatgttgca
aaaaagctaa gccggcgggc agaggaaaac gcctgtagcc ggcgagtgaa
600gacgaaccat cgactgccgt gttccttttc ctcttggagg ttggagtccc
ctgggcgccc 660ccacacggct agacgcctcg gctggttcgc gacgcagccc
cccggccgtg gatgctgcac 720tcgggctcgg gatccgccca ggtagcggcc
tcggacccag gtcctgcgcc caggtcctcc 780cctgcccccc agcgacggag
ccggggccgg gggcggcggc gccgggggca tgcgggtgag 840ccgcggctgc
agaggcctga gcgcctgatc gccgcggacc cgagccgagc ccacccccct
900ccccagcccc ccaccctggc cgcgggggcg gcgcgctcga tctacgcgtt
cggggccccg 960cggggccggg cccggagtcg gcatgaatcg ctgctgggcg
ctcttcctgt ctctctgctg 1020ctacctgcgt ctggtcagcg ccgaggggga
ccccattccc gaggagcttt atgagatgct 1080gagtgaccac tcgatccgct
cctttgatga tctccaacgc ctgctgcacg gagaccccgg 1140agaggaagat
ggggccgagt tggacctgaa catgacccgc tcccactctg gaggcgagct
1200ggagagcttg gctcgtggaa gaaggagcct gggttccctg accattgctg
agccggccat 1260gatcgccgag tgcaagacgc gcaccgaggt gttcgagatc
tcccggcgcc tcatagaccg 1320caccaacgcc aacttcctgg tgtggccgcc
ctgtgtggag gtgcagcgct gctccggctg 1380ctgcaacaac cgcaacgtgc
agtgccgccc cacccaggtg cagctgcgac ctgtccaggt 1440gagaaagatc
gagattgtgc ggaagaagcc aatctttaag aaggccacgg tgacgctgga
1500agaccacctg gcatgcaagt gtgagacagt ggcagctgca cggcctgtga
cccgaagccc 1560ggggggttcc caggagcagc gagccaaaac gccccaaact
cgggtgacca ttcggacggt 1620gcgagtccgc cggcccccca agggcaagca
ccggaaattc aagcacacgc atgacaagac 1680ggcactgaag gagacccttg
gagcctaggg gcatcggcag gagagtgtgt gggcagggtt 1740atttaatatg
gtatttgctg tattgccccc atggggcctt ggagtagata atattgtttc
1800cctcgtccgt ctgtctcgat gcctgattcg gacggccaat ggtgcctccc
ccacccctcc 1860acgtgtccgt ccacccttcc atcagcgggt ctcctcccag
cggcctccgg ctcttgccca 1920gcagctcaag aagaaaaaga aggactgaac
tccatcgcca tcttcttccc ttaactccaa 1980gaacttggga taagagtgtg
agagagactg atggggtcgc tctttggggg aaacgggttc 2040cttcccctgc
acctggcctg ggccacacct gagcgctgtg gactgtcctg aggagccctg
2100aggacctctc agcatagcct gcctgatccc tgaaccc 21372241PRTHomo
sapiens 2Met Asn Arg Cys Trp Ala Leu Phe Leu Ser Leu Cys Cys Tyr
Leu Arg 1 5 10 15 Leu Val Ser Ala Glu Gly Asp Pro Ile Pro Glu Glu
Leu Tyr Glu Met 20 25 30 Leu Ser Asp His Ser Ile Arg Ser Phe Asp
Asp Leu Gln Arg Leu Leu 35 40 45 His Gly Asp Pro Gly Glu Glu Asp
Gly Ala Glu Leu Asp Leu Asn Met 50 55 60 Thr Arg Ser His Ser Gly
Gly Glu Leu Glu Ser Leu Ala Arg Gly Arg 65 70 75 80 Arg Ser Leu Gly
Ser Leu Thr Ile Ala Glu Pro Ala Met Ile Ala Glu 85 90 95 Cys Lys
Thr Arg Thr Glu Val Phe Glu Ile Ser Arg Arg Leu Ile Asp 100 105 110
Arg Thr Asn Ala Asn Phe Leu Val Trp Pro Pro Cys Val Glu Val Gln 115
120 125 Arg Cys Ser Gly Cys Cys Asn Asn Arg Asn Val Gln Cys Arg Pro
Thr 130 135 140 Gln Val Gln Leu Arg Pro Val Gln Val Arg Lys Ile Glu
Ile Val Arg 145 150 155 160 Lys Lys Pro Ile Phe Lys Lys Ala Thr Val
Thr Leu Glu Asp His Leu 165 170 175 Ala Cys Lys Cys Glu Thr Val Ala
Ala Ala Arg Pro Val Thr Arg Ser 180 185 190 Pro Gly Gly Ser Gln Glu
Gln Arg Ala Lys Thr Pro Gln Thr Arg Val 195 200 205 Thr Ile Arg Thr
Val Arg Val Arg Arg Pro Pro Lys Gly Lys His Arg 210 215 220 Lys Phe
Lys His Thr His Asp Lys Thr Ala Leu Lys Glu Thr Leu Gly 225 230 235
240 Ala 31723DNAHomo sapiens 3tcgcggaggc ttggggcagc cgggtagctc
ggaggtcgtg gcgctggggg ctagcaccag 60cgctctgtcg ggaggcgcag cggttaggtg
gaccggtcag cggactcacc ggccagggcg 120ctcggtgctg gaatttgata
ttcattgatc cgggttttat ccctcttctt ttttcttaaa 180catttttttt
taaaactgta ttgtttctcg ttttaattta tttttgcttg ccattcccca
240cttgaatcgg gccgacggct tggggagatt gctctacttc cccaaatcac
tgtggatttt 300ggaaaccagc agaaagagga aagaggtagc aagagctcca
gagagaagtc gaggaagaga 360gagacggggt cagagagagc gcgcgggcgt
gcgagcagcg aaagcgacag gggcaaagtg 420agtgacctgc ttttgggggt
gaccgccgga gcgcggcgtg agccctcccc cttgggatcc 480cgcagctgac
cagtcgcgct gacggacaga cagacagaca ccgcccccag ccccagctac
540cacctcctcc ccggccggcg gcggacagtg gacgcggcgg cgagccgcgg
gcaggggccg 600gagcccgcgc ccggaggcgg ggtggagggg gtcggggctc
gcggcgtcgc actgaaactt 660ttcgtccaac ttctgggctg ttctcgcttc
ggaggagccg tggtccgcgc gggggaagcc 720gagccgagcg gagccgcgag
aagtgctagc tcgggccggg aggagccgca gccggaggag 780ggggaggagg
aagaagagaa ggaagaggag agggggccgc agtggcgact cggcgctcgg
840aagccgggct catggacggg tgaggcggcg gtgtgcgcag acagtgctcc
agccgcgcgc 900gctccccagg ccctggcccg ggcctcgggc cggggaggaa
gagtagctcg ccgaggcgcc 960gaggagagcg ggccgcccca cagcccgagc
cggagaggga gcgcgagccg cgccggcccc 1020ggtcgggcct ccgaaaccat
gaactttctg ctgtcttggg tgcattggag ccttgccttg 1080ctgctctacc
tccaccatgc caagtggtcc caggctgcac ccatggcaga aggaggaggg
1140cagaatcatc acgaagtggt gaagttcatg gatgtctatc agcgcagcta
ctgccatcca 1200atcgagaccc tggtggacat cttccaggag taccctgatg
agatcgagta catcttcaag 1260ccatcctgtg tgcccctgat gcgatgcggg
ggctgctgca atgacgaggg cctggagtgt 1320gtgcccactg aggagtccaa
catcaccatg cagattatgc ggatcaaacc tcaccaaggc 1380cagcacatag
gagagatgag cttcctacag cacaacaaat gtgaatgcag accaaagaaa
1440gatagagcaa gacaagaaaa aaaatcagtt cgaggaaagg gaaaggggca
aaaacgaaag 1500cgcaagaaat cccggtataa gtcctggagc gttccctgtg
ggccttgctc agagcggaga 1560aagcatttgt ttgtacaaga tccgcagacg
tgtaaatgtt cctgcaaaaa cacagactcg 1620cgttgcaagg cgaggcagct
tgagttaaac gaacgtactt gcagatgtga caagccgagg 1680cggtgagccg
ggcaggagga aggagcctcc ctcagggttt cgg 17234215PRTHomo sapiens 4Met
Asn Phe Leu Leu Ser Trp Val His Trp Ser Leu Ala Leu Leu Leu 1 5 10
15 Tyr Leu His His Ala Lys Trp Ser Gln Ala Ala Pro Met Ala Glu Gly
20 25 30 Gly Gly Gln Asn His His Glu Val Val Lys Phe Met Asp Val
Tyr Gln 35 40 45 Arg Ser Tyr Cys His Pro Ile Glu Thr Leu Val Asp
Ile Phe Gln Glu 50 55 60 Tyr Pro Asp Glu Ile Glu Tyr Ile Phe Lys
Pro Ser Cys Val Pro Leu 65 70 75 80 Met Arg Cys Gly Gly Cys Cys Asn
Asp Glu Gly Leu Glu Cys Val Pro 85 90 95 Thr Glu Glu Ser Asn Ile
Thr Met Gln Ile Met Arg Ile Lys Pro His 100 105 110 Gln Gly Gln His
Ile Gly Glu Met Ser Phe Leu Gln His Asn Lys Cys 115 120 125 Glu Cys
Arg Pro Lys Lys Asp Arg Ala Arg Gln Glu Lys Lys Ser Val 130 135 140
Arg Gly Lys Gly Lys Gly Gln Lys Arg Lys Arg Lys Lys Ser Arg Tyr 145
150 155 160 Lys Ser Trp Ser Val Pro Cys Gly Pro Cys Ser Glu Arg Arg
Lys His 165 170 175 Leu Phe Val Gln Asp Pro Gln Thr Cys Lys Cys Ser
Cys Lys Asn Thr 180 185 190 Asp Ser Arg Cys Lys Ala Arg Gln Leu Glu
Leu Asn Glu Arg Thr Cys 195 200 205 Arg Cys Asp Lys Pro Arg Arg 210
215 55598DNAHomo sapiens 5ggcccctcag ccctgctgcc cagcacgagc
ctgtgctcgc cctgcccaac gcagacagcc 60agacccaggg cggcccctct ggcggctctg
ctcctcccga aggatgcttg gggagtgagg 120cgaagctggg cgctcctctc
ccctacagca gcccccttcc tccatccctc tgttctcctg 180agccttcagg
agcctgcacc agtcctgcct gtccttctac tcagctgtta cccactctgg
240gaccagcagt ctttctgata actgggagag ggcagtaagg aggacttcct
ggagggggtg 300actgtccaga gcctggaact gtgcccacac cagaagccat
cagcagcaag gacaccatgc 360ggcttccggg tgcgatgcca gctctggccc
tcaaaggcga gctgctgttg ctgtctctcc 420tgttacttct ggaaccacag
atctctcagg gcctggtcgt cacacccccg gggccagagc 480ttgtcctcaa
tgtctccagc accttcgttc tgacctgctc gggttcagct ccggtggtgt
540gggaacggat gtcccaggag cccccacagg aaatggccaa ggcccaggat
ggcaccttct 600ccagcgtgct cacactgacc aacctcactg ggctagacac
gggagaatac ttttgcaccc 660acaatgactc ccgtggactg gagaccgatg
agcggaaacg gctctacatc tttgtgccag 720atcccaccgt gggcttcctc
cctaatgatg ccgaggaact attcatcttt ctcacggaaa 780taactgagat
caccattcca tgccgagtaa cagacccaca gctggtggtg acactgcacg
840agaagaaagg ggacgttgca ctgcctgtcc cctatgatca ccaacgtggc
ttttctggta 900tctttgagga cagaagctac atctgcaaaa ccaccattgg
ggacagggag gtggattctg 960atgcctacta tgtctacaga ctccaggtgt
catccatcaa cgtctctgtg aacgcagtgc 1020agactgtggt ccgccagggt
gagaacatca ccctcatgtg cattgtgatc gggaatgagg 1080tggtcaactt
cgagtggaca tacccccgca aagaaagtgg gcggctggtg gagccggtga
1140ctgacttcct cttggatatg ccttaccaca tccgctccat cctgcacatc
cccagtgccg 1200agttagaaga ctcggggacc tacacctgca atgtgacgga
gagtgtgaat gaccatcagg 1260atgaaaaggc catcaacatc accgtggttg
agagcggcta cgtgcggctc ctgggagagg 1320tgggcacact acaatttgct
gagctgcatc ggagccggac actgcaggta gtgttcgagg 1380cctacccacc
gcccactgtc ctgtggttca aagacaaccg caccctgggc gactccagcg
1440ctggcgaaat cgccctgtcc acgcgcaacg tgtcggagac ccggtatgtg
tcagagctga 1500cactggttcg cgtgaaggtg gcagaggctg gccactacac
catgcgggcc ttccatgagg 1560atgctgaggt ccagctctcc ttccagctac
agatcaatgt ccctgtccga gtgctggagc 1620taagtgagag ccaccctgac
agtggggaac agacagtccg ctgtcgtggc cggggcatgc 1680cccagccgaa
catcatctgg tctgcctgca gagacctcaa aaggtgtcca cgtgagctgc
1740cgcccacgct gctggggaac agttccgaag aggagagcca gctggagact
aacgtgacgt 1800actgggagga ggagcaggag tttgaggtgg tgagcacact
gcgtctgcag cacgtggatc 1860ggccactgtc ggtgcgctgc acgctgcgca
acgctgtggg ccaggacacg caggaggtca 1920tcgtggtgcc acactccttg
ccctttaagg tggtggtgat ctcagccatc ctggccctgg 1980tggtgctcac
catcatctcc cttatcatcc tcatcatgct ttggcagaag aagccacgtt
2040acgagatccg atggaaggtg attgagtctg tgagctctga cggccatgag
tacatctacg 2100tggaccccat gcagctgccc tatgactcca cgtgggagct
gccgcgggac cagcttgtgc 2160tgggacgcac cctcggctct ggggcctttg
ggcaggtggt ggaggccacg gctcatggcc 2220tgagccattc tcaggccacg
atgaaagtgg ccgtcaagat gcttaaatcc acagcccgca 2280gcagtgagaa
gcaagccctt atgtcggagc tgaagatcat gagtcacctt gggccccacc
2340tgaacgtggt caacctgttg ggggcctgca ccaaaggagg acccatctat
atcatcactg 2400agtactgccg ctacggagac ctggtggact acctgcaccg
caacaaacac accttcctgc 2460agcaccactc cgacaagcgc cgcccgccca
gcgcggagct ctacagcaat gctctgcccg 2520ttgggctccc cctgcccagc
catgtgtcct tgaccgggga gagcgacggt ggctacatgg 2580acatgagcaa
ggacgagtcg gtggactatg tgcccatgct ggacatgaaa ggagacgtca
2640aatatgcaga catcgagtcc tccaactaca tggcccctta cgataactac
gttccctctg 2700cccctgagag gacctgccga gcaactttga tcaacgagtc
tccagtgcta agctacatgg 2760acctcgtggg cttcagctac caggtggcca
atggcatgga gtttctggcc tccaagaact 2820gcgtccacag agacctggcg
gctaggaacg tgctcatctg tgaaggcaag ctggtcaaga 2880tctgtgactt
tggcctggct cgagacatca tgcgggactc gaattacatc tccaaaggca
2940gcaccttttt gcctttaaag tggatggctc cggagagcat cttcaacagc
ctctacacca 3000ccctgagcga cgtgtggtcc ttcgggatcc tgctctggga
gatcttcacc ttgggtggca 3060ccccttaccc agagctgccc atgaacgagc
agttctacaa tgccatcaaa cggggttacc 3120gcatggccca gcctgcccat
gcctccgacg agatctatga gatcatgcag aagtgctggg 3180aagagaagtt
tgagattcgg ccccccttct cccagctggt gctgcttctc gagagactgt
3240tgggcgaagg ttacaaaaag aagtaccagc aggtggatga ggagtttctg
aggagtgacc 3300acccagccat ccttcggtcc caggcccgct tgcctgggtt
ccatggcctc cgatctcccc 3360tggacaccag ctccgtcctc tatactgccg
tgcagcccaa tgagggtgac aacgactata 3420tcatccccct gcctgacccc
aaacccgagg ttgctgacga gggcccactg gagggttccc 3480ccagcctagc
cagctccacc ctgaatgaag tcaacacctc ctcaaccatc tcctgtgaca
3540gccccctgga gccccaggac gaaccagagc cagagcccca gcttgagctc
caggtggagc 3600cggagccaga gctggaacag ttgccggatt cggggtgccc
tgcgcctcgg gcggaagcag 3660aggatagctt cctgtagggg gctggcccct
accctgccct gcctgaagct ccccccctgc 3720cagcacccag catctcctgg
cctggcctga ccgggcttcc tgtcagccag gctgccctta 3780tcagctgtcc
ccttctggaa gctttctgct cctgacgtgt tgtgccccaa accctggggc
3840tggcttagga ggcaagaaaa ctgcaggggc cgtgaccagc cctctgcctc
cagggaggcc 3900aactgactct gagccagggt tcccccaggg aactcagttt
tcccatatgt aagatgggaa 3960agttaggctt gatgacccag aatctaggat
tctctccctg gctgacaggt ggggagaccg 4020aatccctccc tgggaagatt
cttggagtta ctgaggtggt aaattaactt ttttctgttc 4080agccagctac
ccctcaagga atcatagctc tctcctcgca ctttttatcc acccaggagc
4140tagggaagag accctagcct ccctggctgc tggctgagct agggcctagc
cttgagcagt 4200gttgcctcat ccagaagaaa gccagtctcc tccctatgat
gccagtccct gcgttccctg 4260gcccgagctg gtctggggcc attaggcagc
ctaattaatg ctggaggctg agccaagtac 4320aggacacccc cagcctgcag
cccttgccca gggcacttgg agcacacgca gccatagcaa 4380gtgcctgtgt
ccctgtcctt caggcccatc agtcctgggg ctttttcttt atcaccctca
4440gtcttaatcc atccaccaga gtctagaagg ccagacgggc cccgcatctg
tgatgagaat 4500gtaaatgtgc cagtgtggag tggccacgtg tgtgtgccag
tatatggccc tggctctgca 4560ttggacctgc tatgaggctt tggaggaatc
cctcaccctc tctgggcctc agtttcccct 4620tcaaaaaatg aataagtcgg
acttattaac tctgagtgcc ttgccagcac taacattcta 4680gagtattcca
ggtggttgca catttgtcca gatgaagcaa ggccatatac cctaaacttc
4740catcctgggg gtcagctggg ctcctgggag attccagatc acacatcaca
ctctggggac 4800tcaggaacca tgccccttcc ccaggccccc agcaagtctc
aagaacacag ctgcacaggc 4860cttgacttag agtgacagcc ggtgtcctgg
aaagccccaa gcagctgccc cagggacatg 4920ggaagaccac gggacctctt
tcactaccca cgatgacctc cgggggtatc ctgggcaaaa 4980gggacaaaga
gggcaaatga gatcacctcc tgcagcccac cactccagca cctgtgccga
5040ggtctgcgtc gaagacagaa tggacagtga ggacagttat gtcttgtaaa
agacaagaag 5100cttcagatgg taccccaaga aggatgtgag aggtggccgc
ttggagtttg cccctcaccc 5160accagctgcc ccatccctga ggcagcgctc
catgggggta tggttttgtc actgcccaga 5220cctagcagtg acatctcatt
gtccccagcc cagtgggcat tggaggtgcc aggggagtca 5280gggttgtagc
caagacgccc ccgcacgggg agggttggga agggggtgca ggaagctcaa
5340cccctctggg caccaaccct gcattgcagg ttggcacctt acttccctgg
gatccccaga 5400gttggtccaa ggagggagag tgggttctca atacggtacc
aaagatataa tcacctaggt 5460ttacaaatat ttttaggact cacgttaact
cacatttata cagcagaaat gctattttgt 5520atgctgttaa gtttttctat
ctgtgtactt ttttttaagg gaaagatttt aatattaaac 5580ctggtgcttc tcactcac
559861106PRTHomo sapiens 6Met Arg Leu Pro Gly Ala Met Pro Ala Leu
Ala Leu Lys Gly Glu Leu 1 5 10 15 Leu Leu Leu Ser Leu Leu Leu Leu
Leu Glu Pro Gln Ile Ser Gln Gly 20 25 30 Leu Val Val Thr Pro Pro
Gly Pro Glu Leu Val Leu Asn Val Ser Ser 35 40 45 Thr Phe Val Leu
Thr Cys Ser Gly Ser Ala Pro Val Val Trp Glu Arg 50 55 60 Met Ser
Gln Glu Pro Pro Gln Glu Met Ala Lys Ala Gln Asp Gly Thr 65 70 75 80
Phe Ser Ser Val Leu Thr Leu Thr Asn Leu Thr Gly Leu Asp Thr Gly 85
90 95 Glu Tyr Phe Cys Thr His Asn Asp Ser Arg Gly Leu Glu Thr Asp
Glu 100 105 110 Arg Lys Arg Leu Tyr Ile Phe Val Pro Asp Pro Thr Val
Gly Phe Leu 115 120 125 Pro Asn Asp Ala Glu Glu Leu Phe Ile Phe Leu
Thr Glu Ile Thr Glu 130 135 140 Ile Thr Ile Pro Cys Arg Val Thr Asp
Pro Gln Leu Val Val Thr Leu 145 150 155 160 His Glu Lys Lys Gly Asp
Val Ala Leu Pro Val Pro Tyr Asp His Gln 165 170 175 Arg Gly Phe Ser
Gly Ile Phe Glu Asp Arg Ser Tyr Ile Cys Lys Thr 180 185 190 Thr Ile
Gly Asp Arg Glu Val Asp Ser Asp Ala Tyr Tyr Val Tyr Arg 195 200 205
Leu Gln Val Ser Ser Ile Asn Val Ser Val Asn Ala Val Gln Thr Val 210
215 220 Val Arg Gln Gly Glu Asn Ile Thr Leu Met Cys Ile Val Ile Gly
Asn 225 230 235 240 Glu Val Val Asn Phe Glu Trp Thr Tyr Pro Arg Lys
Glu Ser Gly Arg 245 250 255 Leu Val Glu Pro Val Thr Asp Phe Leu Leu
Asp Met Pro Tyr His Ile 260 265 270 Arg Ser Ile Leu His Ile Pro Ser
Ala Glu Leu Glu Asp Ser Gly Thr 275 280 285 Tyr Thr Cys Asn Val Thr
Glu Ser Val Asn Asp His Gln Asp Glu Lys 290 295 300 Ala Ile Asn Ile
Thr Val Val Glu Ser Gly Tyr Val Arg Leu Leu Gly 305 310 315 320 Glu
Val Gly Thr Leu Gln Phe Ala Glu Leu His Arg Ser Arg Thr Leu 325 330
335 Gln Val Val Phe Glu Ala Tyr Pro Pro Pro Thr Val Leu Trp Phe Lys
340 345 350 Asp Asn Arg Thr Leu Gly Asp Ser Ser Ala Gly Glu Ile Ala
Leu Ser 355 360 365 Thr Arg Asn Val Ser Glu
Thr Arg Tyr Val Ser Glu Leu Thr Leu Val 370 375 380 Arg Val Lys Val
Ala Glu Ala Gly His Tyr Thr Met Arg Ala Phe His 385 390 395 400 Glu
Asp Ala Glu Val Gln Leu Ser Phe Gln Leu Gln Ile Asn Val Pro 405 410
415 Val Arg Val Leu Glu Leu Ser Glu Ser His Pro Asp Ser Gly Glu Gln
420 425 430 Thr Val Arg Cys Arg Gly Arg Gly Met Pro Gln Pro Asn Ile
Ile Trp 435 440 445 Ser Ala Cys Arg Asp Leu Lys Arg Cys Pro Arg Glu
Leu Pro Pro Thr 450 455 460 Leu Leu Gly Asn Ser Ser Glu Glu Glu Ser
Gln Leu Glu Thr Asn Val 465 470 475 480 Thr Tyr Trp Glu Glu Glu Gln
Glu Phe Glu Val Val Ser Thr Leu Arg 485 490 495 Leu Gln His Val Asp
Arg Pro Leu Ser Val Arg Cys Thr Leu Arg Asn 500 505 510 Ala Val Gly
Gln Asp Thr Gln Glu Val Ile Val Val Pro His Ser Leu 515 520 525 Pro
Phe Lys Val Val Val Ile Ser Ala Ile Leu Ala Leu Val Val Leu 530 535
540 Thr Ile Ile Ser Leu Ile Ile Leu Ile Met Leu Trp Gln Lys Lys Pro
545 550 555 560 Arg Tyr Glu Ile Arg Trp Lys Val Ile Glu Ser Val Ser
Ser Asp Gly 565 570 575 His Glu Tyr Ile Tyr Val Asp Pro Met Gln Leu
Pro Tyr Asp Ser Thr 580 585 590 Trp Glu Leu Pro Arg Asp Gln Leu Val
Leu Gly Arg Thr Leu Gly Ser 595 600 605 Gly Ala Phe Gly Gln Val Val
Glu Ala Thr Ala His Gly Leu Ser His 610 615 620 Ser Gln Ala Thr Met
Lys Val Ala Val Lys Met Leu Lys Ser Thr Ala 625 630 635 640 Arg Ser
Ser Glu Lys Gln Ala Leu Met Ser Glu Leu Lys Ile Met Ser 645 650 655
His Leu Gly Pro His Leu Asn Val Val Asn Leu Leu Gly Ala Cys Thr 660
665 670 Lys Gly Gly Pro Ile Tyr Ile Ile Thr Glu Tyr Cys Arg Tyr Gly
Asp 675 680 685 Leu Val Asp Tyr Leu His Arg Asn Lys His Thr Phe Leu
Gln His His 690 695 700 Ser Asp Lys Arg Arg Pro Pro Ser Ala Glu Leu
Tyr Ser Asn Ala Leu 705 710 715 720 Pro Val Gly Leu Pro Leu Pro Ser
His Val Ser Leu Thr Gly Glu Ser 725 730 735 Asp Gly Gly Tyr Met Asp
Met Ser Lys Asp Glu Ser Val Asp Tyr Val 740 745 750 Pro Met Leu Asp
Met Lys Gly Asp Val Lys Tyr Ala Asp Ile Glu Ser 755 760 765 Ser Asn
Tyr Met Ala Pro Tyr Asp Asn Tyr Val Pro Ser Ala Pro Glu 770 775 780
Arg Thr Cys Arg Ala Thr Leu Ile Asn Glu Ser Pro Val Leu Ser Tyr 785
790 795 800 Met Asp Leu Val Gly Phe Ser Tyr Gln Val Ala Asn Gly Met
Glu Phe 805 810 815 Leu Ala Ser Lys Asn Cys Val His Arg Asp Leu Ala
Ala Arg Asn Val 820 825 830 Leu Ile Cys Glu Gly Lys Leu Val Lys Ile
Cys Asp Phe Gly Leu Ala 835 840 845 Arg Asp Ile Met Arg Asp Ser Asn
Tyr Ile Ser Lys Gly Ser Thr Phe 850 855 860 Leu Pro Leu Lys Trp Met
Ala Pro Glu Ser Ile Phe Asn Ser Leu Tyr 865 870 875 880 Thr Thr Leu
Ser Asp Val Trp Ser Phe Gly Ile Leu Leu Trp Glu Ile 885 890 895 Phe
Thr Leu Gly Gly Thr Pro Tyr Pro Glu Leu Pro Met Asn Glu Gln 900 905
910 Phe Tyr Asn Ala Ile Lys Arg Gly Tyr Arg Met Ala Gln Pro Ala His
915 920 925 Ala Ser Asp Glu Ile Tyr Glu Ile Met Gln Lys Cys Trp Glu
Glu Lys 930 935 940 Phe Glu Ile Arg Pro Pro Phe Ser Gln Leu Val Leu
Leu Leu Glu Arg 945 950 955 960 Leu Leu Gly Glu Gly Tyr Lys Lys Lys
Tyr Gln Gln Val Asp Glu Glu 965 970 975 Phe Leu Arg Ser Asp His Pro
Ala Ile Leu Arg Ser Gln Ala Arg Leu 980 985 990 Pro Gly Phe His Gly
Leu Arg Ser Pro Leu Asp Thr Ser Ser Val Leu 995 1000 1005 Tyr Thr
Ala Val Gln Pro Asn Glu Gly Asp Asn Asp Tyr Ile Ile 1010 1015 1020
Pro Leu Pro Asp Pro Lys Pro Glu Val Ala Asp Glu Gly Pro Leu 1025
1030 1035 Glu Gly Ser Pro Ser Leu Ala Ser Ser Thr Leu Asn Glu Val
Asn 1040 1045 1050 Thr Ser Ser Thr Ile Ser Cys Asp Ser Pro Leu Glu
Pro Gln Asp 1055 1060 1065 Glu Pro Glu Pro Glu Pro Gln Leu Glu Leu
Gln Val Glu Pro Glu 1070 1075 1080 Pro Glu Leu Glu Gln Leu Pro Asp
Ser Gly Cys Pro Ala Pro Arg 1085 1090 1095 Ala Glu Ala Glu Asp Ser
Phe Leu 1100 1105 74017DNAHomo sapiens 7atggtcagct actgggacac
cggggtcctg ctgtgcgcgc tgctcagctg tctgcttctc 60acaggatcta gttcaggttc
aaaattaaaa gatcctgaac tgagtttaaa aggcacccag 120cacatcatgc
aagcaggcca gacactgcat ctccaatgca ggggggaagc agcccataaa
180tggtctttgc ctgaaatggt gagtaaggaa agcgaaaggc tgagcataac
taaatctgcc 240tgtggaagaa atggcaaaca attctgcagt actttaacct
tgaacacagc tcaagcaaac 300cacactggct tctacagctg caaatatcta
gctgtaccta cttcaaagaa gaaggaaaca 360gaatctgcaa tctatatatt
tattagtgat acaggtagac ctttcgtaga gatgtacagt 420gaaatccccg
aaattataca catgactgaa ggaagggagc tcgtcattcc ctgccgggtt
480acgtcaccta acatcactgt tactttaaaa aagtttccac ttgacacttt
gatccctgat 540ggaaaacgca taatctggga cagtagaaag ggcttcatca
tatcaaatgc aacgtacaaa 600gaaatagggc ttctgacctg tgaagcaaca
gtcaatgggc atttgtataa gacaaactat 660ctcacacatc gacaaaccaa
tacaatcata gatgtccaaa taagcacacc acgcccagtc 720aaattactta
gaggccatac tcttgtcctc aattgtactg ctaccactcc cttgaacacg
780agagttcaaa tgacctggag ttaccctgat gaaaaaaata agagagcttc
cgtaaggcga 840cgaattgacc aaagcaattc ccatgccaac atattctaca
gtgttcttac tattgacaaa 900atgcagaaca aagacaaagg actttatact
tgtcgtgtaa ggagtggacc atcattcaaa 960tctgttaaca cctcagtgca
tatatatgat aaagcattca tcactgtgaa acatcgaaaa 1020cagcaggtgc
ttgaaaccgt agctggcaag cggtcttacc ggctctctat gaaagtgaag
1080gcatttccct cgccggaagt tgtatggtta aaagatgggt tacctgcgac
tgagaaatct 1140gctcgctatt tgactcgtgg ctactcgtta attatcaagg
acgtaactga agaggatgca 1200gggaattata caatcttgct gagcataaaa
cagtcaaatg tgtttaaaaa cctcactgcc 1260actctaattg tcaatgtgaa
accccagatt tacgaaaagg ccgtgtcatc gtttccagac 1320ccggctctct
acccactggg cagcagacaa atcctgactt gtaccgcata tggtatccct
1380caacctacaa tcaagtggtt ctggcacccc tgtaaccata atcattccga
agcaaggtgt 1440gacttttgtt ccaataatga agagtccttt atcctggatg
ctgacagcaa catgggaaac 1500agaattgaga gcatcactca gcgcatggca
ataatagaag gaaagaataa gatggctagc 1560accttggttg tggctgactc
tagaatttct ggaatctaca tttgcatagc ttccaataaa 1620gttgggactg
tgggaagaaa cataagcttt tatatcacag atgtgccaaa tgggtttcat
1680gttaacttgg aaaaaatgcc gacggaagga gaggacctga aactgtcttg
cacagttaac 1740aagttcttat acagagacgt tacttggatt ttactgcgga
cagttaataa cagaacaatg 1800cactacagta ttagcaagca aaaaatggcc
atcactaagg agcactccat cactcttaat 1860cttaccatca tgaatgtttc
cctgcaagat tcaggcacct atgcctgcag agccaggaat 1920gtatacacag
gggaagaaat cctccagaag aaagaaatta caatcagaga tcaggaagca
1980ccatacctcc tgcgaaacct cagtgatcac acagtggcca tcagcagttc
caccacttta 2040gactgtcatg ctaatggtgt ccccgagcct cagatcactt
ggtttaaaaa caaccacaaa 2100atacaacaag agcctggaat tattttagga
ccaggaagca gcacgctgtt tattgaaaga 2160gtcacagaag aggatgaagg
tgtctatcac tgcaaagcca ccaaccagaa gggctctgtg 2220gaaagttcag
catacctcac tgttcaagga acctcggaca agtctaatct ggagctgatc
2280actctaacat gcacctgtgt ggctgcgact ctcttctggc tcctattaac
cctctttatc 2340cgaaaaatga aaaggtcttc ttctgaaata aagactgact
acctatcaat tataatggac 2400ccagatgaag ttcctttgga tgagcagtgt
gagcggctcc cttatgatgc cagcaagtgg 2460gagtttgccc gggagagact
taaactgggc aaatcacttg gaagaggggc ttttggaaaa 2520gtggttcaag
catcagcatt tggcattaag aaatcaccta cgtgccggac tgtggctgtg
2580aaaatgctga aagagggggc cacggccagc gagtacaaag ctctgatgac
tgagctaaaa 2640atcttgaccc acattggcca ccatctgaac gtggttaacc
tgctgggagc ctgcaccaag 2700caaggagggc ctctgatggt gattgttgaa
tactgcaaat atggaaatct ctccaactac 2760ctcaagagca aacgtgactt
attttttctc aacaaggatg cagcactaca catggagcct 2820aagaaagaaa
aaatggagcc aggcctggaa caaggcaaga aaccaagact agatagcgtc
2880accagcagcg aaagctttgc gagctccggc tttcaggaag ataaaagtct
gagtgatgtt 2940gaggaagagg aggattctga cggtttctac aaggagccca
tcactatgga agatctgatt 3000tcttacagtt ttcaagtggc cagaggcatg
gagttcctgt cttccagaaa gtgcattcat 3060cgggacctgg cagcgagaaa
cattctttta tctgagaaca acgtggtgaa gatttgtgat 3120tttggccttg
cccgggatat ttataagaac cccgattatg tgagaaaagg agatactcga
3180cttcctctga aatggatggc tcctgaatct atctttgaca aaatctacag
caccaagagc 3240gacgtgtggt cttacggagt attgctgtgg gaaatcttct
ccttaggtgg gtctccatac 3300ccaggagtac aaatggatga ggacttttgc
agtcgcctga gggaaggcat gaggatgaga 3360gctcctgagt actctactcc
tgaaatctat cagatcatgc tggactgctg gcacagagac 3420ccaaaagaaa
ggccaagatt tgcagaactt gtggaaaaac taggtgattt gcttcaagca
3480aatgtacaac aggatggtaa agactacatc ccaatcaatg ccatactgac
aggaaatagt 3540gggtttacat actcaactcc tgccttctct gaggacttct
tcaaggaaag tatttcagct 3600ccgaagttta attcaggaag ctctgatgat
gtcagatatg taaatgcttt caagttcatg 3660agcctggaaa gaatcaaaac
ctttgaagaa cttttaccga atgccacctc catgtttgat 3720gactaccagg
gcgacagcag cactctgttg gcctctccca tgctgaagcg cttcacctgg
3780actgacagca aacccaaggc ctcgctcaag attgacttga gagtaaccag
taaaagtaag 3840gagtcggggc tgtctgatgt cagcaggccc agtttctgcc
attccagctg tgggcacgtc 3900agcgaaggca agcgcaggtt cacctacgac
cacgctgagc tggaaaggaa aatcgcgtgc 3960tgctccccgc ccccagacta
caactcggtg gtcctgtact ccaccccacc catctag 401781338PRTHomo sapiens
8Met Val Ser Tyr Trp Asp Thr Gly Val Leu Leu Cys Ala Leu Leu Ser 1
5 10 15 Cys Leu Leu Leu Thr Gly Ser Ser Ser Gly Ser Lys Leu Lys Asp
Pro 20 25 30 Glu Leu Ser Leu Lys Gly Thr Gln His Ile Met Gln Ala
Gly Gln Thr 35 40 45 Leu His Leu Gln Cys Arg Gly Glu Ala Ala His
Lys Trp Ser Leu Pro 50 55 60 Glu Met Val Ser Lys Glu Ser Glu Arg
Leu Ser Ile Thr Lys Ser Ala 65 70 75 80 Cys Gly Arg Asn Gly Lys Gln
Phe Cys Ser Thr Leu Thr Leu Asn Thr 85 90 95 Ala Gln Ala Asn His
Thr Gly Phe Tyr Ser Cys Lys Tyr Leu Ala Val 100 105 110 Pro Thr Ser
Lys Lys Lys Glu Thr Glu Ser Ala Ile Tyr Ile Phe Ile 115 120 125 Ser
Asp Thr Gly Arg Pro Phe Val Glu Met Tyr Ser Glu Ile Pro Glu 130 135
140 Ile Ile His Met Thr Glu Gly Arg Glu Leu Val Ile Pro Cys Arg Val
145 150 155 160 Thr Ser Pro Asn Ile Thr Val Thr Leu Lys Lys Phe Pro
Leu Asp Thr 165 170 175 Leu Ile Pro Asp Gly Lys Arg Ile Ile Trp Asp
Ser Arg Lys Gly Phe 180 185 190 Ile Ile Ser Asn Ala Thr Tyr Lys Glu
Ile Gly Leu Leu Thr Cys Glu 195 200 205 Ala Thr Val Asn Gly His Leu
Tyr Lys Thr Asn Tyr Leu Thr His Arg 210 215 220 Gln Thr Asn Thr Ile
Ile Asp Val Gln Ile Ser Thr Pro Arg Pro Val 225 230 235 240 Lys Leu
Leu Arg Gly His Thr Leu Val Leu Asn Cys Thr Ala Thr Thr 245 250 255
Pro Leu Asn Thr Arg Val Gln Met Thr Trp Ser Tyr Pro Asp Glu Lys 260
265 270 Asn Lys Arg Ala Ser Val Arg Arg Arg Ile Asp Gln Ser Asn Ser
His 275 280 285 Ala Asn Ile Phe Tyr Ser Val Leu Thr Ile Asp Lys Met
Gln Asn Lys 290 295 300 Asp Lys Gly Leu Tyr Thr Cys Arg Val Arg Ser
Gly Pro Ser Phe Lys 305 310 315 320 Ser Val Asn Thr Ser Val His Ile
Tyr Asp Lys Ala Phe Ile Thr Val 325 330 335 Lys His Arg Lys Gln Gln
Val Leu Glu Thr Val Ala Gly Lys Arg Ser 340 345 350 Tyr Arg Leu Ser
Met Lys Val Lys Ala Phe Pro Ser Pro Glu Val Val 355 360 365 Trp Leu
Lys Asp Gly Leu Pro Ala Thr Glu Lys Ser Ala Arg Tyr Leu 370 375 380
Thr Arg Gly Tyr Ser Leu Ile Ile Lys Asp Val Thr Glu Glu Asp Ala 385
390 395 400 Gly Asn Tyr Thr Ile Leu Leu Ser Ile Lys Gln Ser Asn Val
Phe Lys 405 410 415 Asn Leu Thr Ala Thr Leu Ile Val Asn Val Lys Pro
Gln Ile Tyr Glu 420 425 430 Lys Ala Val Ser Ser Phe Pro Asp Pro Ala
Leu Tyr Pro Leu Gly Ser 435 440 445 Arg Gln Ile Leu Thr Cys Thr Ala
Tyr Gly Ile Pro Gln Pro Thr Ile 450 455 460 Lys Trp Phe Trp His Pro
Cys Asn His Asn His Ser Glu Ala Arg Cys 465 470 475 480 Asp Phe Cys
Ser Asn Asn Glu Glu Ser Phe Ile Leu Asp Ala Asp Ser 485 490 495 Asn
Met Gly Asn Arg Ile Glu Ser Ile Thr Gln Arg Met Ala Ile Ile 500 505
510 Glu Gly Lys Asn Lys Met Ala Ser Thr Leu Val Val Ala Asp Ser Arg
515 520 525 Ile Ser Gly Ile Tyr Ile Cys Ile Ala Ser Asn Lys Val Gly
Thr Val 530 535 540 Gly Arg Asn Ile Ser Phe Tyr Ile Thr Asp Val Pro
Asn Gly Phe His 545 550 555 560 Val Asn Leu Glu Lys Met Pro Thr Glu
Gly Glu Asp Leu Lys Leu Ser 565 570 575 Cys Thr Val Asn Lys Phe Leu
Tyr Arg Asp Val Thr Trp Ile Leu Leu 580 585 590 Arg Thr Val Asn Asn
Arg Thr Met His Tyr Ser Ile Ser Lys Gln Lys 595 600 605 Met Ala Ile
Thr Lys Glu His Ser Ile Thr Leu Asn Leu Thr Ile Met 610 615 620 Asn
Val Ser Leu Gln Asp Ser Gly Thr Tyr Ala Cys Arg Ala Arg Asn 625 630
635 640 Val Tyr Thr Gly Glu Glu Ile Leu Gln Lys Lys Glu Ile Thr Ile
Arg 645 650 655 Asp Gln Glu Ala Pro Tyr Leu Leu Arg Asn Leu Ser Asp
His Thr Val 660 665 670 Ala Ile Ser Ser Ser Thr Thr Leu Asp Cys His
Ala Asn Gly Val Pro 675 680 685 Glu Pro Gln Ile Thr Trp Phe Lys Asn
Asn His Lys Ile Gln Gln Glu 690 695 700 Pro Gly Ile Ile Leu Gly Pro
Gly Ser Ser Thr Leu Phe Ile Glu Arg 705 710 715 720 Val Thr Glu Glu
Asp Glu Gly Val Tyr His Cys Lys Ala Thr Asn Gln 725 730 735 Lys Gly
Ser Val Glu Ser Ser Ala Tyr Leu Thr Val Gln Gly Thr Ser 740 745 750
Asp Lys Ser Asn Leu Glu Leu Ile Thr Leu Thr Cys Thr Cys Val Ala 755
760 765 Ala Thr Leu Phe Trp Leu Leu Leu Thr Leu Phe Ile Arg Lys Met
Lys 770 775 780 Arg Ser Ser Ser Glu Ile Lys Thr Asp Tyr Leu Ser Ile
Ile Met Asp 785 790 795 800 Pro Asp Glu Val Pro Leu Asp Glu Gln Cys
Glu Arg Leu Pro Tyr Asp 805 810 815 Ala Ser Lys Trp Glu Phe Ala Arg
Glu Arg Leu Lys Leu Gly Lys Ser 820 825 830 Leu Gly Arg Gly Ala Phe
Gly Lys Val Val Gln Ala Ser Ala Phe Gly 835 840 845 Ile Lys Lys Ser
Pro Thr Cys Arg Thr Val Ala Val Lys Met Leu Lys 850 855 860 Glu Gly
Ala Thr Ala Ser Glu Tyr Lys Ala Leu Met Thr Glu Leu Lys 865 870 875
880 Ile Leu Thr His Ile Gly His His Leu Asn Val Val Asn Leu Leu Gly
885 890 895 Ala Cys Thr Lys Gln Gly Gly Pro Leu Met Val Ile Val Glu
Tyr Cys 900 905 910 Lys Tyr Gly Asn Leu Ser Asn Tyr Leu Lys Ser Lys
Arg Asp Leu Phe 915 920 925 Phe Leu Asn Lys Asp Ala Ala Leu His Met
Glu Pro Lys Lys Glu Lys 930 935 940
Met Glu Pro Gly Leu Glu Gln Gly Lys Lys Pro Arg Leu Asp Ser Val 945
950 955 960 Thr Ser Ser Glu Ser Phe Ala Ser Ser Gly Phe Gln Glu Asp
Lys Ser 965 970 975 Leu Ser Asp Val Glu Glu Glu Glu Asp Ser Asp Gly
Phe Tyr Lys Glu 980 985 990 Pro Ile Thr Met Glu Asp Leu Ile Ser Tyr
Ser Phe Gln Val Ala Arg 995 1000 1005 Gly Met Glu Phe Leu Ser Ser
Arg Lys Cys Ile His Arg Asp Leu 1010 1015 1020 Ala Ala Arg Asn Ile
Leu Leu Ser Glu Asn Asn Val Val Lys Ile 1025 1030 1035 Cys Asp Phe
Gly Leu Ala Arg Asp Ile Tyr Lys Asn Pro Asp Tyr 1040 1045 1050 Val
Arg Lys Gly Asp Thr Arg Leu Pro Leu Lys Trp Met Ala Pro 1055 1060
1065 Glu Ser Ile Phe Asp Lys Ile Tyr Ser Thr Lys Ser Asp Val Trp
1070 1075 1080 Ser Tyr Gly Val Leu Leu Trp Glu Ile Phe Ser Leu Gly
Gly Ser 1085 1090 1095 Pro Tyr Pro Gly Val Gln Met Asp Glu Asp Phe
Cys Ser Arg Leu 1100 1105 1110 Arg Glu Gly Met Arg Met Arg Ala Pro
Glu Tyr Ser Thr Pro Glu 1115 1120 1125 Ile Tyr Gln Ile Met Leu Asp
Cys Trp His Arg Asp Pro Lys Glu 1130 1135 1140 Arg Pro Arg Phe Ala
Glu Leu Val Glu Lys Leu Gly Asp Leu Leu 1145 1150 1155 Gln Ala Asn
Val Gln Gln Asp Gly Lys Asp Tyr Ile Pro Ile Asn 1160 1165 1170 Ala
Ile Leu Thr Gly Asn Ser Gly Phe Thr Tyr Ser Thr Pro Ala 1175 1180
1185 Phe Ser Glu Asp Phe Phe Lys Glu Ser Ile Ser Ala Pro Lys Phe
1190 1195 1200 Asn Ser Gly Ser Ser Asp Asp Val Arg Tyr Val Asn Ala
Phe Lys 1205 1210 1215 Phe Met Ser Leu Glu Arg Ile Lys Thr Phe Glu
Glu Leu Leu Pro 1220 1225 1230 Asn Ala Thr Ser Met Phe Asp Asp Tyr
Gln Gly Asp Ser Ser Thr 1235 1240 1245 Leu Leu Ala Ser Pro Met Leu
Lys Arg Phe Thr Trp Thr Asp Ser 1250 1255 1260 Lys Pro Lys Ala Ser
Leu Lys Ile Asp Leu Arg Val Thr Ser Lys 1265 1270 1275 Ser Lys Glu
Ser Gly Leu Ser Asp Val Ser Arg Pro Ser Phe Cys 1280 1285 1290 His
Ser Ser Cys Gly His Val Ser Glu Gly Lys Arg Arg Phe Thr 1295 1300
1305 Tyr Asp His Ala Glu Leu Glu Arg Lys Ile Ala Cys Cys Ser Pro
1310 1315 1320 Pro Pro Asp Tyr Asn Ser Val Val Leu Tyr Ser Thr Pro
Pro Ile 1325 1330 1335 95830DNAHomo sapiens 9actgagtccc gggaccccgg
gagagcggtc agtgtgtggt cgctgcgttt cctctgcctg 60cgccgggcat cacttgcgcg
ccgcagaaag tccgtctggc agcctggata tcctctccta 120ccggcacccg
cagacgcccc tgcagccgcc ggtcggcgcc cgggctccct agccctgtgc
180gctcaactgt cctgcgctgc ggggtgccgc gagttccacc tccgcgcctc
cttctctaga 240caggcgctgg gagaaagaac cggctcccga gttctgggca
tttcgcccgg ctcgaggtgc 300aggatgcaga gcaaggtgct gctggccgtc
gccctgtggc tctgcgtgga gacccgggcc 360gcctctgtgg gtttgcctag
tgtttctctt gatctgccca ggctcagcat acaaaaagac 420atacttacaa
ttaaggctaa tacaactctt caaattactt gcaggggaca gagggacttg
480gactggcttt ggcccaataa tcagagtggc agtgagcaaa gggtggaggt
gactgagtgc 540agcgatggcc tcttctgtaa gacactcaca attccaaaag
tgatcggaaa tgacactgga 600gcctacaagt gcttctaccg ggaaactgac
ttggcctcgg tcatttatgt ctatgttcaa 660gattacagat ctccatttat
tgcttctgtt agtgaccaac atggagtcgt gtacattact 720gagaacaaaa
acaaaactgt ggtgattcca tgtctcgggt ccatttcaaa tctcaacgtg
780tcactttgtg caagataccc agaaaagaga tttgttcctg atggtaacag
aatttcctgg 840gacagcaaga agggctttac tattcccagc tacatgatca
gctatgctgg catggtcttc 900tgtgaagcaa aaattaatga tgaaagttac
cagtctatta tgtacatagt tgtcgttgta 960gggtatagga tttatgatgt
ggttctgagt ccgtctcatg gaattgaact atctgttgga 1020gaaaagcttg
tcttaaattg tacagcaaga actgaactaa atgtggggat tgacttcaac
1080tgggaatacc cttcttcgaa gcatcagcat aagaaacttg taaaccgaga
cctaaaaacc 1140cagtctggga gtgagatgaa gaaatttttg agcaccttaa
ctatagatgg tgtaacccgg 1200agtgaccaag gattgtacac ctgtgcagca
tccagtgggc tgatgaccaa gaagaacagc 1260acatttgtca gggtccatga
aaaacctttt gttgcttttg gaagtggcat ggaatctctg 1320gtggaagcca
cggtggggga gcgtgtcaga atccctgcga agtaccttgg ttacccaccc
1380ccagaaataa aatggtataa aaatggaata ccccttgagt ccaatcacac
aattaaagcg 1440gggcatgtac tgacgattat ggaagtgagt gaaagagaca
caggaaatta cactgtcatc 1500cttaccaatc ccatttcaaa ggagaagcag
agccatgtgg tctctctggt tgtgtatgtc 1560ccaccccaga ttggtgagaa
atctctaatc tctcctgtgg attcctacca gtacggcacc 1620actcaaacgc
tgacatgtac ggtctatgcc attcctcccc cgcatcacat ccactggtat
1680tggcagttgg aggaagagtg cgccaacgag cccagccaag ctgtctcagt
gacaaaccca 1740tacccttgtg aagaatggag aagtgtggag gacttccagg
gaggaaataa aattgaagtt 1800aataaaaatc aatttgctct aattgaagga
aaaaacaaaa ctgtaagtac ccttgttatc 1860caagcggcaa atgtgtcagc
tttgtacaaa tgtgaagcgg tcaacaaagt cgggagagga 1920gagagggtga
tctccttcca cgtgaccagg ggtcctgaaa ttactttgca acctgacatg
1980cagcccactg agcaggagag cgtgtctttg tggtgcactg cagacagatc
tacgtttgag 2040aacctcacat ggtacaagct tggcccacag cctctgccaa
tccatgtggg agagttgccc 2100acacctgttt gcaagaactt ggatactctt
tggaaattga atgccaccat gttctctaat 2160agcacaaatg acattttgat
catggagctt aagaatgcat ccttgcagga ccaaggagac 2220tatgtctgcc
ttgctcaaga caggaagacc aagaaaagac attgcgtggt caggcagctc
2280acagtcctag agcgtgtggc acccacgatc acaggaaacc tggagaatca
gacgacaagt 2340attggggaaa gcatcgaagt ctcatgcacg gcatctggga
atccccctcc acagatcatg 2400tggtttaaag ataatgagac ccttgtagaa
gactcaggca ttgtattgaa ggatgggaac 2460cggaacctca ctatccgcag
agtgaggaag gaggacgaag gcctctacac ctgccaggca 2520tgcagtgttc
ttggctgtgc aaaagtggag gcatttttca taatagaagg tgcccaggaa
2580aagacgaact tggaaatcat tattctagta ggcacggcgg tgattgccat
gttcttctgg 2640ctacttcttg tcatcatcct acggaccgtt aagcgggcca
atggagggga actgaagaca 2700ggctacttgt ccatcgtcat ggatccagat
gaactcccat tggatgaaca ttgtgaacga 2760ctgccttatg atgccagcaa
atgggaattc cccagagacc ggctgaagct aggtaagcct 2820cttggccgtg
gtgcctttgg ccaagtgatt gaagcagatg cctttggaat tgacaagaca
2880gcaacttgca ggacagtagc agtcaaaatg ttgaaagaag gagcaacaca
cagtgagcat 2940cgagctctca tgtctgaact caagatcctc attcatattg
gtcaccatct caatgtggtc 3000aaccttctag gtgcctgtac caagccagga
gggccactca tggtgattgt ggaattctgc 3060aaatttggaa acctgtccac
ttacctgagg agcaagagaa atgaatttgt cccctacaag 3120accaaagggg
cacgattccg tcaagggaaa gactacgttg gagcaatccc tgtggatctg
3180aaacggcgct tggacagcat caccagtagc cagagctcag ccagctctgg
atttgtggag 3240gagaagtccc tcagtgatgt agaagaagag gaagctcctg
aagatctgta taaggacttc 3300ctgaccttgg agcatctcat ctgttacagc
ttccaagtgg ctaagggcat ggagttcttg 3360gcatcgcgaa agtgtatcca
cagggacctg gcggcacgaa atatcctctt atcggagaag 3420aacgtggtta
aaatctgtga ctttggcttg gcccgggata tttataaaga tccagattat
3480gtcagaaaag gagatgctcg cctccctttg aaatggatgg ccccagaaac
aatttttgac 3540agagtgtaca caatccagag tgacgtctgg tcttttggtg
ttttgctgtg ggaaatattt 3600tccttaggtg cttctccata tcctggggta
aagattgatg aagaattttg taggcgattg 3660aaagaaggaa ctagaatgag
ggcccctgat tatactacac cagaaatgta ccagaccatg 3720ctggactgct
ggcacgggga gcccagtcag agacccacgt tttcagagtt ggtggaacat
3780ttgggaaatc tcttgcaagc taatgctcag caggatggca aagactacat
tgttcttccg 3840atatcagaga ctttgagcat ggaagaggat tctggactct
ctctgcctac ctcacctgtt 3900tcctgtatgg aggaggagga agtatgtgac
cccaaattcc attatgacaa cacagcagga 3960atcagtcagt atctgcagaa
cagtaagcga aagagccggc ctgtgagtgt aaaaacattt 4020gaagatatcc
cgttagaaga accagaagta aaagtaatcc cagatgacaa ccagacggac
4080agtggtatgg ttcttgcctc agaagagctg aaaactttgg aagacagaac
caaattatct 4140ccatcttttg gtggaatggt gcccagcaaa agcagggagt
ctgtggcatc tgaaggctca 4200aaccagacaa gcggctacca gtccggatat
cactccgatg acacagacac caccgtgtac 4260tccagtgagg aagcagaact
tttaaagctg atagagattg gagtgcaaac cggtagcaca 4320gcccagattc
tccagcctga ctcggggacc acactgagct ctcctcctgt ttaaaaggaa
4380gcatccacac cccaactccc ggacatcaca tgagaggtct gctcagattt
tgaagtgttg 4440ttctttccac cagcaggaag tagccgcatt tgattttcat
ttcgacaaca gaaaaaggac 4500ctcggactgc agggagccag tcttctaggc
atatcctgga agaggcttgt gacccaagaa 4560tgtgtctgtg tcttctccca
gtgttgacct gatcctcttt tttcattcat ttaaaaagca 4620ttatcatgcc
cctgctgcgg gtctcaccat gggtttagaa caaagagctt caagcaatgg
4680ccccatcctc aaagaagtag cagtacctgg ggagctgaca cttctgtaaa
actagaagat 4740aaaccaggca acgtaagtgt tcgaggtgtt gaagatggga
aggatttgca gggctgagtc 4800tatccaagag gctttgttta ggacgtgggt
cccaagccaa gccttaagtg tggaattcgg 4860attgatagaa aggaagacta
acgttacctt gctttggaga gtactggagc ctgcaaatgc 4920attgtgtttg
ctctggtgga ggtgggcatg gggtctgttc tgaaatgtaa agggttcaga
4980cggggtttct ggttttagaa ggttgcgtgt tcttcgagtt gggctaaagt
agagttcgtt 5040gtgctgtttc tgactcctaa tgagagttcc ttccagaccg
ttagctgtct ccttgccaag 5100ccccaggaag aaaatgatgc agctctggct
ccttgtctcc caggctgatc ctttattcag 5160aataccacaa agaaaggaca
ttcagctcaa ggctccctgc cgtgttgaag agttctgact 5220gcacaaacca
gcttctggtt tcttctggaa tgaataccct catatctgtc ctgatgtgat
5280atgtctgaga ctgaatgcgg gaggttcaat gtgaagctgt gtgtggtgtc
aaagtttcag 5340gaaggatttt acccttttgt tcttccccct gtccccaacc
cactctcacc ccgcaaccca 5400tcagtatttt agttatttgg cctctactcc
agtaaacctg attgggtttg ttcactctct 5460gaatgattat tagccagact
tcaaaattat tttatagccc aaattataac atctattgta 5520ttatttagac
ttttaacata tagagctatt tctactgatt tttgcccttg ttctgtcctt
5580tttttcaaaa aagaaaatgt gttttttgtt tggtaccata gtgtgaaatg
ctgggaacaa 5640tgactataag acatgctatg gcacatatat ttatagtctg
tttatgtaga aacaaatgta 5700atatattaaa gccttatata taatgaactt
tgtactattc acattttgta tcagtattat 5760gtagcataac aaaggtcata
atgctttcag caattgatgt cattttatta aagaacattg 5820aaaaacttga
5830101356PRTHomo sapiens 10Met Gln Ser Lys Val Leu Leu Ala Val Ala
Leu Trp Leu Cys Val Glu 1 5 10 15 Thr Arg Ala Ala Ser Val Gly Leu
Pro Ser Val Ser Leu Asp Leu Pro 20 25 30 Arg Leu Ser Ile Gln Lys
Asp Ile Leu Thr Ile Lys Ala Asn Thr Thr 35 40 45 Leu Gln Ile Thr
Cys Arg Gly Gln Arg Asp Leu Asp Trp Leu Trp Pro 50 55 60 Asn Asn
Gln Ser Gly Ser Glu Gln Arg Val Glu Val Thr Glu Cys Ser 65 70 75 80
Asp Gly Leu Phe Cys Lys Thr Leu Thr Ile Pro Lys Val Ile Gly Asn 85
90 95 Asp Thr Gly Ala Tyr Lys Cys Phe Tyr Arg Glu Thr Asp Leu Ala
Ser 100 105 110 Val Ile Tyr Val Tyr Val Gln Asp Tyr Arg Ser Pro Phe
Ile Ala Ser 115 120 125 Val Ser Asp Gln His Gly Val Val Tyr Ile Thr
Glu Asn Lys Asn Lys 130 135 140 Thr Val Val Ile Pro Cys Leu Gly Ser
Ile Ser Asn Leu Asn Val Ser 145 150 155 160 Leu Cys Ala Arg Tyr Pro
Glu Lys Arg Phe Val Pro Asp Gly Asn Arg 165 170 175 Ile Ser Trp Asp
Ser Lys Lys Gly Phe Thr Ile Pro Ser Tyr Met Ile 180 185 190 Ser Tyr
Ala Gly Met Val Phe Cys Glu Ala Lys Ile Asn Asp Glu Ser 195 200 205
Tyr Gln Ser Ile Met Tyr Ile Val Val Val Val Gly Tyr Arg Ile Tyr 210
215 220 Asp Val Val Leu Ser Pro Ser His Gly Ile Glu Leu Ser Val Gly
Glu 225 230 235 240 Lys Leu Val Leu Asn Cys Thr Ala Arg Thr Glu Leu
Asn Val Gly Ile 245 250 255 Asp Phe Asn Trp Glu Tyr Pro Ser Ser Lys
His Gln His Lys Lys Leu 260 265 270 Val Asn Arg Asp Leu Lys Thr Gln
Ser Gly Ser Glu Met Lys Lys Phe 275 280 285 Leu Ser Thr Leu Thr Ile
Asp Gly Val Thr Arg Ser Asp Gln Gly Leu 290 295 300 Tyr Thr Cys Ala
Ala Ser Ser Gly Leu Met Thr Lys Lys Asn Ser Thr 305 310 315 320 Phe
Val Arg Val His Glu Lys Pro Phe Val Ala Phe Gly Ser Gly Met 325 330
335 Glu Ser Leu Val Glu Ala Thr Val Gly Glu Arg Val Arg Ile Pro Ala
340 345 350 Lys Tyr Leu Gly Tyr Pro Pro Pro Glu Ile Lys Trp Tyr Lys
Asn Gly 355 360 365 Ile Pro Leu Glu Ser Asn His Thr Ile Lys Ala Gly
His Val Leu Thr 370 375 380 Ile Met Glu Val Ser Glu Arg Asp Thr Gly
Asn Tyr Thr Val Ile Leu 385 390 395 400 Thr Asn Pro Ile Ser Lys Glu
Lys Gln Ser His Val Val Ser Leu Val 405 410 415 Val Tyr Val Pro Pro
Gln Ile Gly Glu Lys Ser Leu Ile Ser Pro Val 420 425 430 Asp Ser Tyr
Gln Tyr Gly Thr Thr Gln Thr Leu Thr Cys Thr Val Tyr 435 440 445 Ala
Ile Pro Pro Pro His His Ile His Trp Tyr Trp Gln Leu Glu Glu 450 455
460 Glu Cys Ala Asn Glu Pro Ser Gln Ala Val Ser Val Thr Asn Pro Tyr
465 470 475 480 Pro Cys Glu Glu Trp Arg Ser Val Glu Asp Phe Gln Gly
Gly Asn Lys 485 490 495 Ile Glu Val Asn Lys Asn Gln Phe Ala Leu Ile
Glu Gly Lys Asn Lys 500 505 510 Thr Val Ser Thr Leu Val Ile Gln Ala
Ala Asn Val Ser Ala Leu Tyr 515 520 525 Lys Cys Glu Ala Val Asn Lys
Val Gly Arg Gly Glu Arg Val Ile Ser 530 535 540 Phe His Val Thr Arg
Gly Pro Glu Ile Thr Leu Gln Pro Asp Met Gln 545 550 555 560 Pro Thr
Glu Gln Glu Ser Val Ser Leu Trp Cys Thr Ala Asp Arg Ser 565 570 575
Thr Phe Glu Asn Leu Thr Trp Tyr Lys Leu Gly Pro Gln Pro Leu Pro 580
585 590 Ile His Val Gly Glu Leu Pro Thr Pro Val Cys Lys Asn Leu Asp
Thr 595 600 605 Leu Trp Lys Leu Asn Ala Thr Met Phe Ser Asn Ser Thr
Asn Asp Ile 610 615 620 Leu Ile Met Glu Leu Lys Asn Ala Ser Leu Gln
Asp Gln Gly Asp Tyr 625 630 635 640 Val Cys Leu Ala Gln Asp Arg Lys
Thr Lys Lys Arg His Cys Val Val 645 650 655 Arg Gln Leu Thr Val Leu
Glu Arg Val Ala Pro Thr Ile Thr Gly Asn 660 665 670 Leu Glu Asn Gln
Thr Thr Ser Ile Gly Glu Ser Ile Glu Val Ser Cys 675 680 685 Thr Ala
Ser Gly Asn Pro Pro Pro Gln Ile Met Trp Phe Lys Asp Asn 690 695 700
Glu Thr Leu Val Glu Asp Ser Gly Ile Val Leu Lys Asp Gly Asn Arg 705
710 715 720 Asn Leu Thr Ile Arg Arg Val Arg Lys Glu Asp Glu Gly Leu
Tyr Thr 725 730 735 Cys Gln Ala Cys Ser Val Leu Gly Cys Ala Lys Val
Glu Ala Phe Phe 740 745 750 Ile Ile Glu Gly Ala Gln Glu Lys Thr Asn
Leu Glu Ile Ile Ile Leu 755 760 765 Val Gly Thr Ala Val Ile Ala Met
Phe Phe Trp Leu Leu Leu Val Ile 770 775 780 Ile Leu Arg Thr Val Lys
Arg Ala Asn Gly Gly Glu Leu Lys Thr Gly 785 790 795 800 Tyr Leu Ser
Ile Val Met Asp Pro Asp Glu Leu Pro Leu Asp Glu His 805 810 815 Cys
Glu Arg Leu Pro Tyr Asp Ala Ser Lys Trp Glu Phe Pro Arg Asp 820 825
830 Arg Leu Lys Leu Gly Lys Pro Leu Gly Arg Gly Ala Phe Gly Gln Val
835 840 845 Ile Glu Ala Asp Ala Phe Gly Ile Asp Lys Thr Ala Thr Cys
Arg Thr 850 855 860 Val Ala Val Lys Met Leu Lys Glu Gly Ala Thr His
Ser Glu His Arg 865 870 875 880 Ala Leu Met Ser Glu Leu Lys Ile Leu
Ile His Ile Gly His His Leu 885 890 895 Asn Val Val Asn Leu Leu Gly
Ala Cys Thr Lys Pro Gly Gly Pro Leu 900 905 910 Met Val Ile Val Glu
Phe Cys Lys Phe Gly Asn Leu Ser Thr Tyr Leu 915 920 925 Arg Ser Lys
Arg Asn Glu Phe Val Pro Tyr Lys Thr Lys Gly Ala Arg 930 935 940 Phe
Arg Gln Gly Lys Asp Tyr Val Gly Ala Ile Pro Val Asp Leu Lys 945 950
955 960 Arg Arg Leu Asp Ser Ile Thr Ser Ser Gln Ser Ser Ala Ser Ser
Gly 965 970 975 Phe Val Glu Glu Lys Ser Leu Ser Asp Val Glu Glu Glu
Glu Ala Pro 980 985
990 Glu Asp Leu Tyr Lys Asp Phe Leu Thr Leu Glu His Leu Ile Cys Tyr
995 1000 1005 Ser Phe Gln Val Ala Lys Gly Met Glu Phe Leu Ala Ser
Arg Lys 1010 1015 1020 Cys Ile His Arg Asp Leu Ala Ala Arg Asn Ile
Leu Leu Ser Glu 1025 1030 1035 Lys Asn Val Val Lys Ile Cys Asp Phe
Gly Leu Ala Arg Asp Ile 1040 1045 1050 Tyr Lys Asp Pro Asp Tyr Val
Arg Lys Gly Asp Ala Arg Leu Pro 1055 1060 1065 Leu Lys Trp Met Ala
Pro Glu Thr Ile Phe Asp Arg Val Tyr Thr 1070 1075 1080 Ile Gln Ser
Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile 1085 1090 1095 Phe
Ser Leu Gly Ala Ser Pro Tyr Pro Gly Val Lys Ile Asp Glu 1100 1105
1110 Glu Phe Cys Arg Arg Leu Lys Glu Gly Thr Arg Met Arg Ala Pro
1115 1120 1125 Asp Tyr Thr Thr Pro Glu Met Tyr Gln Thr Met Leu Asp
Cys Trp 1130 1135 1140 His Gly Glu Pro Ser Gln Arg Pro Thr Phe Ser
Glu Leu Val Glu 1145 1150 1155 His Leu Gly Asn Leu Leu Gln Ala Asn
Ala Gln Gln Asp Gly Lys 1160 1165 1170 Asp Tyr Ile Val Leu Pro Ile
Ser Glu Thr Leu Ser Met Glu Glu 1175 1180 1185 Asp Ser Gly Leu Ser
Leu Pro Thr Ser Pro Val Ser Cys Met Glu 1190 1195 1200 Glu Glu Glu
Val Cys Asp Pro Lys Phe His Tyr Asp Asn Thr Ala 1205 1210 1215 Gly
Ile Ser Gln Tyr Leu Gln Asn Ser Lys Arg Lys Ser Arg Pro 1220 1225
1230 Val Ser Val Lys Thr Phe Glu Asp Ile Pro Leu Glu Glu Pro Glu
1235 1240 1245 Val Lys Val Ile Pro Asp Asp Asn Gln Thr Asp Ser Gly
Met Val 1250 1255 1260 Leu Ala Ser Glu Glu Leu Lys Thr Leu Glu Asp
Arg Thr Lys Leu 1265 1270 1275 Ser Pro Ser Phe Gly Gly Met Val Pro
Ser Lys Ser Arg Glu Ser 1280 1285 1290 Val Ala Ser Glu Gly Ser Asn
Gln Thr Ser Gly Tyr Gln Ser Gly 1295 1300 1305 Tyr His Ser Asp Asp
Thr Asp Thr Thr Val Tyr Ser Ser Glu Glu 1310 1315 1320 Ala Glu Leu
Leu Lys Leu Ile Glu Ile Gly Val Gln Thr Gly Ser 1325 1330 1335 Thr
Ala Gln Ile Leu Gln Pro Asp Ser Gly Thr Thr Leu Ser Ser 1340 1345
1350 Pro Pro Val 1355 112305DNAHomo sapiens 11ttcttggggc tgatgtccgc
aaatatgcag aattaccggc cgggtcgctc ctgaagccag 60cgcggggagc gagcgcggcg
gcggccagca ccgggaacgc accgaggaag aagcccagcc 120cccgccctcc
gccccttccg tccccacccc ctacccggcg gcccaggagg ctccccggct
180gcggcgcgca ctccctgttt ctcctcctcc tggctggcgc tgcctgcctc
tccgcactca 240ctgctcgccg ggcgccgtcc gccagctccg tgctccccgc
gccaccctcc tccgggccgc 300gctccctaag ggatggtact gaatttcgcc
gccacaggag accggctgga gcgcccgccc 360cgcgcctcgc ctctcctccg
agcagccagc gcctcgggac gcgatgagga ccttggcttg 420cctgctgctc
ctcggctgcg gatacctcgc ccatgttctg gccgaggaag ccgagatccc
480ccgcgaggtg atcgagaggc tggcccgcag tcagatccac agcatccggg
acctccagcg 540actcctggag atagactccg tagggagtga ggattctttg
gacaccagcc tgagagctca 600cggggtccac gccactaagc atgtgcccga
gaagcggccc ctgcccattc ggaggaagag 660aagcatcgag gaagctgtcc
ccgctgtctg caagaccagg acggtcattt acgagattcc 720tcggagtcag
gtcgacccca cgtccgccaa cttcctgatc tggcccccgt gcgtggaggt
780gaaacgctgc accggctgct gcaacacgag cagtgtcaag tgccagccct
cccgcgtcca 840ccaccgcagc gtcaaggtgg ccaaggtgga atacgtcagg
aagaagccaa aattaaaaga 900agtccaggtg aggttagagg agcatttgga
gtgcgcctgc gcgaccacaa gcctgaatcc 960ggattatcgg gaagaggaca
cggatgtgag gtgaggatga gccgcagccc tttcctggga 1020catggatgta
catggcgtgt tacattcctg aacctactat gtacggtgct ttattgccag
1080tgtgcggtct ttgttctcct ccgtgaaaaa ctgtgtccga gaacactcgg
gagaacaaag 1140agacagtgca catttgttta atgtgacatc aaagcaagta
ttgtagcact cggtgaagca 1200gtaagaagct tccttgtcaa aaagagagag
agagagagag agagagaaaa caaaaccaca 1260aatgacaaaa acaaaacgga
ctcacaaaaa tatctaaact cgatgagatg gagggtcgcc 1320ccgtgggatg
gaagtgcaga ggtctcagca gactggattt ctgtccgggt ggtcacaggt
1380gcttttttgc cgaggatgca gagcctgctt tgggaacgac tccagagggg
tgctggtggg 1440ctctgcaggg cccgcaggaa gcaggaatgt cttggaaacc
gccacgcgaa ctttagaaac 1500cacacctcct cgctgtagta tttaagccca
tacagaaacc ttcctgagag ccttaagtgg 1560tttttttttt tgtttttgtt
ttgttttttt tttttttgtt tttttttttt tttttttttt 1620ttacaccata
aagtgattat taagcttcct tttactcttt ggctagcttt tttttttttt
1680tttttttttt ttttttttaa ttatctcttg gatgacattt acaccgataa
cacacaggct 1740gctgtaactg tcaggacagt gcgacggtat ttttcctagc
aagatgcaaa ctaatgagat 1800gtattaaaat aaacatggta tacctaccta
tgcatcattt cctaaatgtt tctggctttg 1860tgtttctccc ttaccctgct
ttatttgtta atttaagcca ttttgaaaga actatgcgtc 1920aaccaatcgt
acgccgtccc tgcggcacct gccccagagc ccgtttgtgg ctgagtgaca
1980acttgttccc cgcagtgcac acctagaatg ctgtgttccc acgcggcacg
tgagatgcat 2040tgccgcttct gtctgtgttg ttggtgtgcc ctggtgccgt
ggtggcggtc actccctctg 2100ctgccagtgt ttggacagaa cccaaattct
ttatttttgg taagatattg tgctttacct 2160gtattaacag aaatgtgtgt
gtgtggtttg tttttttgta aaggtgaagt ttgtatgttt 2220acctaatatt
acctgttttg tatacctgag agcctgctat gttcttcttt tgttgatcca
2280aaattaaaaa aaaaatacca ccaac 230512196PRTHomo sapiens 12Met Arg
Thr Leu Ala Cys Leu Leu Leu Leu Gly Cys Gly Tyr Leu Ala 1 5 10 15
His Val Leu Ala Glu Glu Ala Glu Ile Pro Arg Glu Val Ile Glu Arg 20
25 30 Leu Ala Arg Ser Gln Ile His Ser Ile Arg Asp Leu Gln Arg Leu
Leu 35 40 45 Glu Ile Asp Ser Val Gly Ser Glu Asp Ser Leu Asp Thr
Ser Leu Arg 50 55 60 Ala His Gly Val His Ala Thr Lys His Val Pro
Glu Lys Arg Pro Leu 65 70 75 80 Pro Ile Arg Arg Lys Arg Ser Ile Glu
Glu Ala Val Pro Ala Val Cys 85 90 95 Lys Thr Arg Thr Val Ile Tyr
Glu Ile Pro Arg Ser Gln Val Asp Pro 100 105 110 Thr Ser Ala Asn Phe
Leu Ile Trp Pro Pro Cys Val Glu Val Lys Arg 115 120 125 Cys Thr Gly
Cys Cys Asn Thr Ser Ser Val Lys Cys Gln Pro Ser Arg 130 135 140 Val
His His Arg Ser Val Lys Val Ala Lys Val Glu Tyr Val Arg Lys 145 150
155 160 Lys Pro Lys Leu Lys Glu Val Gln Val Arg Leu Glu Glu His Leu
Glu 165 170 175 Cys Ala Cys Ala Thr Thr Ser Leu Asn Pro Asp Tyr Arg
Glu Glu Asp 180 185 190 Thr Asp Val Arg 195 136633DNAHomo sapiens
13ttctccccgc cccccagttg ttgtcgaagt ctgggggttg ggactggacc ccctgattgc
60gtaagagcaa aaagcgaagg cgcaatctgg acactgggag attcggagcg cagggagttt
120gagagaaact tttattttga agagaccaag gttgaggggg ggcttatttc
ctgacagcta 180tttacttaga gcaaatgatt agttttagaa ggatggacta
taacattgaa tcaattacaa 240aacgcggttt ttgagcccat tactgttgga
gctacaggga gagaaacagg aggagactgc 300aagagatcat ttgggaaggc
cgtgggcacg ctctttactc catgtgtggg acattcattg 360cggaataaca
tcggaggaga agtttcccag agctatgggg acttcccatc cggcgttcct
420ggtcttaggc tgtcttctca cagggctgag cctaatcctc tgccagcttt
cattaccctc 480tatccttcca aatgaaaatg aaaaggttgt gcagctgaat
tcatcctttt ctctgagatg 540ctttggggag agtgaagtga gctggcagta
ccccatgtct gaagaagaga gctccgatgt 600ggaaatcaga aatgaagaaa
acaacagcgg cctttttgtg acggtcttgg aagtgagcag 660tgcctcggcg
gcccacacag ggttgtacac ttgctattac aaccacactc agacagaaga
720gaatgagctt gaaggcaggc acatttacat ctatgtgcca gacccagatg
tagcctttgt 780acctctagga atgacggatt atttagtcat cgtggaggat
gatgattctg ccattatacc 840ttgtcgcaca actgatcccg agactcctgt
aaccttacac aacagtgagg gggtggtacc 900tgcctcctac gacagcagac
agggctttaa tgggaccttc actgtagggc cctatatctg 960tgaggccacc
gtcaaaggaa agaagttcca gaccatccca tttaatgttt atgctttaaa
1020agcaacatca gagctggatc tagaaatgga agctcttaaa accgtgtata
agtcagggga 1080aacgattgtg gtcacctgtg ctgtttttaa caatgaggtg
gttgaccttc aatggactta 1140ccctggagaa gtgaaaggca aaggcatcac
aatgctggaa gaaatcaaag tcccatccat 1200caaattggtg tacactttga
cggtccccga ggccacggtg aaagacagtg gagattacga 1260atgtgctgcc
cgccaggcta ccagggaggt caaagaaatg aagaaagtca ctatttctgt
1320ccatgagaaa ggtttcattg aaatcaaacc caccttcagc cagttggaag
ctgtcaacct 1380gcatgaagtc aaacattttg ttgtagaggt gcgggcctac
ccacctccca ggatatcctg 1440gctgaaaaac aatctgactc tgattgaaaa
tctcactgag atcaccactg atgtggaaaa 1500gattcaggaa ataaggtatc
gaagcaaatt aaagctgatc cgtgctaagg aagaagacag 1560tggccattat
actattgtag ctcaaaatga agatgctgtg aagagctata cttttgaact
1620gttaactcaa gttccttcat ccattctgga cttggtcgat gatcaccatg
gctcaactgg 1680gggacagacg gtgaggtgca cagctgaagg cacgccgctt
cctgatattg agtggatgat 1740atgcaaagat attaagaaat gtaataatga
aacttcctgg actattttgg ccaacaatgt 1800ctcaaacatc atcacggaga
tccactcccg agacaggagt accgtggagg gccgtgtgac 1860tttcgccaaa
gtggaggaga ccatcgccgt gcgatgcctg gctaagaatc tccttggagc
1920tgagaaccga gagctgaagc tggtggctcc caccctgcgt tctgaactca
cggtggctgc 1980tgcagtcctg gtgctgttgg tgattgtgat catctcactt
attgtcctgg ttgtcatttg 2040gaaacagaaa ccgaggtatg aaattcgctg
gagggtcatt gaatcaatca gcccggatgg 2100acatgaatat atttatgtgg
acccgatgca gctgccttat gactcaagat gggagtttcc 2160aagagatgga
ctagtgcttg gtcgggtctt ggggtctgga gcgtttggga aggtggttga
2220aggaacagcc tatggattaa gccggtccca acctgtcatg aaagttgcag
tgaagatgct 2280aaaacccacg gccagatcca gtgaaaaaca agctctcatg
tctgaactga agataatgac 2340tcacctgggg ccacatttga acattgtaaa
cttgctggga gcctgcacca agtcaggccc 2400catttacatc atcacagagt
attgcttcta tggagatttg gtcaactatt tgcataagaa 2460tagggatagc
ttcctgagcc accacccaga gaagccaaag aaagagctgg atatctttgg
2520attgaaccct gctgatgaaa gcacacggag ctatgttatt ttatcttttg
aaaacaatgg 2580tgactacatg gacatgaagc aggctgatac tacacagtat
gtccccatgc tagaaaggaa 2640agaggtttct aaatattccg acatccagag
atcactctat gatcgtccag cctcatataa 2700gaagaaatct atgttagact
cagaagtcaa aaacctcctt tcagatgata actcagaagg 2760ccttacttta
ttggatttgt tgagcttcac ctatcaagtt gcccgaggaa tggagttttt
2820ggcttcaaaa aattgtgtcc accgtgatct ggctgctcgc aacgtcctcc
tggcacaagg 2880aaaaattgtg aagatctgtg actttggcct ggccagagac
atcatgcatg attcgaacta 2940tgtgtcgaaa ggcagtacct ttctgcccgt
gaagtggatg gctcctgaga gcatctttga 3000caacctctac accacactga
gtgatgtctg gtcttatggc attctgctct gggagatctt 3060ttcccttggt
ggcacccctt accccggcat gatggtggat tctactttct acaataagat
3120caagagtggg taccggatgg ccaagcctga ccacgctacc agtgaagtct
acgagatcat 3180ggtgaaatgc tggaacagtg agccggagaa gagaccctcc
ttttaccacc tgagtgagat 3240tgtggagaat ctgctgcctg gacaatataa
aaagagttat gaaaaaattc acctggactt 3300cctgaagagt gaccatcctg
ctgtggcacg catgcgtgtg gactcagaca atgcatacat 3360tggtgtcacc
tacaaaaacg aggaagacaa gctgaaggac tgggagggtg gtctggatga
3420gcagagactg agcgctgaca gtggctacat cattcctctg cctgacattg
accctgtccc 3480tgaggaggag gacctgggca agaggaacag acacagctcg
cagacctctg aagagagtgc 3540cattgagacg ggttccagca gttccacctt
catcaagaga gaggacgaga ccattgaaga 3600catcgacatg atggacgaca
tcggcataga ctcttcagac ctggtggaag acagcttcct 3660gtaactggcg
gattcgaggg gttccttcca cttctggggc cacctctgga tcccgttcag
3720aaaaccactt tattgcaatg cggaggttga gaggaggact tggttgatgt
ttaaagagaa 3780gttcccagcc aagggcctcg gggagcgttc taaatatgaa
tgaatgggat attttgaaat 3840gaactttgtc agtgttgcct ctcgcaatgc
ctcagtagca tctcagtggt gtgtgaagtt 3900tggagataga tggataaggg
aataataggc cacagaaggt gaactttgtg cttcaaggac 3960attggtgaga
gtccaacaga cacaatttat actgcgacag aacttcagca ttgtaattat
4020gtaaataact ctaaccaagg ctgtgtttag attgtattaa ctatcttctt
tggacttctg 4080aagagaccac tcaatccatc catgtacttc cctcttgaaa
cctgatgtca gctgctgttg 4140aactttttaa agaagtgcat gaaaaaccat
ttttgaacct taaaaggtac tggtactata 4200gcattttgct atctttttta
gtgttaagag ataaagaata ataattaacc aaccttgttt 4260aatagatttg
ggtcatttag aagcctgaca actcattttc atattgtaat ctatgtttat
4320aatactacta ctgttatcag taatgctaaa tgtgtaataa tgtaacatga
tttccctcca 4380gagaaagcac aatttaaaac aatccttact aagtaggtga
tgagtttgac agtttttgac 4440atttatatta aataacatgt ttctctataa
agtatggtaa tagctttagt gaattaaatt 4500tagttgagca tagagaacaa
agtaaaagta gtgttgtcca ggaagtcaga atttttaact 4560gtactgaata
ggttccccaa tccatcgtat taaaaaacaa ttaactgccc tctgaaataa
4620tgggattaga aacaaacaaa actcttaagt cctaaaagtt ctcaatgtag
aggcataaac 4680ctgtgctgaa cataacttct catgtatatt acccaatgga
aaatataatg atcagcaaaa 4740agactggatt tgcagaagtt tttttttttt
ttcttcatgc ctgatgaaag ctttggcaac 4800cccaatatat gtattttttg
aatctatgaa cctgaaaagg gtcagaagga tgcccagaca 4860tcagcctcct
tctttcaccc cttaccccaa agagaaagag tttgaaactc gagaccataa
4920agatattctt tagtggaggc tggatgtgca ttagcctgga tcctcagttc
tcaaatgtgt 4980gtggcagcca ggatgactag atcctgggtt tccatccttg
agattctgaa gtatgaagtc 5040tgagggaaac cagagtctgt atttttctaa
actccctggc tgttctgatc ggccagtttt 5100cggaaacact gacttaggtt
tcaggaagtt gccatgggaa acaaataatt tgaactttgg 5160aacagggttg
gaattcaacc acgcaggaag cctactattt aaatccttgg cttcaggtta
5220gtgacattta atgccatcta gctagcaatt gcgaccttaa tttaactttc
cagtcttagc 5280tgaggctgag aaagctaaag tttggttttg acaggttttc
caaaagtaaa gatgctactt 5340cccactgtat gggggagatt gaactttccc
cgtctcccgt cttctgcctc ccactccata 5400ccccgccaag gaaaggcatg
tacaaaaatt atgcaattca gtgttccaag tctctgtgta 5460accagctcag
tgttttggtg gaaaaaacat tttaagtttt actgataatt tgaggttaga
5520tgggaggatg aattgtcaca tctatccaca ctgtcaaaca ggttggtgtg
ggttcattgg 5580cattctttgc aatactgctt aattgctgat accatatgaa
tgaaacatgg gctgtgatta 5640ctgcaatcac tgtgctatcg gcagatgatg
ctttggaaga tgcagaagca ataataaagt 5700acttgactac ctactggtgt
aatctcaatg caagccccaa ctttcttatc caactttttc 5760atagtaagtg
cgaagactga gccagattgg ccaattaaaa acgaaaacct gactaggttc
5820tgtagagcca attagacttg aaatacgttt gtgtttctag aatcacagct
caagcattct 5880gtttatcgct cactctccct tgtacagcct tattttgttg
gtgctttgca ttttgatatt 5940gctgtgagcc ttgcatgaca tcatgaggcc
ggatgaaact tctcagtcca gcagtttcca 6000gtcctaacaa atgctcccac
ctgaatttgt atatgactgc atttgtgggt gtgtgtgtgt 6060tttcagcaaa
ttccagattt gtttcctttt ggcctcctgc aaagtctcca gaagaaaatt
6120tgccaatctt tcctactttc tatttttatg atgacaatca aagccggcct
gagaaacact 6180atttgtgact ttttaaacga ttagtgatgt ccttaaaatg
tggtctgcca atctgtacaa 6240aatggtccta tttttgtgaa gagggacata
agataaaatg atgttataca tcaatatgta 6300tatatgtatt tctatataga
cttggagaat actgccaaaa catttatgac aagctgtatc 6360actgccttcg
tttatatttt tttaactgtg ataatcccca caggcacatt aactgttgca
6420cttttgaatg tccaaaattt atattttaga aataataaaa agaaagatac
ttacatgttc 6480ccaaaacaat ggtgtggtga atgtgtgaga aaaactaact
tgatagggtc taccaataca 6540aaatgtatta cgaatgcccc tgttcatgtt
tttgttttaa aacgtgtaaa tgaagatctt 6600tatatttcaa taaatgatat
ataatttaaa gtt 6633141089PRTHomo sapiens 14Met Gly Thr Ser His Pro
Ala Phe Leu Val Leu Gly Cys Leu Leu Thr 1 5 10 15 Gly Leu Ser Leu
Ile Leu Cys Gln Leu Ser Leu Pro Ser Ile Leu Pro 20 25 30 Asn Glu
Asn Glu Lys Val Val Gln Leu Asn Ser Ser Phe Ser Leu Arg 35 40 45
Cys Phe Gly Glu Ser Glu Val Ser Trp Gln Tyr Pro Met Ser Glu Glu 50
55 60 Glu Ser Ser Asp Val Glu Ile Arg Asn Glu Glu Asn Asn Ser Gly
Leu 65 70 75 80 Phe Val Thr Val Leu Glu Val Ser Ser Ala Ser Ala Ala
His Thr Gly 85 90 95 Leu Tyr Thr Cys Tyr Tyr Asn His Thr Gln Thr
Glu Glu Asn Glu Leu 100 105 110 Glu Gly Arg His Ile Tyr Ile Tyr Val
Pro Asp Pro Asp Val Ala Phe 115 120 125 Val Pro Leu Gly Met Thr Asp
Tyr Leu Val Ile Val Glu Asp Asp Asp 130 135 140 Ser Ala Ile Ile Pro
Cys Arg Thr Thr Asp Pro Glu Thr Pro Val Thr 145 150 155 160 Leu His
Asn Ser Glu Gly Val Val Pro Ala Ser Tyr Asp Ser Arg Gln 165 170 175
Gly Phe Asn Gly Thr Phe Thr Val Gly Pro Tyr Ile Cys Glu Ala Thr 180
185 190 Val Lys Gly Lys Lys Phe Gln Thr Ile Pro Phe Asn Val Tyr Ala
Leu 195 200 205 Lys Ala Thr Ser Glu Leu Asp Leu Glu Met Glu Ala Leu
Lys Thr Val 210 215 220 Tyr Lys Ser Gly Glu Thr Ile Val Val Thr Cys
Ala Val Phe Asn Asn 225 230 235 240 Glu Val Val Asp Leu Gln Trp Thr
Tyr Pro Gly Glu Val Lys Gly Lys 245 250 255 Gly Ile Thr Met Leu Glu
Glu Ile Lys Val Pro Ser Ile Lys Leu Val 260 265 270 Tyr Thr Leu Thr
Val Pro Glu Ala Thr Val Lys Asp Ser Gly Asp Tyr 275 280 285 Glu Cys
Ala Ala Arg Gln Ala Thr Arg Glu Val Lys Glu Met Lys Lys 290 295 300
Val Thr Ile Ser Val His Glu Lys Gly Phe Ile Glu Ile Lys Pro Thr 305
310 315 320 Phe Ser Gln Leu Glu Ala Val Asn Leu His Glu Val Lys His
Phe Val 325 330
335 Val Glu Val Arg Ala Tyr Pro Pro Pro Arg Ile Ser Trp Leu Lys Asn
340 345 350 Asn Leu Thr Leu Ile Glu Asn Leu Thr Glu Ile Thr Thr Asp
Val Glu 355 360 365 Lys Ile Gln Glu Ile Arg Tyr Arg Ser Lys Leu Lys
Leu Ile Arg Ala 370 375 380 Lys Glu Glu Asp Ser Gly His Tyr Thr Ile
Val Ala Gln Asn Glu Asp 385 390 395 400 Ala Val Lys Ser Tyr Thr Phe
Glu Leu Leu Thr Gln Val Pro Ser Ser 405 410 415 Ile Leu Asp Leu Val
Asp Asp His His Gly Ser Thr Gly Gly Gln Thr 420 425 430 Val Arg Cys
Thr Ala Glu Gly Thr Pro Leu Pro Asp Ile Glu Trp Met 435 440 445 Ile
Cys Lys Asp Ile Lys Lys Cys Asn Asn Glu Thr Ser Trp Thr Ile 450 455
460 Leu Ala Asn Asn Val Ser Asn Ile Ile Thr Glu Ile His Ser Arg Asp
465 470 475 480 Arg Ser Thr Val Glu Gly Arg Val Thr Phe Ala Lys Val
Glu Glu Thr 485 490 495 Ile Ala Val Arg Cys Leu Ala Lys Asn Leu Leu
Gly Ala Glu Asn Arg 500 505 510 Glu Leu Lys Leu Val Ala Pro Thr Leu
Arg Ser Glu Leu Thr Val Ala 515 520 525 Ala Ala Val Leu Val Leu Leu
Val Ile Val Ile Ile Ser Leu Ile Val 530 535 540 Leu Val Val Ile Trp
Lys Gln Lys Pro Arg Tyr Glu Ile Arg Trp Arg 545 550 555 560 Val Ile
Glu Ser Ile Ser Pro Asp Gly His Glu Tyr Ile Tyr Val Asp 565 570 575
Pro Met Gln Leu Pro Tyr Asp Ser Arg Trp Glu Phe Pro Arg Asp Gly 580
585 590 Leu Val Leu Gly Arg Val Leu Gly Ser Gly Ala Phe Gly Lys Val
Val 595 600 605 Glu Gly Thr Ala Tyr Gly Leu Ser Arg Ser Gln Pro Val
Met Lys Val 610 615 620 Ala Val Lys Met Leu Lys Pro Thr Ala Arg Ser
Ser Glu Lys Gln Ala 625 630 635 640 Leu Met Ser Glu Leu Lys Ile Met
Thr His Leu Gly Pro His Leu Asn 645 650 655 Ile Val Asn Leu Leu Gly
Ala Cys Thr Lys Ser Gly Pro Ile Tyr Ile 660 665 670 Ile Thr Glu Tyr
Cys Phe Tyr Gly Asp Leu Val Asn Tyr Leu His Lys 675 680 685 Asn Arg
Asp Ser Phe Leu Ser His His Pro Glu Lys Pro Lys Lys Glu 690 695 700
Leu Asp Ile Phe Gly Leu Asn Pro Ala Asp Glu Ser Thr Arg Ser Tyr 705
710 715 720 Val Ile Leu Ser Phe Glu Asn Asn Gly Asp Tyr Met Asp Met
Lys Gln 725 730 735 Ala Asp Thr Thr Gln Tyr Val Pro Met Leu Glu Arg
Lys Glu Val Ser 740 745 750 Lys Tyr Ser Asp Ile Gln Arg Ser Leu Tyr
Asp Arg Pro Ala Ser Tyr 755 760 765 Lys Lys Lys Ser Met Leu Asp Ser
Glu Val Lys Asn Leu Leu Ser Asp 770 775 780 Asp Asn Ser Glu Gly Leu
Thr Leu Leu Asp Leu Leu Ser Phe Thr Tyr 785 790 795 800 Gln Val Ala
Arg Gly Met Glu Phe Leu Ala Ser Lys Asn Cys Val His 805 810 815 Arg
Asp Leu Ala Ala Arg Asn Val Leu Leu Ala Gln Gly Lys Ile Val 820 825
830 Lys Ile Cys Asp Phe Gly Leu Ala Arg Asp Ile Met His Asp Ser Asn
835 840 845 Tyr Val Ser Lys Gly Ser Thr Phe Leu Pro Val Lys Trp Met
Ala Pro 850 855 860 Glu Ser Ile Phe Asp Asn Leu Tyr Thr Thr Leu Ser
Asp Val Trp Ser 865 870 875 880 Tyr Gly Ile Leu Leu Trp Glu Ile Phe
Ser Leu Gly Gly Thr Pro Tyr 885 890 895 Pro Gly Met Met Val Asp Ser
Thr Phe Tyr Asn Lys Ile Lys Ser Gly 900 905 910 Tyr Arg Met Ala Lys
Pro Asp His Ala Thr Ser Glu Val Tyr Glu Ile 915 920 925 Met Val Lys
Cys Trp Asn Ser Glu Pro Glu Lys Arg Pro Ser Phe Tyr 930 935 940 His
Leu Ser Glu Ile Val Glu Asn Leu Leu Pro Gly Gln Tyr Lys Lys 945 950
955 960 Ser Tyr Glu Lys Ile His Leu Asp Phe Leu Lys Ser Asp His Pro
Ala 965 970 975 Val Ala Arg Met Arg Val Asp Ser Asp Asn Ala Tyr Ile
Gly Val Thr 980 985 990 Tyr Lys Asn Glu Glu Asp Lys Leu Lys Asp Trp
Glu Gly Gly Leu Asp 995 1000 1005 Glu Gln Arg Leu Ser Ala Asp Ser
Gly Tyr Ile Ile Pro Leu Pro 1010 1015 1020 Asp Ile Asp Pro Val Pro
Glu Glu Glu Asp Leu Gly Lys Arg Asn 1025 1030 1035 Arg His Ser Ser
Gln Thr Ser Glu Glu Ser Ala Ile Glu Thr Gly 1040 1045 1050 Ser Ser
Ser Ser Thr Phe Ile Lys Arg Glu Asp Glu Thr Ile Glu 1055 1060 1065
Asp Ile Asp Met Met Asp Asp Ile Gly Ile Asp Ser Ser Asp Leu 1070
1075 1080 Val Glu Asp Ser Phe Leu 1085 1510RNAArtificial
SequenceSynthetic anti-VEGF aptamer 15gaagaauugg 10168RNAArtificial
SequenceSynthetic anti-VEGF aptamer 16uuggacgc 8178RNAArtificial
SequenceSynthetic anti-VEGF aptamer 17gugaaugc 81827RNAArtificial
SequenceSynthetic anti-VEGF aptamer 18cggaaucagu gaaugcuuau acauccg
271927RNAArtificial SequenceSynthetic anti-VEGF aptamer
19cggaaucagu gaaugcuuau acauccg 272032DNAArtificial
SequenceSynthetic anti-PDGF aptamer 20caggcuacgn cgtagagcau
cantgatccu gt 322130DNAArtificial SequenceSynthetic anti-PDGF
aptamer 21caggctacgc gtagagcatc atgatcctgt 302232DNAArtificial
SequenceSynthetic anti-PDGF aptamer 22caggcuacgn cgtagagcau
cantgatccu gt 322332DNAArtificial SequenceSynthetic anti-PDGF
aptamer 23caggcuacgn cgtagagcau cantgatccu gt 3224118PRTArtificial
SequenceSynthetic anti-VEGF antibody 24Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Tyr Asp Phe Thr His Tyr 20 25 30 Gly Met Asn
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly
Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55
60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Lys Tyr Pro Tyr Tyr Tyr Gly Thr Ser His Trp
Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu 115
25110PRTArtificial SequenceSynthetic anti-VEGF antibody 25Asp Ile
Gln Leu Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20
25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu
Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys Arg Thr Val 100 105 110 26118PRTArtificial
SequenceSynthetic anti-VEGF antibody 26Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Tyr Thr Phe Thr Asn Tyr 20 25 30 Gly Met Asn
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly
Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55
60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala Tyr
65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
Tyr Cys 85 90 95 Ala Lys Tyr Pro His Tyr Tyr Gly Ser Ser His Trp
Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu 115
27110PRTArtificial SequenceSynthetic anti-VEGF antibody 27Asp Ile
Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20
25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu
Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys Arg Thr Val 100 105 110 28123PRTArtificial
SequenceSynthetic anti-VEGF antibody 28Glu Val Gln Leu Val Glu Ser
Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser
Cys Ala Ala Ser Gly Tyr Xaa Phe Thr Xaa Tyr 20 25 30 Gly Met Asn
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Gly
Trp Ile Asn Thr Tyr Thr Gly Glu Pro Thr Tyr Ala Ala Asp Phe 50 55
60 Lys Arg Arg Phe Thr Phe Ser Leu Asp Thr Ser Lys Ser Thr Ala
Tyr65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val
Tyr Tyr Cys 85 90 95 Ala Lys Tyr Pro Xaa Tyr Tyr Gly Xaa Ser His
Trp Tyr Phe Asp Val 100 105 110 Trp Gly Gln Gly Thr Leu Val Thr Val
Ser Ser 115 120 2911PRTArtificial SequenceSynthetic anti-VEGF
antibody 29Ser Ala Ser Gln Asp Ile Ser Asn Tyr Leu Asn 1 5 10
307PRTArtificial SequenceSynthetic anti-VEGF antibody 30Phe Thr Ser
Ser Leu His Ser 1 5 319PRTArtificial SequenceSynthetic anti-VEGF
antibody 31Gln Gln Tyr Ser Thr Val Pro Trp Thr 1 5
32108PRTArtificial SequenceSynthetic anti-VEGF antibody 32Asp Ile
Gln Xaa Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15
Asp Arg Val Thr Ile Thr Cys Ser Ala Ser Gln Asp Ile Ser Asn Tyr 20
25 30 Leu Asn Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Val Leu
Ile 35 40 45 Tyr Phe Thr Ser Ser Leu His Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile
Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Tyr Cys Gln
Gln Tyr Ser Thr Val Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys Arg 100 105 3310PRTArtificial SequenceSynthetic
anti-VEGF antibody 33Gly Tyr Asp Phe Thr His Tyr Gly Met Asn 1 5 10
3414PRTArtificial SequenceSynthetic anti-VEGF antibody 34Tyr Pro
Tyr Tyr Tyr Gly Thr Ser His Trp Tyr Phe Asp Val 1 5 10
* * * * *